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Periodontology has been one of the most glamorous fields of dentistry with numerous 
exciting papers published so far which open up completely novel pathways. “The 
more we go into it, the more complex it becomes.” This is quite true for 
Periodontology. However, this complexity not only attracts even more scientists to 
work in this field, but also stimulates building new bridges between multiple 
disciplines to make the story clear.  
Periodontal diseases are among the most common chronic infectious and 
inflammatory diseases in the world. Pathogenesis of periodontal diseases has two 
major aspects: the microbial basis and the host response. Knowledge of both aspects 
has been increasing in a parallel manner. This book comprises reviews from renowned 
experts in the field of periodontology, and also findings from innovating studies.  
Section one comprises reviews on etiopathology of periodontitis. In the chapter by 
Kimura et al. possible roles of the pathogenic factors of P. gingivalis in the pathogenic 
events, such as colonization in gingival crevices, invasion into gingival tissues, and 
induction of inflammatory responses and alveolar bone loss, are addressed. The 
authors conclude that further studies are obviously required to elucidate the 
mechanism of the polymicrobial pathogenicity in periodontal breakdown and suggest 
what kinds of putative periodontopathic bacteria could participate in the synergistic 
pathogenicity with P. gingivalis. 
Exopolysaccharide productivities in many bacteria have been associated with 
pathogenicity in mammalian hosts as providing extracellular matrices to form biofilm. 
Yamanaka et al. describe the possibility that a single species biofilm in the oral cavity 
can cause persistent chronic periodontitis, along with the importance of dental plaque 
formation and maturation with sucrose-derived polysaccharides. 
Development of chair-side diagnostic tests for determining periodontal disease 
presence, absence or activity is still a challenge in periodontology. The use of oral 
fluids such as gingival crevicular fluid, whole saliva and oral rinse, has been suggested 
as a means of evaluating host-derived products and exogenous components for 
disease susceptibility, as potential sources and diagnostic markers, respectively.  
X Preface 
 
Hernandez et al. analyze the mechanisms involved in the periodontal tissues 
breakdown during chronic periodontitis, with a special focus on the role of T cells, 
matrix metalloproteinases and the development of chair-side point-of-care diagnostic 
aids applicable to monitor both periodontal and systemic inflammation.  
Changes in gingival tissue in relation to periodontal diseases, homeostasis of 
extracellular matrix and the role of growth factors and cytokines in periodontal 
diseases, are discussed by Pisoschi et al. The authors highlight the literature on growth 
factor involvement in periodontal disease and our contribution in this field, in order to 
sustain their use as biomarkers of active periodontal disease and future therapeutic 
tools. An overview is provided of gingival crevicular fluid and salivary growth factors 
as potential biomarkers of periodontal disease and growth factors as therapeutic tools 
in periodontal disease. The authors conclude that high-throughput technologies 
applied for assessment of gingival crevicular fluid and saliva will give new promises 
for the use of growth factors as objective biomarkers in periodontal disease.  
Smokers are accepted to be more susceptible to advanced and aggressive forms of 
periodontitis than non-smokers. Furthermore, tobacco smoking has been suggested to 
modify the periodontal response to microbial challenge by microbial dental plaque 
bacteria. In this review by Buduneli, an up-to-date literature review is provided on the 
effects of smoking on host response in chronic periodontitis and its effects on the 
response to periodontal treatment. 
Metabolic syndrome and periodontal diseases both have very high prevalence. 
Possible interaction mechanisms between metabolic syndrome and periodontal 
diseases are discussed by Cifone et al. It is stated by the authors that metabolic 
syndrome is closely related to oxidative stress and advanced glycation end-products. 
The authors conclude that the literature suggests involvement of all the conditions and 
pathologies causing oxidative stress, production of advanced glycation end-products, 
and activation of the relevant receptors in the aetiology and severity of periodontal 
diseases. 
Section two comprises reviews or reports on various treatment approaches applicable 
to periodontitis. Open gingival embrasures contribute to retention of food debris and 
can adversely affect the health of the periodontium. They are more common in adult 
patients with bone loss. Park et al. provide an up-to-date review of the relationship 
between periodontal diseases and open gingival embrasures. Possible ways of 
correcting open gingival embrasures are discussed in terms of orthodontic and 
restorative measures both in natural teeth and dental implants. 
Aggressive periodontitis constitutes a group of rare and rapidly progressing forms of 
periodontitis that are frequently characterized by an early age of clinical onset. In this 
report, Yamaguchi et al. document initial periodontal treatment followed by 
regenerative treatment in a case of aggressive periodontitis. 
        Preface XI 
 
Morimoto-Yamashita et al. provide a review on the current knowledge on Japanese 
apricot, Ume, including its correlation with some diseases and periodontitis. The 
authors mention the anti-cancer, anti-microbial, and anti-inflammatory effects of Ume 
and suggest that its extracts may have a place in the treatment of periodontal diseases. 
In the future, it may be added to toothpastes, mouth rinses and other oral products 
that can be used easily by the majority of the population ranging from youngsters to 
the elderly. 
Various health behavior theories have been established academically so far. The 
adherence of periodontal disease patients to health-promoting behavior is considered 
critical for the prevention and successful treatment of periodontal disease. Kakudate 
and Morito describe the relationship between oral self-care and self-efficacy as it 
relates to chronic periodontitis patients.  
Beta-glucan affects the immune function through macrophage activation and 
establishment of T helper 1 dominance. Tissue destruction seen in periodontal disease 
may be inhibited by the usage of this immunomodulating agent. Acar et al. present the 
results of a controlled study investigating the effects of nonsurgical periodontal 
therapy with adjunctive use of systemic beta-glucan on clinical, microbiological 
parameters and gingival crevicular fluid transforming growth factor-beta 1 levels in 
chronic periodontitis patients over a three-month period. 
Nastri and Caruso discuss the potential applications of lasers in periodontal treatment. 
It is stated by the authors that laser treatment may serve as an adjunct or alternative to 
conventional periodontal therapy for its various characteristics, such as ablation or 
vaporization, haemostasis and sterilization effect. Periodontal applications of CO2 
laser, Nd:YAG, Nd:YAP, Er:YAG, diode, argon, and alexandrite laser are discussed 
with their advantages and disadvantages. Photodynamic therapy with lasers is also 
dealt with by the authors. 
This book emphasises some very important aspects in the pathogenesis of 
periodontitis as well as modern treatment approaches. The reviews provide valuable 
contributions and the reports present novel findings.  
 
Dr. Nurcan Buduneli 
Department of Periodontology 
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Pathogenic Factors of  
P. gingivalis and the Host Defense Mechanisms 
Shigenobu Kimura1, Yuko Ohara-Nemoto2,  
Yu Shimoyama1, Taichi Ishikawa1 and Minoru Sasaki1 
1Iwate Medical University,  
2Nagasaki University Graduate School of Biomedical Sciences,  
Japan 
1. Introduction 
Periodontal diseases are the inflammatory diseases triggered specifically by some selected 
microorganisms, i.e., periodontopathic bacteria, accumulated in and around the gingival 
crevice. Among periodontopathic bacteria, Porphyromonas gingivalis, a black-pigmented 
gram-negative anaerobic rod, has been implicated as a major pathogen of chronic 
periodontitis (Hamada et al., 1991; Lamont & Jenkinson, 1998). Recent studies using DNA-
DNA hybridization that permits the examination of large numbers of species in large 
numbers of plaque samples also indicated the increased prevalence of P. gingivalis as well as 
other ‘red complex species’ (P. gingivalis, Treponema denticola and Tannerella forsythensis) in 
the subjects with chronic periodontitis (Socransky & Haffajee, 2002). However, it is also 
evident that the colonization of the putative pathogenic bacteria in subgingival plaque is not 
sufficient for the initiation/onset of periodontitis, since most periodontopathic bacteria 
including P. gingivalis may also be present at sound sites (Haffajee et al., 2009). Thus, the 
onset and progress of chronic periodontitis is based on the balance between the 
pathogenesis of the periodontopathic microorganisms and the host-defense against them 
(host-parasite relationship). 
The pathogenic factors of P. gingivalis including fimbriae, hemagglutinin, capsule, 
lipopolysaccharide (LPS), outer membrane vesicles, organic metabolites such as butyric 
acid, and various enzymes such as Arg- and Lys-gingipains, collagenase, gelatinase and 
hyaluronidase, could contribute to the induction of chronic periodontitis in diverse ways; P. 
gingivalis could colonize to gingival crevices by the fimbriae-mediated adherence to gingival 
epithelial cells, the proteases may have the abilities to destroy periodontal tissues directly or 
indirectly, and the LPS could elicit a wide variety of inflammatory responses of periodontal 
tissues and alveolar bone losses. Although the complex interaction to the host response 
fundamentally responsible for chronic periodontitis cannot be reproduced in vitro, the 
studies with animal models that P. gingivalis can induce experimental periodontitis with 
alveolar bone losses (Kimura et al., 2000a; Oz & Puleo, 2011) clearly indicate that P. gingivalis 
is a major causative pathogen of chronic periodontitis, and its pathogenic factors could be 
potentially involved solely or cooperatively in every step of the onset and progression of the 
disease. A recent study that the DNA vaccine expressing the adhesion/hemagglutinin 
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domain of Arg-gingipain prevented the P. gingivalis–induced alveolar bone loss in mice 
(Muramatsu et al., 2011) may support in part the hypothesis. 
In this chapter, we will address not the every pathogenic factor of P. gingivalis in tern, but 
the roles of the factors and their relationship in the pathogenic events of this microorganism, 
such as the colonization in gingival crevices, the invasion into gingival tissues, and the 
induction of inflammatory responses and alveolar bone losses. 
2. Colonization in gingival crevices 
The colonization of P. gingivalis in gingival crevices is the first step in the development of 
chronic periodontitis. However, it does not necessarily induce the periodontal destruction, 
but a prerequisite for onset of chronic periodontitis. In adults, P. gingivalis can be detected 
from periodontally healthy sites as well as diseased sites, although the number of the 
microorganisms is generally lower than that in diseased sites (Dzink et al., 1988; Hamada et 
al., 1991). In contrast, P. gingivalis is scarcely detected in the samples from oral cavities of 
children (Kimura et al., 2002; Kimura & Ohara-Nemoto, 2007). Our 2-year longitudinal 
study revealed that P. gingivalis as well as Prevotella intermedia and T. denticola appear to be 
transient organisms in the plaques of healthy children (Ooshima et al., 2003). From the point 
of view on host-parasite relationship in chronic periodontitis, the children’s host-defense of 
antibiotic components in saliva and gingival crevicular fluid (GCF) could efficiently prevent 
the initial colonization and/or proliferation of these periodontal pathogens, resulting in the 
arrest of periodontal diseases in healthy children. 
Nevertheless, it was also demonstrated that children whose parents were colonized by the 
BANA-positive periodontpathic species including P. gingivalis, T. denticola, and  
T. forsythensis were 9.8 times more likely to be colonized by these species, and children 
whose parents had clinical evidence of periodontitis were 12 times more likely to be 
colonized the species (Watson et al., 1994). The vertical transmission of P. gingivalis, 
however, has been still controversial; vertical as well as horizontal transmission was 
speculated in the research on 564-members of American families (Tuite-McDonnell et al., 
1997), whereas vertical (parents-to-children) transmission has rarely been observed in  
the Netherlands (Van Winkelhoff & Boutaga, 2005), in Finland (Asikainen & Chen, 1999), 
and in the research of 78 American subjects (Asikainen et al., 1996). In the latter reports, 
since horizontal transmission of P. gingivalis between adult family members was 
considerable, it was suggested that P. gingivalis commonly colonizes in an established oral 
microbiota. According to these observations, it was also suggested that the vertical and 
horizontal transmission of P. gingivalis could be controlled by periodontal treatment 
involving elimination of the pathogen in diseased individuals and by oral hygiene 
instructions.  
The major habitat of P. gingivalis is subgingival plaques in gingival crevices. However,  
P. gingivalis can be detected in the tongue coat samples from periodontally healthy and 
diseased subjects (Dahlén et al., 1992; Kishi et al., 2002). Clinical studies suggested that tongue 
coat could be a dominant reservoir of P. gingivalis (Kishi et al., 2002; Faveri et al., 2006). 
Furthermore, our recent study with 165 subjects aged 85 years old indicated that P. gingivalis 
as well as P. intermedia, T. denticola and T. forsythensis was found more frequently in tongue 
coat samples from dentate than edentulous subjects, and the prevalence of P. gingivalis was 
significantly related to the number of teeth with a periodontal pocket depth ≥ 4 mm (Kishi et 
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al., 2010). Thus, it can be speculated that an adequately stable circulation of P. gingivalis 
between subgingival plaque and tongue coat occurs over time in dentate individuals. In 
addition, tooth loss, which is synonymous with loss of the gingival crevice, may affect the oral 
microflora population, resulting in a significant decrease in P. gingivalis.  
Despite the host defense mechanisms in saliva and GCF, P. gingivalis can adhere and then 
colonize in gingival crevices to a variety of surface components lining the gingival crevicular 
cells and the tooth surface. The adhesive ability of P. gingivalis is mainly mediated by the 
fimbriae, although other bacterial components such as vesicles, hemagglutinin, and 
proteases may play an adjunctive role (Naito et al, 1993). Fimbriae are the thin, filamentous, 
and proteinaceous surface appendages found in many bacterial species, and these fimbriae 
are claimed to play an important role in the virulence of a number of oral and non-oral 
pathogens such as uropathogenic Escherichia coli and Neisseria gonorrehoeae. Fimbriae of P. 
gingivalis were first recognized on the outer surface by electron microscopic observation 
(Slots & Gibbons, 1978; Okuda et al., 1981), and were isolated and purified to a homogeneity 
from strain 381 by a simple and reproducible method using DEAE Sepharose 
chromatography (Yoshimura et al., 1984). Fimbriae of P. gingivalis 381 are composed of 
constituent (subunit) protein, fimbrillin, with a molecular weight of 40-42 kDa by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (Ogawa et al., 1991; Hamada et al., 1994). 
Lee et al.（1991） compared fimbriae diversities of size and amino terminal sequence of 
fimbrillins from various P. gingivalis strains; they differed in molecular weights ranging 
from 40.5 to 49 kDa and were classified into four types (types I to IV) based on the amino 
terminal sequences of fimbrillins. Further molecular and epidemiological studies using PCR 
method to differentiate possibly varied bacterial pathogenicity revealed that P. gingivalis 
fimbriae are classified into six genotypes based on the diversity of the fimA genes encoding 
each fimbrillin (types I to V, and type Ib), and that P. gingivalis with type II fimA is most 
closely associated with the progression of chronic periodontitis (Amano et al., 1999a; 
Nakagawa et al., 2000 & 2002b) (Table 1). A recent study with the mutants in which fimA of 
ATCC 33277 (type I strain) was substituted with type II fimA and that of OMZ314 (type II 
strain) with type I fimA indicated that type II fimbriae is a critical determinant of P. gingivalis 
adhesion to epithelial cells (Kato et al., 2007). 
 
fimA type Odds ratio 95% confidence interval P value 
I 0.20 0.1 – 0.4 0.0000 
Ib 6.51 2.9 – 14.6 0.0000 
II 77.80 31.1 – 195.4 0.0000 
III 2.51 1.1 – 5.8 0.0246 
IV 7.54 3.5 – 16.0 0.0000 
V 1.05 0.6 – 1.8 0.8525 
Table 1. Relationship of fimA types in chronic periodontitis 
P. gingivalis fimbriae possess a strong ability to interact with host proteins such as salivary 
proteins, extracellular matrix proteins, epithelial cells, and fibroblast, which promote the 
colonization of P. gingivalis to the oral cavity (Naito & Gibbons, 1988; Hamada et al., 1998). 
These bindings are specific and occur via protein-protein interactions through definitive 
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domain of Arg-gingipain prevented the P. gingivalis–induced alveolar bone loss in mice 
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domains of fimbriae and host proteins. The real-time observation by biomolecular 
interaction analysis (BIAcore) showed specific and intensive interaction to salivary proteins 
and extracellular matrix proteins (Table 2). The binding components in saliva are acidic 
proline-rich protein (PRP), proline-rich glycoprotein (PRG), and statherin (Amano et al., 
1996a, 1996b & 1998). P. gingivalis fimbriae also show significant interactions with 
extracellular matrix proteins including fibronectin and laminin (Kontani et al., 1996; Amano 
et al., 1999b). Therefore, P. gingivalis cells can bind to tooth surface and upper gingival 
crevice that is covered with saliva. Although a deeper portion of the gingival crevice could 
not be contaminated with saliva, P. gingivalis can bind directly to sulcular epithelial cells via 
interaction with extracellular matrix proteins. 
In addition, Arg-gingipains produced by P. gingivalis can enhance the adherence of purified 
fimbriae to fibroblasts and matrix proteins; Arg-gingipains can expose a cryptitope in the 
matrix protein molecule, i.e. the C-terminal Arg residue of the host matrix proteins, so that 
the organism can adhere to the surface layer in gingival crevices through fimbrial-Arg 
interaction (Kontani et al., 1996 & 1997). 
 
Host protein ka (1/M/s) Kdis (1/s) Ka (1/M) 
 PRP 2.61 x 103 1.60 x 10-3 1.63 x 106 
 PRG 3.38 x 103 2.08 x 10-3 1.62 x 106 
 Statherin 2.49 x 103 1.68 x 10-3 1.48 x 106 
 Laminin 3.62 x 103 1.68 x 10-3 2.15 x 106 
 Fibronectin 3.46 x 103 1.60 x 10-3 2.16 x 106 
 Thrombospondin 3.01 x 103 1.33 x 10-3 2.26 x 106 
 Type I collagen 3.04 x 103 1.10 x 10-3 2.76 x 106 
 Vitronectin 4.16 x 103 1.10 x 10-3 3.79 x 106 
 Elastin 3.72 x 103 1.21 x 10-3 3.08 x 106 
 Anti-fimbriae IgG 6.11 x 103 5.00 x 10-3 1.22 x 107 
Table 2. Binding constants of P. gingivalis fimbriae to host proteins 
In gingival crevices, serum antimicrobial components consecutively exude through the 
junctional epithelium, termed GCF. GCF originates from plasma exudates, thus contains 
IgG, IgA, complements and cellular elements. It is noted that 95% of the cellular elements 
are polymorphonuclear leukocytes (PMNL) and the remainder being lymphocytes and 
monocytes, even in the GCF from clinically healthy gingival crevices, indicating that PMNL 
are the principal cell of GCF (Genco & Mergenhagen, 1982). PMNL come into direct contact 
with plaque bacteria in the gingival crevice and actively phagocytose them. The protective 
function of PMNL in human periodontal diseases is demonstrated by the fact that patients 
with PMNL disorders, e.g. Chédiak-Higashi syndrome, lazy leukocyte syndrome, cyclic 
neutropeni, chronic granulomatous disease and diabetes mellitus, have usually rapid and 
severe periodontitis (Genco, 1996; da Fonseca & Fontes, 2000; Delcourt-Debruyne et al., 
2000; Meyle & Gonzáles, 2001; Lalla et al., 2007). Furthermore, quantitative analyses using 
flow cytometer revealed that about 50% of the patients with localized and generalized 
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aggressive periodontitis exhibited depression of phagocytic function of peripheral blood 
PMNL (Kimura et al., 1992 & 1993), suggesting that the functional abnormalities of PMNL 
are implicated in the pathogenesis of both forms of aggressive periodontitis. Thus, PMNL 
could play an important role in gingival crevices as innate immunity to prevent the 
colonization and/or proliferation of P. gingivalis, resulting in the arrest of periodontal 
diseases in healthy subjects.  
The gingival crevice is bathed in saliva that contains a lot of antibiotic agents, such as 
lysozyme, lactoferrin, peroxydase and secretary IgA. In addition, the sulcular epithelium 
acts as a physical barrier against intruders (Cimasoni, 1983). Furthermore, our recent study 
indicated that the sulcular epithelial cells could be a substantial producer of secretory 
leukocyte protease inhibitor (SLPI) that functions inhibitory to the pathogenic P. gingivalis 
infection (Ishikawa et al., 2010). SLPI has been recognized as not only a protease inhibitor 
but also an important defense component in innate immunity in mucosal secretory fluids. 
To elucidate the functional role in innate immunity in gingival crevices, we investigated the 
SLPI production from a gingival epithelial cell line, GE1, with or without the stimulation of 
the lyophilized whole cells of P. gingivalis (Pg-WC) and the LPS (Pg-LPS), and the inhibitory 
effect of SLPI on P. gingivalis proteases. The real-time RT-PCR analyses indicated that the 
unstimulated GE1 cells showed low, but significant levels of SLPI mRNA expression, which 
was augmented by the stimulation with Pg-LPS as well as Pg-WC (Fig. 1). The 
augmentation of SLPI mRNA expression in GE1 cells was accompanied by the inductions of 
IL-6, TNF-α and IL-1β mRNA expressions. Although it was reported that IL-6 could induce 
macrophages to produce SLPI, the kinetics analyses suggested that the augmentation of 
SLPI production in GE1 cells could not be a second response to the IL-6 induced by the 
stimulant, but a direct response by the P. gingivalis antigens. Further experiments using 
rSLPI indicated that SLPI showed a direct inhibitory effect on the P. gingivalis protease of 
Lys-gingipain (Fig. 2). Thus the results suggested that the SLPI production by gingival 
epithelial cells could increase in response to P. gingivalis through the stimulation with its 
pathogenic constituents. 
 
Fig. 1.  SLPI mRNA expression of GE1 cells and the augmentation with P. gingivalis LPS. 
GE1 cells were incubated without or with Pg-LPS or Pg-WC. The mRNA levels of SLPI were 
measured by real-time RT-PCR. Mean ± S.D. 
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Fig. 1.  SLPI mRNA expression of GE1 cells and the augmentation with P. gingivalis LPS. 
GE1 cells were incubated without or with Pg-LPS or Pg-WC. The mRNA levels of SLPI were 
measured by real-time RT-PCR. Mean ± S.D. 
 




Fig. 2. Inhibitory effect of SLPI on the Lys-gingipain activity. Proteolytic activity toward His-
Glu-Lys-MCA was measured with P. gingivalis extracellular proteases or trypsin without 
SLPI (open bar) or with 50 µg/ml (closed bar) and 100 µg/ml (dotted bar) of rSLPI. 
3. Invasion into gingival tissues 
Ultrastructural study demonstrated bacterial invasion in the apical gingiva of patients 
suffering from advanced chronic periodontitis (Frank, 1980; Saglie et al., 1986; Kim et al., 2010). 
In disease legions, the barrier of PMNL present in the gingival crevice (periodontal pocket) is 
insufficient to prevent plaque bacterial invasion of the pocket walls, and subgingival plaque 
bacteria including P. gingivalis penetrate gingival epithelium. The bacterial penetration and 
access to the connective tissue is augmented by enlargement of the intercellular spaces of the 
junctional epithelium caused by destruction of intercellular junctions. P. gingivalis Arg- and 
Lys-gingipains are involved in degradation of several types of intercellular junctions and 
extracellular matrix proteins in host tissues. Intercellular presence of subgingival plaque 
bacteria was specifically demonstrated in the regions. However, intracellular bacteria have not 
been inevitably noticed in the cases of advanced chronic periodontitis except bacteria in 
phagocytic vacuoles of PMNL by ultrastructural studies. 
On the other hand, invasion or internalization of P. gingivalis is observed in the cultures of 
gingival epithelial cells (Lamont et al., 1992 & 1995), oral epithelial KB cells (Duncan et al., 
1993), and aortic and heart endothelial cells (Deshpande et al., 1998). Invasion of bacteria is 
quantitated by the standard antibiotic protection assay using gentamicin and metronidazole. 
Under optimal inoculation conditions at a multiplicity of infection of 1:100, approximately 10% 
of P. gingivalis are recovered intracellularly from epithelial cells at 90 to 300 min after 
incubation. The invasion efficiency for KB cells and endothelial cells is reported to be much 
lower, around 0.1%. With these cells, adherence of P. gingivalis to the cell surface commonly 
induces microvilli protruding and the attached bacterial cells are surrounded by microbilli on 
the cell surface (Fig. 3A). Adherence of P. gingivalis to eukaryotic cell surface is relevantly 
mediated with fimbriae, and it was reported that a fimbriae-deficient mutant exhibited a 
greater reduction in invasion compared with adherence (Weinberg et al., 1997). Therefore, it is 
speculated that fimbrillin interacts with cell surface receptor, permitting P. gingivalis invasion. 
Among the six fimA types, the adhesion to a human epithelial cell line was more significant in 
P. gingivalis harboring the type II fimA than those with other fimA types. Accordingly, invasion 
of the type II fimA bacteria was most efficiently demonstrated (Nakagawa et al., 2002b). Host 
receptor candidates including β2 and α5β1-integrin have been reported to interact with  
P. gingivalis fimbrillin. 
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Following the attachment of P. gingivalis to cells, the invasion process requires the 
involvement of both microfilament (actin polymerization) and microtubule activities. This 
property is similar to those of N. gonorrhoeae and enteropathogenic E. coli. In addition, 
proteolytic activity is involved in P. gingivalis invasion, whereas de novo protein synthesis 
both in P. gingivalis and eukaryotic cells are not inevitably needed (Lamont et al., 1995; 
Deshpande et al., 1998).  
Although effects of staurosporine, a broad-spectrum inhibitor of protein kinases, on 
invasion are varied among targeted cells, protein phosphorylation is surely involved in P. 
gingivalis invasion. A recent report by Tribble et al. (2006) demonstrated that a haloacid 
dehalogenase family serine phosphatase, SerB653, secreted from P. gingivalis regulates 
microtubule dynamics in human immortalized gingival keratinocytes. The 
dephosphorylation activity of SerB653 is closely related to the optimal invasion and 
intracellular survival of the microorganism. The pull-down assay revealed Hsp90 and 
GAPDH as interactive candidates for SerB653. Both proteins are known to be 
phosphorylated and may play a role in modulation of microtubules for initiation of the 
bacterial invasion into epithelial cells. 
We have recently succeeded in monitoring the P. gingivalis invasion process into porcine 
carotid endothelial cells in culture by time-laps movie (a part of the results is shown as Fig. 
3B) (Hayashi M., Ohara-Nemoto, Y. & Kawamura, T., unpublished data of Cine-Science Lab. 
Co., Tokyo, Japan). Our movie clearly showed swift entering of the bacteria inside the cell 
through cell membrane. Intracellular movement of P. gingivalis was also observed, 
suggesting an interaction of the bacteria with microtubules. After 3-h invasion, P. gingivalis 
was located around the nuclei (Fig. 3B). This observation is in good accord with previous 
data, which showed accumulation of internalized recombinant FimA-microspheres around 
the epithelial cell nuclei (Nakagawa et al., 2002a). 
 
Fig. 3. Entry of P. gingivalis into endothelial cells. P. gingivalis ATCC 33277 was co-cultured 
with porcine carotid endothelial cells. (A) Scanning electron micrograph. P. gingivalis 
(observed in white) was surrounded by microvilli protruding from endothelial cell.  
Bar = 0.5 µm. (B) P. gingivalis inside the cell. A representative scene at 3 h after 
internalization from time-laps microscopic imaging with phase contrast microscopy. 
Arrowheads indicate P. gingivalis observed near the nucleus. 
Molecular events of intracellular signal transduction that occur after invasion of P. gingivalis 
have been poorly defined. P. gingivalis invasion induces transient increase in cytosolic Ca2+ 
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3B) (Hayashi M., Ohara-Nemoto, Y. & Kawamura, T., unpublished data of Cine-Science Lab. 
Co., Tokyo, Japan). Our movie clearly showed swift entering of the bacteria inside the cell 
through cell membrane. Intracellular movement of P. gingivalis was also observed, 
suggesting an interaction of the bacteria with microtubules. After 3-h invasion, P. gingivalis 
was located around the nuclei (Fig. 3B). This observation is in good accord with previous 
data, which showed accumulation of internalized recombinant FimA-microspheres around 
the epithelial cell nuclei (Nakagawa et al., 2002a). 
 
Fig. 3. Entry of P. gingivalis into endothelial cells. P. gingivalis ATCC 33277 was co-cultured 
with porcine carotid endothelial cells. (A) Scanning electron micrograph. P. gingivalis 
(observed in white) was surrounded by microvilli protruding from endothelial cell.  
Bar = 0.5 µm. (B) P. gingivalis inside the cell. A representative scene at 3 h after 
internalization from time-laps microscopic imaging with phase contrast microscopy. 
Arrowheads indicate P. gingivalis observed near the nucleus. 
Molecular events of intracellular signal transduction that occur after invasion of P. gingivalis 
have been poorly defined. P. gingivalis invasion induces transient increase in cytosolic Ca2+ 
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concentration in gingival epithelial cells, suggesting an involvement of a Ca2+-dependent 
signaling pathway (Izutsu et al., 1996). P. gingivalis internalization inhibits secretion of IL-8 
by gingival epithelial cells (Darveau et al., 1998; Nassar et al., 2002), whilst interaction via 
integrin induced expression of IL-1β and TNF-α genes in mouse peritoneal macrophages 
(Takeshita et al., 1998). Since challenge of oral bacterial substances or purified P. gingivalis 
LPS to an immortal mouse gingival epithelial cell line GE1 induced gene expression of IL-
1α, IL-1β, IL-6, TNF-α and SLPI (Hatakeyama et al., 2001; Ishikawa et al., 2010), the cytokine 
production may be induced not only by bacterial invasion but also via a Toll-like receptor 
pathway activated by pathogen-associated molecular patterns in host cells. These findings 
raise a possibility that signal transduction caused by P. gingivalis invasion modulates cell 
promotion, resulting in gingival tissue destruction. 
We monitored the dysfunction of endothelial cells for the first time on co-culture with P. 
gingivalis ATCC 33277 by time-laps microscopic imaging. Endothelial cell attachment 
became loose at 3 h after bacterial inoculation. Furthermore, cell atrophy was evident at 22 h 
(Fig. 4) (Hayashi M., Ohara-Nemoto, Y. & Kawamura, T., unpublished data). Therefore, it is 
of interest whether cellular dysfunction is caused by P. gingivalis invasion into host cells or 
mediated by intercellular signaling through host cell surface. 
 
Fig. 4. Dysfunction of endothelial cells caused by co-culture with P. gingivalis. Porcine 
carotid endothelial cells were cultured with P. gingivalis ATCC 33277 at 37C. Time-laps 
microscopic imaging was taken for 22 h. (A) Normal endothelial cells. Images at 3 h (B) and 
22 h (C) after addition of P. gingivalis. Bar = 30 µm. 
4. Induction of inflammatory responses 
Chronic periodontitis is recognized as a B-cell-rich lesion that includes immunoglobulin G-
producing plasma cells. However, the immunohistopathological studies revealed that B cell 
activation in periodontitis lesions by substances from plaque bacteria is, at least in major 
part, polyclonal, since the immunoglobulin showed a broad spectrum of antibody 
specificities, as is expected of polyclonal activation (Page, 1982). LPS from the outer 
membrane of gram-negative bacteria elicits a wide variety of responses that may contribute 
to inflammation and host defense. LPS stimulates various cell types including pre-B cells 
and B cells, and LPS activates most B cells (polyclonal B cell activation) without regard to its 
antigen specificity (Snow, 1994). Although P. gingivalis LPS is composed of unique 
constituents and exhibits characteristic immunological activities (Fujiwara et al., 1990 & 
1994; Kimura et al., 1995 & 2000b), P. gingivalis LPS can be a potent polyclonal activator of B 
cells (Mihara et al., 1994), thus, it appears that P. gingivalis LPS could play a central role in 
the B cell activation in periodontitis lesions.  
 
Pathogenic Factors of P. gingivalis and the Host Defense Mechanisms 
 
11 
P. gingivalis LPS in gingival tissues could not only elicit a wide variety of responses of gingival 
fibroblasts and periodontal ligament fibroblasts to produce inflammatory cytokines (Agarwal 
et al., 1995; Yamaji et al., 1995), but also modulate immunocompetent cell responses, especially 
B cell activation, that may deteriorate the inflammatory condition. The immunoregulatory 
disorder is demonstrated in chronic periodontitis patients (Kimura et al., 1991).   
It is also possible that the proteolytic enzymes of gingipains and collagenase produced by  
P. gingivalis could destroy periodontal tissue directly or indirectly, leading the progression 
of the disease (Holt et al., 1999; Potempa et al., 2000). Moreover, the organic metabolites 
such as ammonia, propionate and butyrate could exhibit the ability of disruption of the host 
immune system and the toxicity against the gingival epithelium (Tsuda et al., 2010). Thus, in 
chronic periodontitis, the pathogenic factors of P. gingivalis could contribute to the gingival 
inflammation in diverse ways, which results in the alveolar bone losses. 
5. Induction of alveolar bone losses 
In order to investigate the host-parasite relationship in periodontal diseases, animal models 
are critically important, since they provide the information about the complex pathogenic 
mechanism in periodontal diseases. To date, various models including rodents, rabbits, pigs, 
dogs, and nonhuman primates, have been used to model human periodontitis, and there are 
clear evidences from the literatures demonstrating alveolar bone losses in the animals 
infected with P. gingivalis (Holt et al., 1988; Kimura et al., 2000a, Wang et al., 2007; Oz & 
Puleo, 2011). In rodent models, however, a relatively large number of bacteria have often 
been used for a successful establishment (Klausen, 1991), since some periodontopathic 
bacteria including P. gingivalis are reported to be not easily established in the murine mouth 
(Wray & Grahame, 1992). In many instances, 108-109 bacteria in the suspension were applied 
into the oral cavity two or three times, with or without ligation (Oz & Puleo, 2011). In these 
studies, therefore, the precise inoculum size of the bacteria into the gingival crevice was 
unknown. Furthermore, it is possible that the pathogenicity of the bacteria with higher 
activity in the initial colonization in the oral cavity may have been overestimated, regardless 
of their bone resorbing potential. Then, we developed P. gingivalis-adhered ligatures on 
which 4.29 ± 0.23 logCFU/mm of P. gingivalis 381 cells were pre-adhered, and had applied it 
(1 X 105 P. gingivalis cells per mouse) on the first molar in the right maxillary quadrant of a 
mouse with sterile instruments (Kimura et al., 2000a). P. gingivalis was recovered in 95% of 
the infected mice on 1 week, and 58% on 15 weeks after the single infection with a  
P. gingivalis-adhered ligature in mouse gingival sulcus, indicating that, by means of this 
method, the establishment of P. gingivalis in murine mouths is not transient. The long-lasting 
infection of P. gingivalis in mice resulted in the site-specific alveolar bone breakdown on 
weeks 13 to 15, although sham-infected mice showed some alveolar bone breakdown in the 
ligation sites. These findings are supported by the linear regression analysis showing a 
significant positive correlation between the number of recovered P. gingivalis and alveolar 
bone loss. Furthermore, the P. gingivalis-induced alveolar bone loss seemed to be localized 
around the infected site. Thus, it is strongly suggested that the colonization of a critical 
amount of P. gingivalis for a certain period in gingival crevices may cause the periodontal 
breakdown at the site of colonization. 
P. gingivalis could induce alveolar bone loss in diverse ways; P. gingivalis could influence 
both bone metabolism by Toll-like receptor signaling and bone remodeling by the receptor 
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In order to investigate the host-parasite relationship in periodontal diseases, animal models 
are critically important, since they provide the information about the complex pathogenic 
mechanism in periodontal diseases. To date, various models including rodents, rabbits, pigs, 
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ligation sites. These findings are supported by the linear regression analysis showing a 
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around the infected site. Thus, it is strongly suggested that the colonization of a critical 
amount of P. gingivalis for a certain period in gingival crevices may cause the periodontal 
breakdown at the site of colonization. 
P. gingivalis could induce alveolar bone loss in diverse ways; P. gingivalis could influence 
both bone metabolism by Toll-like receptor signaling and bone remodeling by the receptor 
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activator of NF-κB (RANK) signaling (Zhang et al., 2011). Among the pathogenic factors of 
P. gingivalis, a major causative factor in alveolar bone losses may be ascribed to the LPS. P. 
gingivalis LPS can induce in vitro the osteoclast formation directly, and also indirectly by the 
cytokine production from gingival fibroblasts (Slots and Genco, 1984; Zubery, 1998; Scheres 
et al., 2011). Moreover, an in vivo study indicated that P. gingivalis LPS injection resulted in 
significantly more bone loss versus PBS injections in both the rats with and without diabetes 
on normal diets (Kador et al., 2011).  
In addition, an alternative hypothesis of etiology of development/onset of chronic 
periodontitis, ‘polymicrobial pathogenicity’, has been proposed, although a number of 
findings supporting the pathogenicity of P. gingivalis in periodontal diseases. The 
hypothesis is based on the observation in periodontitis patients that the colonization of  ‘red 
complex species’ (P. gingivalis, T. denticola and T. forsythensis) strongly related to pocket 
depth and bleeding on probing (Socransky et al., 1998), and in a rat model that the rats 
infected with the polymicrobial consortium of the ‘red complex species’ exhibited 
significantly increased alveolar bone loss compared to those in the rats infected with one of 
the microbes (Kesavalu et al., 2007). However, the synergistic pathogenicity is still 
controversial; Orth et al. (2011) reported that co-inoculation with P. gingivalis and T. denticola 
induced alveolar bone losses synergistically in a murine model, whereas no synergistic 
virulence of the mixed infection with P. gingivalis and T. denticola was showed in a rat 
experimental periodontitis model (Verma et al., 2010).  
The hypothesis of the synergistic polymicrobial pathogenicity does not exclude the 
pathogenicity of P. gingivalis, but acknowledges also the significant role of the local 
environmental conditions in subgingival plaques that could govern the periodontopathic 
potential of P. gingivalis. Further studies are obviously required to elucidate the mechanism 
of the polymicrobial pathogenicity in periodontal breakdown and what kinds of putative 
periodontopathic bacteria could participate in the synergistic pathogenicity with P. 
gingivalis. 
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induced alveolar bone losses synergistically in a murine model, whereas no synergistic 
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The hypothesis of the synergistic polymicrobial pathogenicity does not exclude the 
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environmental conditions in subgingival plaques that could govern the periodontopathic 
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1. Introduction  
Exopolysaccharide (EPS) productivities in many bacteria have been associated with 
pathogenicity in mammalian hosts as providing extracellular matrices to form biofilm  
(Costerton et al., 1995). Bacteria assuming biofilm-forming capacity have enormous 
advantages in establishing persistent infections (Costerton et al., 1999). Chronic periodontitis 
is caused by dental plaque known as a complex biofilm which consists of several hundred 
different species of bacteria (Chen, 2001; Socransky and Haffajee, 2002; Lovegrove, 2004). 
While sucrose-derived homopolysaccharides are well known substrates which mediate 
adhesion of bacteria to the tooth surface and co-aggregation interactions between species of 
oral bacteria in the dental plaque (Russell, 2009), recent studies suggest that each bacterium 
produces distinctive EPS components in a sucrose-independent manner and can form so 
called single species biofilm (Branda et al., 2005). In the oral cavity, several species of oral 
bacteria are known to produce their own EPS with this manner (Okuda et al., 1987; Dyer 
and Bolton, 1985; Kaplan et al., 2004; Yamane et al., 2005; Yamanaka et al., 2009; Yamanaka 
et al., 2010). In this chapter, we will describe a possibility that a single species biofilm in the 
oral cavity can cause persistent chronic periodontitis along with the importance of dental 
plaque formation and maturation with sucrose-derived polysaccharides. 
2. Dental plaque formation with sucrose-derived polysaccharides 
Dental plaque is defined as a community of oral bacteria on a tooth surface in which 
microorganisms are found embedded in EPS and intimately communicate each other via 
several different communication pathways such as auto-/co-aggregation, metabolic 
communication, quorum sensing and competent stimulation peptides (Rickard et al., 2008). 
A recent study using pyrosequencing technique showed that dental plaque harbors nearly 
7000 species-level phylotypes (Keijser et al., 2008). Therefore, dental plaque is described as 
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mix-/multi-species biofilm as well. A widely accepted theory of dental plaque formation is 
an organized sequence of events (Marsh, 2004). 1) The enamel surface of tooth is covered by 
acquired pellicle which consists of salivary proteins. 2) Initial colonizers of oral bacteria 
adhere on the tooth surface via physico-chemical interactions between the bacterial cell 
surface and the pellicle matrices, and then establish firmer adhesin-receptor mediated 
attachment. A study (Nyvad and Kilian, 1987) using cultivation technique showed that the 
initial colonizers are predominated by streptococci such as Streptococcus sanguinis, 
Streptococcus oralis and Streptococcus mitis. Gram-positive rod Actinomyces spp, veillonellae, 
and Rothia mucilaginosa were frequently found in the early stage of plaque formation (Nyvad 
and Kilian, 1987). After the colonization of these pioneers, bacteria that have 
glucosyltransferase (GTF) or fructosyltransferase (FTF) start to provide sucrose-derived EPS 
as plaque substrates (Russell, 2009). The EPS can be soluble or insoluble and the latter make 
a major contribution to the structural integrity of dental plaque and can consolidate the 
attachment of bacteria in dental plaque. Among previously known initial colonizers, S. 
sanguinis can provide water-soluble/insoluble EPSs because this organism possesses both 
GTF and FTF. In this environmental niche, co-adhesion between initial colonizers and 
secondary colonizers occurs. 4) Then, more secondary species adhere to the developing 
dental plaque resulting in the increased number of bacteria through the continued 
integration and cell divisions (Rickard et al., 2008). 5) When dental plaque as multi-species 
biofilm has developed and become matured, the flora gradually changes from Gram-
positive cocci and Actinomyces to the one containing certain amount of Gram-negative 
organisms (Chen, 2001; Herrera et al., 2008; Paster et al., 2001; Socransky et al., 1998). The 
change in dental plaque flora is also associated with the extension of the plaque 
subgingivally, and it is evidently shown that this phenomenon causes the plaque-associated 
complex symptoms in periodontal tissues (Darby and Curtis, 2001; Dahlen, 1993). This 
theory well explains the dental plaque formation, maturation and the plaque-associated 
complex in modern day since the production and consumption of sucrose increased 
dramatically in nineteenth century. However, considering the facts that ancient specimens 
showed carious lesions localized on the root surfaces and simultaneous absence of coronal 
lesions, oral microorganisms might have a strategy in sucrose-independent manner to form 
dental plaque on the tooth surface around the gingival crevice. The periodontal bone loss is 
also found on the ancient specimens (Meller et al., 2009; Gerloni et al., 2009). Therefore, it is 
conceivable that the dental plaque developed in sucrose-independent manner could be 
pathogenic for periodontal tissues and can cause chronic periodontitis lesions. 
2.1 Initial colonizers on the tooth surface and their capacity to form biofilm  
More recent studies using molecular methods and a retrievable enamel chip model have 
revealed a new line-up of initial colonizers though the early dental plaque microflora varies 
at subject-specific basis (Diaz et al., 2006; Kolenbrander et al., 2005). In initial plaque on the 
chip at four to eight hours, Streptococcus spp. was dominant while Veillonella, Gemella, 
Prevotella, Niesseria, Actinomyces and Rothia were also frequently found. Among streptococci, 
S. oralis, S. mitis, S. infantis, S. sanguinis, S. parasanguinis, S. gordonii, S. cristatus and S. bovis 
were found in the early dental plaque. Although this bacterial community can be given 
substrates by bacteria which synthesize EPS in sucrose-dependent manner, we recently 
found that several bacteria newly nominated as initial colonizers have the ability to produce 
their own EPS in sucrose-independent manner and to form biofilms.  
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The presence of dense meshwork structures under scanning electron microscopy (SEM) is a 
typical feature for biofilm forming organisms. The appearances of Escherichia hermannii  
(Yamanaka et al., 2010) with or without EPS production in SEM observation are shown in 
Figure 1. E. hermannii YS-11 isolated from persistent apical periodontitis lesions produced 
EPS and exhibited cell surface meshwork structures (Fig. 1A). The meshwork structures of 
E. hermannii YS-11 disappeared when wzt, one of the ABC-transporter genes, was disrupted 
by transposon random insertion mutagenesis (Fig. 1B). Complementation of this gene to the 
transposant restored and dramatically augmented the formation of meshwork structures 
(Fig. 1, C and D). Such phenotypes are similar to those of Pseudomonas aeruginosa, a 
prototype of biofilm-forming bacteria (Kobayashi, 1995; Yasuda et al., 1999), Escherichia coli 
(Prigent-Combaret et al., 2000; Uhlich et al., 2006), Salmonella (Anriany et al., 2001; Jain and 
Chen, 2006), and Vibrio cholerae (Wai et al., 1998).  
 
Fig. 1. Scanning electron micrographs showing surface structures of Escherichia hermannii 
strain YS-11 (A; wild type), strain 455 (B; wzt- transposant) and strain 455-LM  
(strain 455 with pWZT; C: without IPTG induction; D: with IPTG induction). Bars = 3 μm  
When we observed the surface structures of isolates from saliva of healthy volunteers or 
from chronic peripheral periodontitis lesions by SEM, similar cell surface-associated 
meshwork-like structures were observed on Neisseria, S. parasanguinis, S. mitis, Rothia 
dentocariosa, Rothia mucilaginosa (Yamane et al., 2010), Prevotella intermedia (Yamanaka et al., 
2009), Prevotella nigrescens (Yamane et al., 2005) and Actinomyces oris (Fig. 2). We have 
investigated the clinical isolates of P. intermedia and P. nigrescens with meshwork structures 
and found that the organisms can produce their own unique EPS in sucrose-independent 
manner (see below). However, it is still unclear whether other initial colonizers posses the 
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Fig. 1. Scanning electron micrographs showing surface structures of Escherichia hermannii 
strain YS-11 (A; wild type), strain 455 (B; wzt- transposant) and strain 455-LM  
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meshwork structures with the same manner. It is important to note that similar tubule-like 
structures are formed by bacterial nanotubes (Dubey and Ben-Yehuda, 2011) or amyloids 
(Dueholm et al., 2010).  
 
Fig. 2. Scanning electron micrographs showing cell surface structures of oral bacteria known 
as initial colonizers. A colony of each clinical isolate was used for SEM observation and 
identification by 16S rRNA gene sequencing. Bars = 2 μm.  
2.1.1 Single species biofilm with unique EPS production on the outside of oral cavity 
Practically all bacteria living in their own environmental niche have the capacity to form 
biofilm by a self-synthesized matrix that holds the cells together and tightly attaches the 
bacterial cells to the underlying surface. Polysaccharide is a major component of the matrix 
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in most bacterial biofilms although recent studies have shown that constituents of biofilm 
matrix vary and that extracellular nucleic acids (Wu and Xi, 2009) or secreted proteins 
(Latasa et al., 2006) are also used as the matrix. Recent investigations have revealed that each 
biofilm-forming bacterium produces distinctive EPS components e.g. alginate and/or Psl 
found in P. aeruginosa (Ryder et al., 2007), acidic polysaccharide of Burkholderia cepacia 
(Cerantola et al., 1999), collanic acid, poly-β-1,6-GlcNAc (PGA) or cellulose found in E. coli 
(Junkins and Doyle, 1992) (Wang et al., 2004; Danese et al., 2000), cellulose of Salmonella 
(Solano et al., 2002; Zogaj et al., 2001), amorphous EPS containing N-acetylglucosamine 
(GlcNAc), D-mannose, 6-deoxy-D-galactose and D-galactose of V. cholerae (Wai et al., 1998; 
Yildiz and Visick, 2009), polysaccharide intercellular adhesin (PIA) of Staphylococcus (Rupp 
et al., 1999), and glucose and mannose rich components found in Bacillus subtilis biofilm 
(Hamon and Lazazzera, 2001; Ren et al., 2004; Yamane et al., 2009). An enteric pathogen 
Campylobacter jejuni produces EPS that reacts with calcofulor white, indicating the 
polysaccharide harbors β1-3 and/or β1-4 linkages. The production of this EPS is 
considered to be involved in the stress response of this organism together with its surface-
associated lipooligosaccharide and capsular polysaccharides (McLennan et al., 2008). 
Persistent infections caused by biofilm-forming bacteria have been abundantly reported, 
however, understanding the molecular basis for the synthesis of biofilm matrices is still 
limited. The bacteria assuming the ability to produce their own polysaccharides and causing 
infectious diseases (biofilm infections) are listed in Table 1. 
 
EPS-producing bacteria Constituents of EPS Biofilm infection 
Pseudomonas aeruginosa 
Alginate, Psl (mannose- and galactose- 
rich polysaccharide) or Pel (glucose 
rich polysaccharide) 
Cystic fibrosis pneumonia, 
contact lenses infection, 
central venous catheter 
infections 
Burkholderia cepacia Acidic branched heptasaccharide Cystic fibrosis pneumonia (cepacia syndrome) 
Escherichia coli Cellulose, colonic acid or poly-β-1,6- GlcNAc (PGA) 
Intestinal disorders, urinary 
tract infections, urinary 
catheter infections 
Vibrio cholerae Glucose- and galactose-rich polysaccharide 
Cholera, diarrheal diseases 
(the EPS protects this 
organism from environ- 
mental stress) 
Salmonella enterica serovar 
Typhimurium Cellulose Gastroenteritis 
Staphylococcus aureus 
Staphylococcus epidermidis 
Staphylococcal polysaccharide  
intercellular adhesion (PIA) 
Endocarditis, central 
venous catheter infections, 
urinary catheter infections 
Bacillus subtilis Glucose- and mannose-rich polysaccharide  
Opportunistic infections, 
apical periodontitis 
Campylobacter jejuni EPS contains β1-3 and/or β1-3 linkages Bacterial gastroenteritis 
Table 1. EPS-producing bacteria on the outside of oral cavity, constituents of EPS and 
related diseases. 
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Oral streptococci such as anginosus group, mitis-group and salivarius-group and Rothia are 
known to cause biofilm infections on prosthetic heart valves and artificial voice prosthesis 
(Donlan, 2001). Interestingly, some clinical isolates of Streptococcus intermedius and 
Streptococcus salivarius exhibit dense meshwork structures around their cells suggesting 
these organisms can form single species biofilm on medical devices though we still do not 
know the constituents of the matrices (Matsumoto-Mashimo et al., 2008) (Fig. 3). 
 
Fig. 3. Scanning electron micrographs showing cell surface structures of clinically isolated  
S. intermedius and S. salivarius. Bars = 2 μm.  
2.1.2 Biofilm-forming bacteria from chronic periodontitis lesions and the chemical 
composition of their EPS  
As described above, several periodontopathic bacteria are known to produce EPS or 
capsular polysaccharides. The production of mannose-rich polysaccharide by 
Capnocytophaga ochracea has been reported (Dyer and Bolton, 1985). The mannose-rich EPS 
provides this organism with a protection from attack by the human innate immune 
system (Bolton et al., 1983). Kaplan et al. (2004) reported that Aggregatibacter 
actinomycetemcomitans has a gene cluster which is homologous to E. coli pgaABCD and 
encodes the production of poly-ß-1,6-GlcNAc (PGA) (Wang et al., 2004). We found that P. 
intermedia strain 17 produced a large amount of EPS, with mannose constituting more 
than 80% of the polysaccharides (Yamanaka et al., 2009). The growth of strain 17 was 
slower than that of P. intermedia ATCC 25611 (a reference strain for P. intermedia). 
Viscosity of spent culture media of strain 17 was higher than that of ATCC 25611. 
Transmission electron microscopy of negatively stained purified EPS showed fine fibrous 
structures that are formed in bundles. Meshwork structures were represented on latex 
beads coated with the purified EPS (Fig. 4).  
We have also reported that a clinical isolate of P. nigrescens can produce a copious amount of 
EPS consisting of mannose (88%), glucose (4.3%), fructose (2.7%), galactose (2.1%), arabinose 
(1%) and small amounts of xylose, rhamnose and ribose. Methylation analysis suggested 
that the EPS is composed of highly branched (1-2)-linked mannose residues (Yamane et al., 
2005). Okuda et al. (1987) reported that P. intermedia 25611, Porphyromonas gingivalis 381 and 
P. gingivalis ATCC 33277 had capsular structures around the cells and that the capsular 
polysaccharides extracted from P. gingivalis 381 contained galactose and glucose as their 
major constituents. P. gingivalis W83 is known to produce capsular polysaccharides, and the 
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genetic locus for capsule biosynthesis has been identified (Aduse-Opoku et al., 2006). 
However, these reference strains in our laboratory do not produce capsular polysaccharide 
or EPS. One possibility is that the tested strains had lost their ability to produce capsular 
polysaccharides or EPS because of multiple in vitro passages of the organisms in the 
laboratory. Although the molecular basis for biofilm formation in Rothia still needs to be 
elucidated, Yamane et al. (2010) determined the whole genome sequence of R.mucilaginosa 
DY-18, a clinical isolate from persistent apical periodontitis lesions with an ability to 




Fig. 4. Comparison of growth (A), viscosity of spent culture media (B) and phenotype 
between P. intermedia strain 17 and ATCC 25611. Bars in C = 1 μm. Transmission electron 
micrograph of negatively stained purified EPS from P. intermedia 17 cultures (D).  
Bar = 500 nm. Meshwork structures represented on EPS-coated latex beads  
(2 μm in diameter)(E). Bars = 5 μm. 
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2.1.3 EPS productivity and biofilm phenotype as virulence factors  
It is evidently shown that the slime/EPS production is critical for bacteria to exhibit the 
resistance to the neutrophil phagocytosis, though some EPS are not essential to bacterial 
adherence to host cells or for systemic virulence. Jesaitis et al. (2003) demonstrated that 
human neutrophils that settled on P. aeruginosa biofilms became phagocytically engorged, 
partially degranulated, and engulfed planktonic bacteria released from the biofilms. 
Deighton et al. (1996) compared the virulence of slime-positive Staphylococcus epidermidis 
with that of slime-negative strain in a mouse model of subcutaneous infection and 
showed that biofilm-positive strains produced significantly more abscesses that persisted 
longer than biofilm-negative strains. Our previous studies showed that P. nigrescens as 
well as P. intermedia with mannose-rich EPS showed stronger ability to induce abscesses 
in mice than those of a naturally occurring variant or chemically-induced mutant that lack 
the ability to produce EPS. TEM observations revealed that test strains with mannose-rich 
EPS appeared to be recognized by human neutrophils but not internalized (Yamane et al., 
2005; Yamanaka et al., 2009). Leid et al. (2002) have shown that human neutrophils can 
easily penetrate S. aureus biofilms but fail to phagocytose the bacteria. Similarly, in the 
murine model of systemic infection, the deletion of ica locus necessary for the biosynthesis 
of surface polysaccharide of S. aureus significantly reduces its virulence. A study in the 
early 1970s clearly showed that addition of the slime from P. aeruginosa cultures to E. coli 
or S. aureus dramatically inhibited phagocytosis by neutrophils (Schwarzmann and Boring 
III, 1971). In our previous study, we observed the restoration of the induction of abscess 
formation in mice when the purified EPS from the biofilm-forming strain of P. nigrescens 
was added to the cultures of a biofilm-non-forming mutant and injected into mice 
(Yamane et al., 2005). Though we have to carefully investigate the possibility that multiple 
mutations exist in EPS negative variants and lead to the observed incapability to induce 
abscesses in mice, it is conceivable that biofilm bacteria being held together by EPS might 
present a huge physical challenge for phagocytosing neutrophils. As a consequence of 
these neutrophils being frustrated by their inability to phagocytose this bacterial mass, 
this might trigger the unregulated release of bactericidal compounds that could cause 
tissue injury as shown in the inflammatory pathway associated with lung injury or 
chronic wounds (Moraes et al., 2006; Bjarnsholt et al., 2008). The cellular components from 
neutrophils themselves are known to exert a stimulatory effect on the developing P. 
aeruginosa biofilm when the host fails to eradicate the infection. We recently compared the 
level of pathogenicity on the clinical strains of P. intermedia with EPS productivity to those 
of several laboratory reference strains of periodontopathic bacteria (P.intermedia ATCC 
25611, P. gingivalis ATCC 33277, P. gingivalis 381 and P. gingivalis W83; strains without 
producing polysaccharides as described above) in terms of the abscess formation in mice. 
EPS-producing P. intermedia strains 17 and OD1-16 induced abscess lesions in mice at 107 
CFU, but other periodontopathic bacteria did not when tested at this cell concentration 
(Yamanaka et al. 2011). Resistance of P. intermedia with EPS productivity against the 
phagocytic activity of human neutrophils was stronger than those of P. intermedia ATCC 
25611 and P. gingivalis ATCC 33277 that lack the capacity to produce polysaccharides (Fig. 
5). Therefore, it is plausible that the antiphagocytic effect of EPS confers the ability to P. 
intermedia to induce abscess in mice at a small inoculation size. 
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Fig. 5. Resistance of EPS-producing P. intermedia strain 17 against the phagocytic activity of 
human neutrophils. Test strains were co-cultured with human neutrophils for 90 min. 
Under transmission electron microscopy (TEM), 30 neutrophils were arbitrarily selected, 
and the number of bacterial cells engulfed in each cell was counted. Strain 17 cells were not 
engulfed by neutrophils. In contrast, P. intermedia ATCC 25611 and P. gingivalis ATCC 33277 
cells were internalized and found within cytoplasmic vacuoles.  
3. Conclusion 
The matured dental plaque via the ordered sequence of events is undoubtedly a very 
important reservoir of periodontopathic pathogens. However, combined recent evidences 
together, it is plausible that initial colonizers including Gram-negative anaerobes can form 
biofilm by a self-synthesized matrix. If the initial colonizers assume an ability to produce 
EPS, this could contribute to the pathogenicity of the organisms by conferring their ability to 
evade the host’s innate defense response. Some of the initial colonizers who have formed 
their own biofilm might be recognized by neutrophils in the gingival crevice but the 
neutrophils can not eradicate the bacterial cells due to the existence of EPS as the matrix of 
biofilm. This could be one of many etiologies of tissue injury found in chronic periodontitis 
lesions. Our hypothetical idea is described in Figure 6.  
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Fig. 6. Schematic depiction of tissue injury by neutrophils frustrated with unsuccessful 
phagocytosis of EPS-producing bacterial cells.  
Finally, it is important to point out that many virulence phenotypes, especially the EPS 
productivity, expressed in natural environmental niches could be immediately lost through 
laboratory passages (Fux et al., 2005). Therefore, freshly isolated clinical strains are needed 
to re-evaluate the pathogenicity of periodontopathic bacteria isolated from the dental plaque 
or periodontal lesions.  
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Periodontitis is a chronic infection that results from the interaction of periodontopathogenic 
bacteria and host inflammatory and immune responses and is the most common bacterial 
infection worldwide. Estimates reveal that 10-15 % of adults have advanced periodontitis, 
and periodontal disease can contribute to widespread oral health dysfunction and enhanced 
susceptibility to other systemic diseases (Pussinen et al. 2007).  
Bacterial biofilms are regarded to be the primary aetiological factor in the initiation of 
gingival inflammation and subsequent destruction of periodontal tissues (Offenbacher 1996) 
and three major specific pathogens have been repeatedly identified as etiologic agents, 
namely Aggregatibacter (Actinobacillus) actinomycetemcomitans (Aa), Porphyromonas gingivalis 
(Pg) and Tannerella forsythia (Tf) (Socransky et al. 1998). Although chronic exposure to 
bacteria and their products is a prerequisite for gingival inflammation and periodontal 
tissue destruction to occur, the major causative factor of soft- and hard- tissue breakdown 
associated with periodontitis is currently attributed to the host’s immune-inflammatory 
response to bacterial challenge. Furthermore, the nature of the inflammatory response might 
determine the destructive character of the disease (Gemmell, Yamazaki, and Seymour 2002). 
The theoretical manner in which periodontal disease progresses has long been a subject of 
debate. It is currently agreed that destructive periodontal disease progresses by means of 
asynchronous bursts of activity (Haffajee and Socransky 1986). According to this theory, 
periodontal tissue support is lost during short, acute episodes followed by prolonged 
periods of quiescence (Reddy, Palcanis, and Geurs 1997). This model implies that etiologic 
factors involved in periodontal tissue destruction would change according to the sequential 
occurrence of episodes of disease activity and quiescence or remission. 
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Periodontitis is a chronic infection that results from the interaction of periodontopathogenic 
bacteria and host inflammatory and immune responses and is the most common bacterial 
infection worldwide. Estimates reveal that 10-15 % of adults have advanced periodontitis, 
and periodontal disease can contribute to widespread oral health dysfunction and enhanced 
susceptibility to other systemic diseases (Pussinen et al. 2007).  
Bacterial biofilms are regarded to be the primary aetiological factor in the initiation of 
gingival inflammation and subsequent destruction of periodontal tissues (Offenbacher 1996) 
and three major specific pathogens have been repeatedly identified as etiologic agents, 
namely Aggregatibacter (Actinobacillus) actinomycetemcomitans (Aa), Porphyromonas gingivalis 
(Pg) and Tannerella forsythia (Tf) (Socransky et al. 1998). Although chronic exposure to 
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associated with periodontitis is currently attributed to the host’s immune-inflammatory 
response to bacterial challenge. Furthermore, the nature of the inflammatory response might 
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periods of quiescence (Reddy, Palcanis, and Geurs 1997). This model implies that etiologic 
factors involved in periodontal tissue destruction would change according to the sequential 
occurrence of episodes of disease activity and quiescence or remission. 
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Determination of periodontal diagnosis and the extent and severity of periodontal tissue 
damage through standard periodontal assessment has traditionally been based on an array 
of clinical measurements, including probing depth (PD), clinical attachment level (CAL), 
bleeding on probing (BOP), plaque index (PI) and radiographic findings. Though disease 
activity is generally associated to the loss of soft or hard tissue attachment to the tooth, 
recording of clinical attachment by periodontal probing at sequential examinations is the 
most common method to diagnose a progressive periodontal disease (Reddy, Palcanis, and 
Geurs 1997). However, clinical measurements provide information about past periodontal 
tissue destruction and do not elucidate the current state of the disease activity nor predict 
the future bone resorption (Armitage 2004). Thus, despite the value of these clinical 
methods, such techniques often result in inconsistent diagnoses, as well as an inability to 
reliably predict a patient´s response to treatment (Offenbacher et al. 2007). A reason for the 
limited success in predicting the future course of disease in some individuals is that the 
clinical phenotype does not reflect the underlying biologic processes that occur at the 
biofilm-gingival interface (Offenbacher et al. 2007). 
The biologic phenotype underlying chronic periodontitis, including the biofilm and the host 
response, tend to vary among individuals despite a similar clinical diagnostic category 
(Offenbacher et al. 2007). Consequently, disease screening should ideally be based on 
clinical determinations and the biologic phenotype (Page and Kornman 1997). Other 
associated factors include environmental exposures, as well as differences in genetic and 
possibly epigenetic composition (Page and Kornman 1997). 
The biological changes underlying the transition process from gingival health to early 
inflammatory changes involve local increase in vascular permeability, edema and the 
recruitment and activation of polymorphonuclear neutrophils (PMN) (Delima and Van 
Dyke 2003). Acquired immune response becomes involved once antigen-presenting cells 
interact with immunocompetent cells, such as T and B lymphocytes, leading to the 
expansion of antibody-secreting plasma cells and the development of the chronic lesion 
(Gemmell and Seymour 2004). Bacterial–host interactions at the biofilm–periodontium 
interface trigger the synthesis of cytokines and other inflammatory mediators that promote 
the release of enzymes and bone-associated molecules that finally induce the alterations of 
the connective tissue metabolism and the destruction of the tooth supporting alveolar bone 
(Bhavsar, Guttman, and Finlay 2007; Graves 2008; Houri-Haddad, Wilensky, and Shapira 
2007).  
In addition to local periodontal tissue involvement, chronic infection of the periodontium 
together with continuous up-regulation of pro-inflammatory responses and immune 
mediators may contribute to systemic sequel including diabetes, preterm delivery of low-
weight birth babies, lung inflammation, arthritis and cardiovascular diseases (CVD). In fact, 
numerous case-control and cohort studies have demonstrated that periodontitis patients 
exert increased risk for CVD, acute myocardial infarction (AMI), peripheral arterial disease 
and CVD, relative to patients with healthy periodontium (Mattila, Pussinen, and Paju 2005; 
Chen et al. 2008; Mattila et al. 2000; Alfakry et al. 2011; Persson et al. 2003). Although the 
associations of periodontal diseases with CVD have been investigated in several clinical 
studies the pathogenic mechanisms and links between both diseases are not completely 
clarified (Bahekar et al. 2007; Buduneli et al. 2011).  
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A major challenge in clinical periodontics is to find a reliable molecular marker of 
periodontal support loss with high sensitivity, specificity and utility (Buduneli & Kinane 
2011). Molecules derived from inflamed host tissue and pathogenic bacteria have the 
potential of being used as markers of periodontitis; however, molecular markers of bone 
resorption have advantages as they relate to specificity for bone, easy detection, pre-analytic 
stability and availability of sensitive and specific assays for detection (Forde et al. 2006). Up 
to now, at least 90 different components in gingival crevicular fluid (GCF) and oral fluids 
have been evaluated as possible biomarkers for diagnosis of periodontal disease and they 
can be divided into three major groups: (1) host derived enzymes and their inhibitors, (2) 
inflammatory mediators and host response modifiers, and (3) by-products of tissue 
breakdown, mainly of bone resorption (Lamster and Ahlo 2007). 
Recently, the use of oral fluids such as GCF, whole saliva and oral rinse as a means of 
evaluating host-derived products, as well as exogenous components (for instance: oral 
microorganisms and microbial products), has been suggested as potential sources and 
diagnostic markers, respectively for disease susceptibility (Sahingur and Cohen 2004; 
Buduneli and Kinane 2011). In fact, as whole saliva represents a pooled sample with 
contributions from all periodontal sites, analysis of biomarkers in saliva may provide an 
overall assessment of disease status as opposed to site-specific GCF analysis. This review 
will analyze the mechanisms involved in the breakdown of periodontal supporting tissues 
during chronic periodontitis, with a special focus on the role of T cells, matrix 
metalloproteinases (MMPs) and the development of chair side point-of-care diagnostic aids 
applicable to monitor both, periodontal and systemic inflammation. 
2. T cells and related cytokines 
Nowadays, it has been clearly demonstrated that increases in receptor activator of nuclear 
factor-kappa B ligand (RANKL) mRNA and protein levels in periodontal tissues stimulate 
the differentiation of monocyte-macrophage precursor cells into osteoclasts and the 
maturation and survival of the osteoclasts, leading to alveolar bone loss (Hernandez et al. 
2006; Ohyama et al. 2009; Nagasawa et al. 2007; Gaffen and Hajishengallis 2008; Crotti et al. 
2003; Hofbauer and Heufelder 2001; Kawai et al. 2006; Vernal et al. 2004). In this context, 
during inflammatory response characteristic of periodontitis, proinflammatory cytokines, 
such as interleukin (IL)-1β, IL-6, IL-17, and tumor necrosis factor (TNF)-α, can stimulate 
periodontal osteoblasts to express membrane-bound RANKL (Gaffen and Hajishengallis 
2008; Acosta-Rodriguez et al. 2007; Harrington, Mangan, and Weaver 2006; Mosmann and 
Sad 1996; Graves 2008). In addition to osteoblasts, RANKL is expressed by a number of 
other cell types, mainly CD4+ T lymphocytes (Kawai et al. 2006). 
CD4+ T lymphocytes represent one of the main components of the adaptive immune 
response and are the predominant cell type present in periodontitis gingival tissues 
(Hofbauer and Heufelder 2001; Kawai et al. 2006). After antigenic stimulation, naïve CD4+ T 
cells proliferate and may differentiate into distinct effector subsets, which have been 
classically divided on the basis of their cytokine production profiles into T helper (Th) 1 and 
Th2 cells (Mosmann et al. 1986). Th1 cells are characterized by the secretion of interferon 
(IFN)-γ, IL-2, IL-12, TNF-α and TNF-β, and are involved in the eradication of intracellular 
pathogens. Conversely, Th2 cells are characterized by secretion of IL-4, IL-5, IL-6, IL-9 and 
IL-13, which are potent activators of B cells, are involved in the elimination of extracellular 
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microorganisms and parasitic infections, and are also responsible for allergic disorders 
(Mosmann and Sad 1996; Mosmann and Coffman 1989). 
More recently, two new subsets of CD4+ T lymphocytes have been characterized, the Th17 
subset, which follows different polarizing conditions and displays different functional 
activities than Th1 and Th2 cells, and the regulatory T (Treg) cell subset with suppressor 
functions (Mosmann and Sad 1996). Activated human Th17 cells are phenotypically 
identified as CCR2+CCR5- (Honma et al. 2007), whereas human memory CD4+ T cells 
producing IL-17 and expressing transcription factor related to orphan nuclear receptor C2 
(RORC2) mRNA are CCR6+CCR4+ (Acosta-Rodriguez et al. 2007). Th17 cells secrete several 
pro-inflammatory cytokines such as IL-6, IL-17, IL-21, IL-22, IL-23, IL-26, TNF-α, and 
particularly RANKL (Liang et al. 2006; Harrington et al. 2005; Park et al. 2005). 
The role of Th17 cells in host defence against pathogens is just emerging, particularly  
on their destructive potential in periodontal diseases. Increased levels of IL-17 were 
detected in GCF and in biopsy samples from periodontal lesions, both at the mRNA  
and protein levels, in patients with chronic periodontitis and these increased levels have 
been associated to CD4+ T cells (Takayanagi 2005; Vernal et al. 2005; Takahashi et al. 
2005). Furthermore, RANKL was synthesized within periodontal lesions where IL-17  
was produced by activated gingival T cells (Takahashi et al. 2005; Kramer and Gaffen 
2007). These data are reinforced by the over-expression of RORC2 mRNA in active lesions 
from chronic periodontitis patients (Dezerega et al. 2010). Taken together, these data 
establish that Th17 cells represent the osteoclastogenic Th subset on CD4+ T lymphocytes, 
inducing osteoclastogenesis and bone resorption through synthesizing IL-17 and RANKL 
(Figure 1). 
Diverse studies have analyzed the concentrations of RANKL and osteoprotegerin (OPG) in 
GCF of periodontitis patients and healthy subjects. In general, they show great variation 
from study to study, but the ratio of RANKL/OPG has a consistent tendency to increase 
from periodontal health to periodontitis and to decrease following non-surgical periodontal 
treatment (Bostanci et al. 2008, Buduneli et al. 2009). In a cross-sectional study, Bostanci et al. 
(2008) quantified the RANKL and OPG levels in GCF from 21 healthy subjects, 22 gingivitis, 
28 chronic periodontitis (CP), 25 generalized aggressive periodontitis (GAgP) and 11 CP 
immunosuppressed patients, detecting that RANKL levels increased and OPG decreased in 
periodontitis patients compared with either gingivitis or healthy individuals, and concluded 
that RANKL/OPG ratio may predict disease occurrence (Bostanci et al. 2007). The same 
authors analyzed the GCF levels of TACE, an enzyme involved in the activation and 
secretion of RANKL from Th17 lymphocytes. They found that GCF TNF-alpha converting 
enzyme (TACE) levels were higher in periodontitis and TACE showed positive correlation 
with PD, CAL, and GCF RANKL concentration (Bostanci et al. 2008). In an intervention 
study (Buduneli et al. 2009), GCF levels of RANKL, OPG, and IL-17 were determined at 
baseline and also 4 weeks after completion of initial periodontal treatment in 10 smoker and 
10 non-smoker patients with chronic periodontitis. The authors concluded that neither 
smoking nor periodontal inflammation seemed to influence GCF RANKL levels in 
systemically healthy patients with chronic periodontitis. Smoking and non-smoking patients 
with chronic periodontitis were affected similarly by the initial periodontal treatment with 
regard to GCF IL-17 and OPG concentrations. 
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On the other hand, Buduneli et al. (2008) selected 67 untreated CP and 44 maintenance 
patients and established RANKL and OPG salivary levels, demonstrating that RANKL and 
OPG may be affected by smoking and significant differences between treated versus 
untreated CP were found. CP patients (35 subjects) and 38 periodontally healthy subjects 
were analyzed by Sakellari et al. (2008). The GCF levels of RANKL increased in CP patients 
compared with healthy controls and these higher levels correlated with detection of 
Treponema denticola and Porphyromonas gingivalis, but not with clinical parameters (Sakellari, 
Menti, and Konstantinidis 2008). Arikan et al. (2011) evaluated RANKL, OPG, ICTP, and 
albumin levels in peri-implant sulcular fluid samples from 18 root-type implants with peri-
implantitis in 12 patients and 21 clinically healthy implants in 16 other patients. The authors 
suggested that local levels of carboxyterminal telopeptide pyridinoline cross-links of type I 
collagen (ICTP) and OPG reflect an increased risk of alveolar bone loss around dental 
implants, and their local levels may help to distinguish diseased and healthy sites (Arikan, 
Buduneli, and Lappin 2011). Finally, Silva et al. (2008) performed a longitudinal follow-up of 
56 patients affected of moderate to severe CP until determination of disease progression, 
detecting higher RANKL, IL-1β levels and MMP-13 activity in active sites compared with 
inactive sites (Silva et al. 2008). Taken together, RANKL levels are promising as discloser of 
periodontal disease activity. Finally, carboxyterminal telopeptide pyridinoline cross-links of 
type I collagen (ICTP), released into the periodontal tissues as a consequence of MMP-
mediated alveolar bone resorption has been suggested to predict future bone loss, to 
correlate with clinical parameters and putative periodontal pathogens, and also to reduce 
following periodontal therapy, representing a potentially valuable diagnostic marker for 
periodontal disease (Giannobile, Al-Shammari, and Sarment 2003).  
3. Matrix metalloproteinases (MMPs): Destructive versus regulative roles 
Periodontal tissue homeostasis depends on the balanced and regulated degradation of 
extracellular matrix (ECM) proteins. In addition, the molecular organization of extracellular 
matrix is known to profoundly influence cell behavior. An unbalance in favor of collagenous 
matrix degradation will result in the loss of periodontal supporting tissue, the hallmark of 
chronic periodontitis (Reynolds and Meikle 1997). MMPs enclose a family of genetically 
distinct but structurally related zinc-dependent proteolytic enzymes that can synergistically 
degrade almost all extracellular matrix and basement membrane components and regulate 
several cellular processes, including inflammatory responses (McQuibban et al. 2001; 
McQuibban et al. 2002; Overall, McQuibban, and Clark-Lewis 2002). The 23 MMPs 
expressed in humans are classified based on their primary structures and substrate 
specificities into different groups that include collagenases (MMP-1, -8, -13), gelatinases 
(MMP-9, -2), membrane-type MMPs (MT-MMPs, MMP-14, -15, -16, -17, -24, -25) and other 
MMPs (Folgueras et al. 2004).  
MMPs share a basic structure composed of three domains, namely the pro-peptide, catalytic 
and the hemopexin-like domain; the latter is linked to the catalytic domain via a flexible 
hinge region. The proteolytic activity of MMPs is subjected to a complex regulation that 
involves three major steps (Kessenbrock, Plaks, and Werb 2010): 1) gene expression, 2) 
conversion of zymogen to active enzyme and 3) specific inhibitors. MMPs are initially 
synthesized as pro-enzymes which are enzymatically inactive because of the interaction 
between the cysteine residue of the prodomain with the zinc ion of the catalytic site, known 
as cysteine switch. Disruption of this interaction through proteolytic removal of the 
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involves three major steps (Kessenbrock, Plaks, and Werb 2010): 1) gene expression, 2) 
conversion of zymogen to active enzyme and 3) specific inhibitors. MMPs are initially 
synthesized as pro-enzymes which are enzymatically inactive because of the interaction 
between the cysteine residue of the prodomain with the zinc ion of the catalytic site, known 
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prodomain or chemical modification results in enzyme activation. There are several 
proteinases that mediate MMP activation, including plasmin, furin and active MMPs that 
assemble in enzymatic amplifying loops. Once activated, the most important physiological 
inhibitors are tissue inhibitors of MMPs (TIMPs) -1, -2, -3 and -4 (Folgueras et al. 2004). 
Herein, the pathophysiological significance of increased MMP expression in periodontitis 
will rely ultimately on the presence of endogenous inhibitors and activating enzymes that 
will determine overall MMP activity (Sorsa, Mantyla et al. 2011; Buduneli and Kinane 2011). 
MMPs, especially those with collagen-degrading properties, such as MMP-8, MMP-13 and 
MMP-9, have been recognized as the key proteases involved in destructive periodontal 
diseases and have widely been demonstrated in inflamed periodontal tissues and in oral 
fluids in association with supporting tissue loss by different analytic methods, including 
ELISA, immunofluorometric assays (IFMA), checkerboard method and immuno blots, 
(Folgueras et al. 2004; McQuibban et al. 2001; McQuibban et al. 2002; Overall, McQuibban, 
and Clark-Lewis 2002; Sorsa et al. 2006; Sorsa, Tjaderhane, and Salo 2004). All human MMPs 
are known to exist in multiple forms, i.e. latent pro-forms, active or activated forms, 
fragmented species, complexed species and cell-bound forms (Sorsa, Mantyla et al. 2011). 
The expression of different MMP isoforms in oral fluid samples can be analyzed with 
western immunoblotting, whereas a limitation of conventional MMP immunoassays used in 
periodontal research, such as ELISA, is that they do not differentiate these forms.  
MMP-8 is mainly produced by neutrophils (PMN), but it can also be expressed by gingival 
fibroblasts, endothelial cells, epithelial cells, plasma cells, macrophages and bone cells 
(Heikkinen et al. 2010). MMP-8 is the major collagenolytic MMP in gingival tissue and oral 
fluids and elevated levels have been associated with the severity of periodontal 
inflammation and disease (Mantyla et al. 2006), whereas basal physiologic levels might be 
associated to tissue homeostasis and even to be protective against disease (Kuula et al. 2009). 
Among total collagenases in GCF, MMP-8 accounts for about 80%, whereas MMP-13, for up 
to 18% and MMP-1 is seldom detected (Golub et al. 2008).  
MMP-13 has been identified in gingival sulcular epithelium, fibroblasts, macrophages, 
plasma cells and osteoblasts (Tervahartiala et al. 2000; Hernandez et al. 2006; Rydziel, 
Durant, and Canalis 2000). MMP-13 has been implicated in bone resorptive process, along 
with MMP-9 (Hill et al. 1995; Hill et al. 1994; Holliday et al. 1997). Total MMP-13 levels, as 
well as proenzyme (~60 kDa) and its active forms (~45-50 kDa), have been shown to increase 
in chronic periodontitis versus healthy sites in GCF in association with clinical periodontal 
parameters (Tervahartiala et al. 2000; Kiili et al. 2002; Ilgenli et al. 2006).  
MMP-9 is the major gelatinase in oral fluids (Makela et al. 1994). As MMP-8, MMP-9 is 
present in granules of PMN and it is also expressed in a variety of other cell types, including 
resident periodontal cells, such as fibroblasts, keratinocytes and infiltrating leukocytes, like 
macrophages and plasma cells (Sorsa, Tjaderhane, and Salo 2004; Makela et al. 1994). Total 
MMP-9 levels and its active form have been demonstrated to significantly increase with 
periodontal inflammation in comparison to controls, composed of gingivitis and healthy 
subjects, and to drop along with inflammation  after periodontal therapy (Makela et al. 1994; 
Bildt et al. 2008) (Figure 1). 
Genetic variations can influence MMP transcription levels and protein synthesis. Despite the 
genetic background of periodontal diseases and the wide involvement of MMP-9, MMP-8 
and MMP-13, MMP gene polymorphisms studied in different ethnic populations have not 
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been able to conclude specific associations with the susceptibility to develop periodontitis or 
disease severity. Similar allele and genotype frequencies have been demonstrated at the 
MMP-9 -1562 and –R+279Q polymorphic sites between periodontitis patients and healthy 
controls, despite the presence of significantly increased protein levels in serum and saliva of 
diseased subjects (Isaza-Guzman et al. ; Loo et al. 2011; de Souza et al. 2005; Chen et al. 2007; 
Gurkan et al. 2008). Nevertheless, the -1572T allele might be associated with a severe form of 
chronic periodontitis in men (Holla et al. 2006). Similarly, no differences in MMP-13- 77 
A/G and -11 A /12 A polymorphic sites have been found for periodontitis patients (Pirhan 
et al. 2009), whereas no genetic studies are currently available for MMP-8.  
Regarding, especially MMP-8, -9 and -13, it is noteworthy that clinical progression of 
periodontitis in active versus inactive sites and/or patients has been repeatedly demonstrated 
to be reflected as pathologically excessive elevation of either active MMP forms, i.e. conversion 
of latent pro-form to active form, or enzyme activity assessed by functional assays, i.e. total 
activated enzyme unbound to TIMPs, in GCF/peri-implant sulcular fluid (PISF), mouth-rinse 
and saliva samples collected from periodontitis/peri-implantitis sites and patients (Hernandez 
et al. 2010; Hernandez Rios et al. 2009; Sorsa, Mantyla et al. 2011). Regarding 
periodontitis/peri-implantitis progression in disease-active sites, pro-MMP-8, -9 and -13 have 
been demonstrated to be activated by independent and/or co-operative cascades involving 
other host proteinases (MMPs, serine proteases), reactive oxygen species and/or microbial 
proteases (Buduneli et al. 2011; Hernandez et al. 2010; Hernandez Rios et al. 2009). GCF 
collagenase activity and MMP-8 activation are also found to correlate with the levels of type I 
collagen breakdown fragments overcoming the protective shield provided by TIMP-1 
(Reinhardt et al. 2010; Sorsa, Mantyla et al. 2011). Similarly, MMP-13 activity and ICTP have 
shown to increase in active sites compared with inactive sites from progressive periodontitis 
patients or healthy subjects (Hernandez Rios et al. 2009). 
Clinical trials testing subantimicrobial dose doxycycline (SDD, synthetic FDA-approved 
MMP-inhibitor) medication have repeatedly reported an association between improvement 
of clinical parameters and reduction of GCF and serum MMP-8, -13 and -9 activation and 
levels (Reinhardt et al. 2010, Sorsa et al. 2011). It is possible to monitor the effect of 
periodontal treatment and adjunctive SDD medication by point-of-care MMP-8 
immunoassays (Sorsa, Tervahartiala et al. 2011). 
MMPs can also act by regulating many other MMP activation cascades. This later role could 
even be more significant in periodontal tissue destruction than direct collagenolytic activity, 
in a way that a subtle change in regulating MMPs might result in widespread MMP 
activation and consequent tissue destruction (Folgueras et al. 2004; Hernandez et al. 2010). 
MMP-14 activates the collagenases MMP-8 and MMP-13 in vitro (Holopainen et al. 2003; 
Folgueras et al. 2004; Han et al. 2007; Dreier et al. 2004; Knauper et al. 1996). Several studies 
using experimental models associate MMP—14, -13, -9 and -2 over expression with bone 
resorption, and the inhibition of bone loss by the addition of an MMP inhibitor (de Aquino 
et al. 2009; Rifas and Arackal 2003; Garlet et al. 2006; Cesar Neto et al. 2004; Trombone et al. 
2009). In vitro studies have revealed that MMP-13 might initiate bone resorption by 
generating collagen fragments that can activate osteoclasts (Holliday et al. 1997) and 
proMMP-9 (Knauper et al. 1997). Active MMP-9 in turn, further digests denatured collagen 
derived from MMP-13 activity (Hill et al. 1995), is thought to act over preosteoclast 
recruitment to sites for osteoclast differentiation and bone resorption, and activates 
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proMMP-13 and proMMP-2. On the other hand, proMMP-13 can also be activated by active 
MMP-14, MMP-2 and MMP-13 in vitro (Knauper et al. 1996). Nevertheless, whether these 
enzymes proteolytically interact in vivo is not clear, yet. 
Adding of recombinant MMP-13 to gingival tissue from chronic periodontitis patients has 
been reported to result in elevated proMMP-9 and proMMP-2 activation rates, but only the 
former was significant. Furthermore, addition of MMP-13 specific synthetic inhibitor CL-
82198 prevented proMMP-9 activation (Hernandez Rios et al. 2009). These results suggest an 
activation cascade involving MMP-13, MMP-9 and possibly MMP-2 in periodontitis 
progression. Higher MMP-14 levels have also been found in gingival tissue from 
periodontitis subjects compared to healthy gingiva (Oyarzun et al. 2010) and soluble forms 
of MMP-14 have been described in periodontitis GCF (Tervahartiala et al. 2000), showing a 
trend to be higher in active sites in comparison to inactive ones in patients with progressive 
periodontitis (Hernandez et al. 2010). Moreover, a positive correlation between active MMP-
14 and active MMP-13 in periodontitis GCF was found, suggesting proteolytic activation to 
occur in vivo (Hernández et al. 2011). Thus, this novel proteolytic cascade could perpetuate 
periodontal soft and hard tissue destruction in a feed forward manner. Conversely, MMP-14 
has been inversely correlated to MMP-8 in GCF from active sites in progressive 
periodontitis, and thus this proteolytic activation mechanism might be of minor importance 
in disease progression (Hernandez et al. 2010; Hernandez, Dutzan et al. 2011). 
MMPs can also regulate many biological processes through limited proteolysis of matrix and 
non-matrix bioactive molecules, such as immune-inflammatory response and wound healing, 
among others, through either 1) hydrolysis of extracellular matrix to allow cell migration, 2) 
cleavage of binding proteins and releasing of soluble bioactive molecules from extracellular 
matrix reservoir or cell compartment and 3) by processing bioactive molecules, modifying 
their biological activity (Korpi et al. 2009; Lin et al. 2008; Tester et al. 2007; Van Den Steen et al. 
2003; Van Lint et al. 2005; Gutierrez-Fernandez et al. 2007; Hernandez et al. 2011).  
It has been recently reported that Porphyromonas gingivalis-induced experimental 
periodontitis in MMP-8 knock-out mouse model resulted in a more severe disease 
phenotype and reduced levels of mouse lipopolysaccharide (LPS)-induced CXC chemokine 
(LIX/CXCL5) than their wild type counterparts (Kuula et al. 2009; Hernandez et al. 2011). 
LIX/CXCL5 and its human homologue, granulocyte chemotactic protein-2 (GCP-2/CXCL6) 
have been proposed to regulate neutrophil influx to periodontal tissues at the oral interface, 
where they represent the first line of defense against periodontal pathogens (Kebschull et al. 
2009; Hernandez et al. 2011). Accordingly, several studies support a role for MMP-8 in PMN 
trafficking in different inflammation models. LIX/CXCL5 levels have also shown to 
diminish in other MMP-8 knock-out mouse models (Gutierrez-Fernandez et al. 2007; 
Nilsson, Jonsson, and Dabrosin 2009), such as TNF-induced lethal hepatitis model (Van Lint 
et al. 2005), and reduced levels of transforming growth factor (TGF)-β1 in MMP-8-/- mice 
have been associated with PMN impaired infiltration and wound healing (Gutierrez-
Fernandez et al. 2007). All these potential regulatory mechanisms together or alone may lead 
to an impaired PMN influx to the sites of inflammation in MMP-8 deficient mice and alter 
disease expression. Similarly, MMP-9 activity was shown to down regulate TGF-β1 protein 
levels in breast cancer cells exposed to tamoxifen (Nilsson, Jonsson, and Dabrosin 2009; 
Balbin et al. 2003). In addition, recent evidence supports that MMP-13 might also influence 
soluble protein levels from RANKL/OPG axis (Nannuru et al. 2010). 
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Fig. 1. The host response during periodontitis with emphasis on T cells and matrix 
metalloproteinases (MMPs) in periodontal tissue breakdown. As result of chronic stimuli from 
periodontopathogenic biofilm an immune-inflammatory response is established in periodontal 
tissues. The major features are the synthesis of inflammatory cytokines, such as IL-1β, IL-12, 
TNF-α and pathologically elevated matrix metalloproteinases (MMPs) synthesis and 
activation, specially MMP-8, MMP-9, and MMP-13. These MMPs degrade extracellular matrix, 
particularly collagen I, and they also influence periodontal immune-inflammatory response 
through limited proteolysis. Th17 cells may be activated as consequence of antigen 
presentation and contribute to bone destruction by secreting IL-17 and RANKL. IL-17 
increases the inflammatory response and induces RANKL expression by osteoblastic cells. 
RANKL induces an increment in the osteoclast differentiation/maturation and alveolar  
bone resorption. MMP-13 produced by osteoblasts and MMP-9 from osteoclasts participate  
in the degradation of organic bone matrix. IL: interleukin; MMP: matrix metalloproteinase; 
TNF: tumor necrosis factor; TGF: transforming growth factor; OC: Osteoclast;  
APC: Antigen presenting cell; PMN: neutrophil; MO: macrophage; OBL: osteoblast. 
4. Oral fluid chair-side point-of-care technologies and their systemic 
applications 
Oral fluids [GCF, saliva, mouth-rinse, PISF] contain various molecular mediators often 
called biomarkers that reflect several physiological and pathological conditions. Qualitative 
and quantitative changes in the oral fluid biomarkers have been found to exert significance 
in the adjunctive diagnostics and treatment of various oral and systemic disorders. 
 
Pathogenesis and Treatment of Periodontitis 
 
40
proMMP-13 and proMMP-2. On the other hand, proMMP-13 can also be activated by active 
MMP-14, MMP-2 and MMP-13 in vitro (Knauper et al. 1996). Nevertheless, whether these 
enzymes proteolytically interact in vivo is not clear, yet. 
Adding of recombinant MMP-13 to gingival tissue from chronic periodontitis patients has 
been reported to result in elevated proMMP-9 and proMMP-2 activation rates, but only the 
former was significant. Furthermore, addition of MMP-13 specific synthetic inhibitor CL-
82198 prevented proMMP-9 activation (Hernandez Rios et al. 2009). These results suggest an 
activation cascade involving MMP-13, MMP-9 and possibly MMP-2 in periodontitis 
progression. Higher MMP-14 levels have also been found in gingival tissue from 
periodontitis subjects compared to healthy gingiva (Oyarzun et al. 2010) and soluble forms 
of MMP-14 have been described in periodontitis GCF (Tervahartiala et al. 2000), showing a 
trend to be higher in active sites in comparison to inactive ones in patients with progressive 
periodontitis (Hernandez et al. 2010). Moreover, a positive correlation between active MMP-
14 and active MMP-13 in periodontitis GCF was found, suggesting proteolytic activation to 
occur in vivo (Hernández et al. 2011). Thus, this novel proteolytic cascade could perpetuate 
periodontal soft and hard tissue destruction in a feed forward manner. Conversely, MMP-14 
has been inversely correlated to MMP-8 in GCF from active sites in progressive 
periodontitis, and thus this proteolytic activation mechanism might be of minor importance 
in disease progression (Hernandez et al. 2010; Hernandez, Dutzan et al. 2011). 
MMPs can also regulate many biological processes through limited proteolysis of matrix and 
non-matrix bioactive molecules, such as immune-inflammatory response and wound healing, 
among others, through either 1) hydrolysis of extracellular matrix to allow cell migration, 2) 
cleavage of binding proteins and releasing of soluble bioactive molecules from extracellular 
matrix reservoir or cell compartment and 3) by processing bioactive molecules, modifying 
their biological activity (Korpi et al. 2009; Lin et al. 2008; Tester et al. 2007; Van Den Steen et al. 
2003; Van Lint et al. 2005; Gutierrez-Fernandez et al. 2007; Hernandez et al. 2011).  
It has been recently reported that Porphyromonas gingivalis-induced experimental 
periodontitis in MMP-8 knock-out mouse model resulted in a more severe disease 
phenotype and reduced levels of mouse lipopolysaccharide (LPS)-induced CXC chemokine 
(LIX/CXCL5) than their wild type counterparts (Kuula et al. 2009; Hernandez et al. 2011). 
LIX/CXCL5 and its human homologue, granulocyte chemotactic protein-2 (GCP-2/CXCL6) 
have been proposed to regulate neutrophil influx to periodontal tissues at the oral interface, 
where they represent the first line of defense against periodontal pathogens (Kebschull et al. 
2009; Hernandez et al. 2011). Accordingly, several studies support a role for MMP-8 in PMN 
trafficking in different inflammation models. LIX/CXCL5 levels have also shown to 
diminish in other MMP-8 knock-out mouse models (Gutierrez-Fernandez et al. 2007; 
Nilsson, Jonsson, and Dabrosin 2009), such as TNF-induced lethal hepatitis model (Van Lint 
et al. 2005), and reduced levels of transforming growth factor (TGF)-β1 in MMP-8-/- mice 
have been associated with PMN impaired infiltration and wound healing (Gutierrez-
Fernandez et al. 2007). All these potential regulatory mechanisms together or alone may lead 
to an impaired PMN influx to the sites of inflammation in MMP-8 deficient mice and alter 
disease expression. Similarly, MMP-9 activity was shown to down regulate TGF-β1 protein 
levels in breast cancer cells exposed to tamoxifen (Nilsson, Jonsson, and Dabrosin 2009; 
Balbin et al. 2003). In addition, recent evidence supports that MMP-13 might also influence 
soluble protein levels from RANKL/OPG axis (Nannuru et al. 2010). 
The Role of Immuno-Inflammatory Response in the Pathogenesis  




Fig. 1. The host response during periodontitis with emphasis on T cells and matrix 
metalloproteinases (MMPs) in periodontal tissue breakdown. As result of chronic stimuli from 
periodontopathogenic biofilm an immune-inflammatory response is established in periodontal 
tissues. The major features are the synthesis of inflammatory cytokines, such as IL-1β, IL-12, 
TNF-α and pathologically elevated matrix metalloproteinases (MMPs) synthesis and 
activation, specially MMP-8, MMP-9, and MMP-13. These MMPs degrade extracellular matrix, 
particularly collagen I, and they also influence periodontal immune-inflammatory response 
through limited proteolysis. Th17 cells may be activated as consequence of antigen 
presentation and contribute to bone destruction by secreting IL-17 and RANKL. IL-17 
increases the inflammatory response and induces RANKL expression by osteoblastic cells. 
RANKL induces an increment in the osteoclast differentiation/maturation and alveolar  
bone resorption. MMP-13 produced by osteoblasts and MMP-9 from osteoclasts participate  
in the degradation of organic bone matrix. IL: interleukin; MMP: matrix metalloproteinase; 
TNF: tumor necrosis factor; TGF: transforming growth factor; OC: Osteoclast;  
APC: Antigen presenting cell; PMN: neutrophil; MO: macrophage; OBL: osteoblast. 
4. Oral fluid chair-side point-of-care technologies and their systemic 
applications 
Oral fluids [GCF, saliva, mouth-rinse, PISF] contain various molecular mediators often 
called biomarkers that reflect several physiological and pathological conditions. Qualitative 
and quantitative changes in the oral fluid biomarkers have been found to exert significance 
in the adjunctive diagnostics and treatment of various oral and systemic disorders. 
 
Pathogenesis and Treatment of Periodontitis 
 
42
Periodontal diseases are reflected in oral fluids as elevated levels of host cell-derived tissue 
destructive proteolytic enzymes, i.e. MMP-8, -9 and  -13 , neutrophil elastase , α2-macroglobulin, 
oxygen radical producer myeloperoxidase (MPO), pro-inflammatory mediators, (C Reactive 
Protein (CRP), IL-1β, TNF-α, macrophage inflammatory protein -1) and bone remodeling 
markers (alkaline phosphatase, ICTP, RANKL, osteoprotegrin and osteocalcin). Among these 
periodontitis-related oral fluid biomarkers, especially MMP-8, -9 and -13, as well as MPO are 
potential candidates for chair-side point-of-care oral fluid assays (Hernandez et al. 2010; 
Leppilahti et al. 2011; Sorsa, Tervahartiala et al. 2011). Low GCF volume and low biomarker 
levels in all oral fluids are characteristic during periodontal health, but the biomarker contents 
increase along with the severity of periodontal inflammation (Pussinen et al. 2007).  
GCF, salivary and mouth-rinse biomarker analysis can provide adjunctive information for 
health care professionals alongside traditional oral clinical examination whether periodontal 
disease is present, whether treatment or medication is required or if the treatment or 
medication has been effective. GCF represents site specific analysis of studied biomarkers 
and volume. However, molecular analysis of GCF elution can be time consuming while 
most of the GCF analytic assays are laboratory based and usually cannot be performed in a 
chair-side manner. These procedures, as well as GCF sampling, are technically demanding 
and the GCF volume can be very small (1-5 µl). Despite these apparent diagnostic and 
technical disadvantages, GCF is still considered as a candidate potential oral fluid for the 
development of adjunctive non-invasive chair-side point of-care diagnostic technology 
(Sorsa et al. 1999; Sorsa et al. 2006; Sorsa, Tjaderhane, and Salo 2004; Mantyla et al. 2006; 
Mantyla et al. 2003; Munjal et al. 2007), especially because tissue destructive MMPs and their 
bioactive regulators can conveniently be measured by distinct catalytic and non-catalytic 
immunoassays from GCF (Sorsa et al. 2010).  
In relation to GCF, collection of salivary and mouth-rinse samples is more convenient, 
practical, rapid and non-invasive and requires neither professional stuff nor specific 
materials. It could even be carried out by patients themselves. Saliva and mouth-rinse 
represent a pooled sample from all periodontal sites providing an overall assessment of 
periodontal disease and health at subject level. Whole saliva can be affected by molecular 
constituents and cellular remnants from other oral niches, as well as systemic conditions 
(Buduneli et al. 2011; Buduneli and Kinane 2011) which should be considered when it is 
used for diagnostics.  
MMP-8 or collagenase-2/neutrophil-collagenase is the major type of interstitial collagenase 
present in human periodontitis-affected gingival tissue, GCF, PISF, saliva and mouth-rinse 
samples (Sorsa et al. 2006). Antibodies applied in the immunoassays for the detection of 
MMPs and their regulators affect the measurement outcome (Leppilahti et al. 2011; Gursoy 
et al. 2010; Sorsa et al. 2010; Sorsa, Mantyla et al. 2011). Nevertheless, especially MMP-8 
immunoassays and activity assays targeting PMN-type MMP-8 isoenzyme species in oral 
fluids have been found to be useful to differentiate periodontitis/peri-implantitis and 
gingivitis sites/patients as well as healthy sites/subjects (Mantyla et al. 2006; Mantyla et al. 
2003; Hernandez et al. 2010; Sorsa et al. 2010; Sorsa, Mantyla et al. 2011). Although 
periodontal clinical examination is necessary and cannot be substituted by any other means 
in periodontal diagnostics, biomarker testing could give relevant clinical adjunctive 
information about the individual’s host response levels, although there is no known normal 
range at present. 
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Selective antibodies for detection of active MMP-8 in oral fluids have been utilized as 
adjunctive diagnostic point-of-care/chair-side tests identifying sites susceptible for 
periodontitis progression and periodontitis affected patients (Leppilahti et al. 2011; Mantyla 
et al. 2006; Sorsa, Mantyla et al. 2011; Sorsa, Tervahartiala et al. 2011). We have recently 
investigated levels of GCF MMP-8 with two different chair-side (dentoAnalyzer by 
dentognostics GmbH and MMP-8 specific chair-side dip-stick test) and two laboratory 
methods (immunofluorometric assay, IFMA, and commercial ELISA) (Sorsa et al. 2010). 
IFMA, dentoAnalyzer and MMP-8 specific chair-side dip-stick test results were well in line. 
Results obtained with MMP-8 commercial ELISA kit were not in line with recordings by 
other methods. Both IFMA and dentoAnalyzer device detected the GCF samples’ MMP-8 
levels with equal reliability. The chair-side dip stick test results were in line with results 
with these two other methods but the capability of the dip-stick test to differentiate the 
sample levels were rougher. The chair-side dip-stick test detected especially the sites with 
high MMP-8 levels. 
The differences between dentoAnalyzer, IFMA, dipstick and commercial ELISA MMP-8 
analysis of GCF levels can be, at least in part, explained by the evidently different 
specificities and sensitivities between antibodies used in these assays. DentoAnalyzer, IFMA 
and dipstick assays use same antibody (Hanemaaijer et al. 1997). Regarding serum and 
plasma MMP-8 determinations by using both IFMA and commercial ELISA, significantly 
higher serum MMP-8 values were recorded relative to plasma, and the differences were 
most notable with high serum MMP-8 concentrations as measured using IFMA (Tuomainen 
et al. 2008; Emingil et al. 2008). The antibody used in dentoAnalyzer, IFMA and dip-stick 
exerts high sensitivity to both PMN- and fibroblast-type MMP-8 isotypes and especially 
their active forms (Hanemaaijer et al. 1997; Sorsa et al. 1999). 
Although several studies have demonstrated the central role of MMP-8 in periodontitis, it 
has not been shown that it is predictive of disease progression, i.e. that the increased MMP-8 
concentration in GCF would precede the occurrence of attachment loss (AL). This problem 
arises from the nature of periodontitis and from the accuracy of diagnosing a site as 
progressing with clinical or radiological methods. Disease progression is regarded to be 
mostly episodic, occurs only infrequently and is slow in most chronic periodontitis patients. 
During a study period, it is likely that only a small number of sites with AL can be 
confirmed. Additionally, only a small group of periodontitis patients manifest multiple 
progressing sites (Chambers et al. 1991; Mantyla et al. 2006). In our previous study, we 
could not make a conclusion about the predictive value of MMP-8 testing (Mantyla et al. 
2006). However, we concluded that repeatedly elevated GCF MMP-8 levels indicate the sites 
at risk of periodontal AL and that testing of MMP-8 site specifically from GCF is a valuable 
diagnostic aid which supplements the traditional methods especially from selected sites in 
the maintenance phase of periodontitis patients who are at continuous risk for periodontitis 
recurrence. Periodontitis patients’ GCF MMP-8 levels decrease after conventional 
periodontitis hygiene phase treatment. However, the levels remain higher than in gingivitis 
patients’ or in periodontally healthy subjects’ GCF (Mantyla et al. 2003). This is valid also in 
periodontitis patients’ shallow sites, as well as sites with no attachment loss, and tells about 
the elevated basic host response of periodontitis subjects (Mantyla et al. 2006; Mantyla et al. 
2003) (Figure 2). 
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Fig. 2. MMP-8 levels in gingival crevicular fluid from subjects with moderate and severe 
chronic periodontitis. The box plot shows MMP-8 IFMA levels (µg/l) from patients 
suffering of moderate chronic periodontitis (4 patients, 34 sites) and severe chronic 
periodontitis (10 patients, 81 sites). Same sites from each patient were analyzed before any 
periodontitis treatment (baseline), one month after treatment (scaling and root planing), and 
with two-month interval during the maintenance phase (2-10 month). From each patient 
both shallow and deep sites at baseline were included into analyzed sites. The figure shows 
that GCF MMP-8 levels decrease in both groups after treatment but remain at comparatively 
high levels in severe periodontitis at each point in time indicating the higher level of host 
response. Box plots also show the wide ranges of MMP-8 levels, which are typical for 
biomarkers, and ranges become wider with the severity of the disease. 
Based on other recent findings the salivary and oral rinse chair-side sample analysis of MMP-8 
can be clinically useful in rough screening to identify individuals with periodontitis or to 
analyze the individual level of host response. Simultaneous analysis of MMP-8 and TIMP-1 
could be beneficial (Leppilahti et al. 2011). The oral fluid testing could give valuable additional 
information about the control of inflammation which today is based on the clinical findings, that 
is shallower or eliminated periodontal pockets and less bleeding on probing. Salivary and oral 
rinse sample analysis may be useful in defining the optimal period between periodontal 
maintenance visits after active periodontal treatment. During the active treatment phase it could 
be possible to monitor the decrease of salivary and oral rinse MMP-8 levels; at the end of the 
active treatment phase it would show the individual optimal biomarker level to keep the host 
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response in control. At best the biomarker level could be monitored by screening home self-test 
to indicate when the cut-off for possibly unsafe biomarker level is reached. Also the effect of 
MMP-8 inhibiting SDD  medication could be monitored by analyzing the salivary and oral rinse 
MMP-8 levels to find out when a possible break in medication would be possible or when the 
medication should be taken again (Golub et al. 2008; Reinhardt et al. 2010). Screening type 
testing from saliva or oral rinse would also be applicable for differentiation of the borderline 
between gingivitis and peridontitis, because gingivitis patients’ MMP-8 levels are shown to be 
significantly lower than periodontitis patients’ levels (Mantyla et al. 2003). Thus, the levels 
repeatedly approaching to those of peridontitis could be used to indicate patients at risk. 
The point-of-care MMP-8 immuno-technologies from oral fluids and serum/plasma can be 
well adapted for monitoring of systemic inflammation (Tuomainen et al. 2007; Buduneli and 
Kinane 2011). In this regard, the elevation of serum and plasma MMP-8 has been associated 
with AMI, CVD and sepsis (Buduneli et al. 2011; Lauhio et al. 2011; Sorsa, Tervahartiala et 
al. 2011). Furthermore, a recent study on salivary MMP-8 assessed by Western immunoblot 
analysis in patients with or without acute myocardial infarction revealed that elevated 
salivary MMP-8 activation is associated with AMI (Buduneli et al. 2011). Moreover, elevated 
serum MMP-8 levels have recently been demonstrated to be associated with total outcome 
in a multicentre and prospective cohort study in sepsis; serum MMP-8 levels were 
significantly higher among non-survivors that among survivors. Thus elevated oral fluid 
and serum MMP-8 can be considered as a potential risk factor for systemic diseases such as, 
but not limited to, CVD, sepsis, diabetes, stroke, arthritis and pulmonary diseases (Kardesler 
et al. 2010; Biyikoglu et al. 2009; Buduneli et al. 2011; Ozcaka et al. 2011). In addition, oral 
MMP-8 activation as a consequence of AMI may contribute to progression of periodontitis 
and/or oral discomfort. However, oral fluid point-of-care diagnostics contains many 
potential confounders. The various medications together with systemic diseases (mental 
disorders / psychiatric diseases, nephritic syndrome) can affect the levels of potential 
periodontitis and CVD biomarkers in saliva and serum/plasma (Alfakry et al. 2011; Sorsa, 
Tervahartiala et al. 2011; Buduneli et al. 2011). Accordingly, the beneficial and reducing 
effects of lymecycline (a tetracycline-derivate) on serum MMP-8 levels could be monitored 
by MMP-8 immunoassay in reactive arthritis (Lauhio et al. 2011). In fact, serum MMP-8 
levels may reflect defensive molecular processes in certain malignancies (Korpi et al. 2008) 
and also HIV-infection has been found to affect the level of MMPs and their regulators in 
oral fluid and serum/plasma (Mellanen et al. 2006). 
5. Concluding remarks 
Periodontal tissue destruction derived from chronic periodontitis occurs as consequence to 
the activation of immune-inflammatory response of the host to bacterial challenge. Major 
events comprise pro-inflammatory cytokine production and collagenolytic MMPs, such as 
MMP-8, MMP-13 and MMP-9 leading to soft periodontal tissue breakdown. Activation of 
Th17 subset of T lymphocytes will induce the synthesis of IL-17 and RANKL. These 
cytokines along with bone MMPs, will lead ultimately to octeoclastogenesis and alveolar 
bone resorption. Qualitative and/or quantitative changes in  oral fluid biomarkers might be 
useful as adjunctive diagnostics and treatment of periodontitis. Among them, it appears that 
MMP-8 point-of-care diagnostics exert a huge potential in oral diagnostics and forms a 
diagnostic link from oral cavity to systemic inflammatory conditions. 
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1. Introduction  
Periodontal disease is one of the major dental pathologies that affect human populations 
worldwide at high prevalence rates (Petersen, 2003). Periodontal diseases represents a 
family of heterogeneous chronic inflammatory lesions that involve the periodontium, a 
connective tissue protected by the epithelium, important to attach the teeth to the bone in 
the jaws and to support the teeth during function (Taylor, 2003). It is well known that 
periodontal diseases are caused by the interaction between periodontopathogens, almost 
gram-negative bacteria that grows on the teeth, and the host immune response to the 
chronic infection which results in tissue destruction (Ratcliff & Johnson, 1999; Reynolds & 
Meikle, 1997).  
Gingivitis and periodontitis are the two main periodontal diseases and may be present 
concurrently. Gingivitis is a form of periodontal disease in which gingival tissues are 
inflamed but their destruction is mild and reversible while periodontitis is a chronic 
inflammatory response to the subgingival bacteria with irreversible changes (Armitage, 
1999). Periodontium destruction is characterized by loss of connective tissue attachment and 
bone around the teeth in conjunction with the formation of periodontal pockets due to 
apical migration of the junctional epithelium (Champagne et al., 2003). Periodontal disease 
progression is episodic in nature on a tooth site level, but more recently, it has been realized 
that it is principally patient-based rather than site-based (Zia et al., 2011); the host related 
risk factors could be the key to better understand disease evolution. The available evidence 
shows that important risk factors for periodontal disease relate to poor oral hygiene, tobacco 
use, excessive alcohol consumption, stress, and diabetes mellitus (Laurina et al., 2009; Taylor 
& Borgnakke, 2008). Degrees of inflammation and fibrosis depend on these risk factors but 
recently the genetic basis of many aspects of the periodontal host response has been 
discussed in reference to disorders predisposing to periodontal disease (Bartold & 
Narayanan, 2006; Kinane & Hart, 2003). 
Clinical hallmarks of periodontal disease are represented by the redness and swelling of the 
gingival margin around the neck of the teeth, recession of the gums, tooth looseness, 
changes in tooth alignment and halitosis (Taylor, 2003). Recently, it has been accepted that 
during chronic periodontal disease, morphological changes in the architecture of the 
extracellular matrix of the gingiva could occur and lead to gingival enlargement. This refers 
to the overgrowth of the gingiva characterized by the expansion and accumulation of the 
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connective tissue with occasional presence of increased cell number. These changes are 
unspecific, appearing in gingival enlargement associated to chronic inflammation but also 
when other risk factors exist (inheritance, systemic diseases, such as diabetes mellitus, and 
drugs administration). The most common form of gingival overgrowth is that drug-induced, 
by anti-seizure drugs, such as phenytoin, immunosuppressive agents, such as cyclosporine, 
and some calcium antagonists (verapamil, diltiazem, dihidropyridines, most notably 
nifedipine) (Dongari-Bagtzoglou et al., 2004; Seymour, 2006).  
Histological assessment showed that independently of the etiological factor involved, 
changes of the mucosa refer both to the gingival epithelium and the lamina propria (Banita 
et al., 2008, 2011). There is now general agreement that all gingival overgrowth lesions 
contain fibrotic or expanded connective tissue with various levels of inflammation and an 
enlarged gingival epithelium. As soon as plaque accumulates adjacent to the gingival 
margin, inflammatory cells infiltrate in the subjacent connective tissue and initiate its 
destruction. Simultaneously with collagen destruction, wound repair occurs, which results 
in fibrosis and scarring coexisting at the foci of inflammation (Bartold & Narayanan, 2006). 
According to this sequence of events, the stages of inflammation, matrix destruction and 
repair succeed each other in the development of periodontal disease.  
Important player for the regulation of gingival connective tissue homeostasis is the 
fibroblast, cell able to synthesize and breakdown the collagen fibers and other proteins from 
the ground substance. In vitro studies have shown that fibroblasts from human normal 
gingiva produce collagens type I and type III, while cells derived from gingiva of patients 
with chronic periodontitis failed to produce detectable amounts of type III collagen 
(Hammouda et al., 1980; Chavier et al., 1984, as cited in Bartold & Narayanan, 2006). 
Buduneli et al. (2001a) investigated total collagen content and collagen type I, III, IV, V and 
VI content in gingival connective tissue of chronic periodontitis as well as aggressive 
periodontitis patients and clinically healthy subjects. It was suggested that different collagen 
types present in various periodontitis categories may be related with diverse pathogenic 
mechanisms acting in these diseases. In our previous studies we observed the abundance of 
type I collagen in the extracellular matrix of the gingival tissue obtained from patients with 
chronic periodontitis. In accordance with reference data, we suggest two explanations for 
this: despite the degradation of the fibrilar collagen, cells are able to synthesize a new type 
of collagen, type I trimer which accumulates in the gingiva (Narayanan et al., 1985, as cited 
in Bartold & Narayanan, 2006) or that inflamed human gingiva contains fibroblasts with 
different phenotype than those from the normal tissue, the myofibroblasts, able to 
synthesize a large amount of collagen.  
Pathogenic pathways involved in the imbalance of connective tissue homeostasis in 
periodontal inflammatory diseases are complex, and specific mediation is not completely 
understood. Activation of matrix metalloproteinases (MMPs) is one of the most important 
evolving under a rigorous control.  
Growth factors and cytokines play an important role in regulation of the gingival 
extracellular matrix turnover. Tumor necrosis factor-α (TNF-α) and interleukins induce the 
expression of MMPs while transforming growth factor-β (TGF-β) down-regulates their 
synthesis and secretion and promotes the production of their natural tissue inhibitors, 
TIMPs (Bartold & Narayanan, 2006). Connective tissue growth factor (CTGF) is another 
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important mediator of tissue remodelling which stimulates fibroblasts to produce 
extracellular matrix constituents, so its expression correlates positively with the degree of 
gingival fibrosis (Heng et al., 2006; Trackman & Kantarci, 2004). Local conditions favour 
angiogenesis in periodontal tissues being characterized by an increased expression of the 
vascular endothelial growth factor (VEGF), this cytokine acting also to complete the greater 
ability of regeneration of the gingiva (Lucarini et al. 2009).   
At the beginning, specialists tried to diagnose the stage of periodontal disease depending 
on the relation between the clinical appearances and the presence of some specific cell 
populations or specific matrix components (Havemose-Poulsen & Holmstrup, 1997; 
Romanos et al., 1993). Traditional clinical measurements (probing pocket depth, bleeding 
on probing, clinical attachment loss, plaque index) used for the diagnosis of periodontium 
health are often of limited usefulness because they are not sufficiently accurate to discern 
between previous periodontal disease and present disease activity. There is a need for 
development of new diagnostic tools to allow earlier detection of active disease, predict 
disease progression and evaluate the response to periodontal therapy, thereby improving 
the clinical management of patients with periodontal diseases. Advances in periodontal 
diseases diagnostic research are moving toward methods whereby periodontal risk can be 
identified and quantified by objective measures such as biomarkers. Gingival crevicular 
fluid (GCF) and salivary levels of several growth factors, cytokines and enzymes of host 
origin appear to hold the greatest promise as valuable biomarkers in assessing 
development of periodontal disease (Buduneli & Kinane, 2011; Giannobile et al., 2003; 
Gurkan et al., 2008; Goncalves et al., 2009; Kaufman & Lamster, 2000; Pisoschi et al., 2010; 
Wright et al., 2000). 
In the last decade, scientists began to use signaling molecules such as growth factors in their 
quest to restore destroyed tooth support (Anusaksathien & Giannobile, 2002) and this 
reason request a very good knowledge of the biological actions of growth factors, both 
summative and redundant, in the specific “milieu” of periodontal diseases.  
This paper highlights a brief review of the literature on growth factors involvement in 
periodontal disease and our contribution in this field, in order to sustain their use as 
biomarkers of active periodontal disease and future therapeutic tools.  
2. Changes of the gingival tissues in periodontal disease 
Periodontium includes four tissues located near the teeth: i) root cementum, ii) periodontal 
ligament; iii) alveolar bone, and iv)the part of the gingiva facing the tooth (dentogingival 
junction) (Nanci & Bosshardt, 2006). Gingiva or gums represent the mucosal tissue that 
covers the alveolar bone. Healthy gingiva is pale pink or pigmented and wrap tightly 
around the neck of the teeth (Taylor, 2003). Histologically, gingiva consists of two types of 
tissues - the epithelium that covers a connective tissue, chorion or lamina propria. A 
keratinized stratified squamous epithelium protects the lamina propria of the gingiva on its 
masticatory surfaces and a non-keratinized epithelium protects the lamina propria on its 
crevicular and junctional surfaces. During normal or pathological conditions such as 
inflammation, the periodontal connective tissues, including the gingiva, undergo many 
changes. Clinically detected gingival overgrowth – term used to substitute the former 
”gingival hypertrophy” or ”gingival hyperplasia”, because the changes of this clinical 
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important mediator of tissue remodelling which stimulates fibroblasts to produce 
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condition are more complex (Dongari-Bagtzoglou et al., 2004) - is one of the alterations 
recently postulated to occur in chronic periodontitis. It is caused by a variety of etiological 
factors and is exacerbated by local bacterial biofilm accumulation, because the 
periodontopathogens products act on the gingival tissues activating cellular events that 
induce the alteration of connective tissue homeostasis and the destruction of the alveolar 
bone (Reynolds & Meikle, 1997). Clinical characteristics of different forms of gingival 
overgrowth have been previously reviewed (Marshall & Bartold, 1998, 1999; Seymour et al., 
2000). Gingival overgrowth is characterized by enlarged and occasionally inflamed gums 
(the interdental papilla and the free gingival margins increase in size and thickness 
progressively covering the tooth crown). Besides the one associated with periodontal 
disease, gingival overgrowth can be inherited (hereditary gingival fibromatosis), sometimes 
associated with other systemic diseases (such as diabetes mellitus) or with idiopathic origin. 
The majority of cases, however, occur as a side-effect of systemic medications, including the 
anti-seizure drug phenytoin, the immunosuppressive agent cyclosporin A and certain anti-
hypertensive calcium-channel-blockers (verapamil, diltiazem and dihidropyridines, most 
notably nifedipine) (Seymour, 2006; Trackman & Kantarci, 2004). There is now general 
agreement that all gingival overgrowth lesions contain fibrotic or expanded connective 
tissues with various levels of inflammation and an enlarged gingival epithelium. The 
degrees of inflammation, fibrosis, and cellular pattern depend on the risk factor if it is 
identified: the duration, dose, and identity of the drug, the quality of oral hygiene, and the 
individual susceptibility that stems from genetic factors and environmental influences. 
Histological assessment showed that independently of the etiological factor involved, 
changes of the mucosa are unspecific and refer both to the gingival epithelium and the 
lamina propria. Our previous studies of chronic periodontitis gingival samples revealed 
epithelial hypertrophy with a thick stratified squamous epithelium showing an alternation 
between keratinized and non-keratinized areas with the increase of the spinous layer 
(acanthosis) associated with acantholysis (Banita et al., 2008, 2011). Epithelium bended 
deeply into the lamina propria to form the so called “rete pegs” (Fig.1.).  
 
 
Fig. 1. Gingival enlarged epithelium in chronic periodontitis (Masson staining x 10) 
Gingival tissues assessed showed also the thickness of the lamina propria due to an 
excessive deposition of connective tissue. It was an important accumulation of thick collagen 
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bundles with a various number of fibroblasts and the constant presence of pro-inflammatory 
cells (lymphocytes and macrophages) and numerous de novo capillaries (Fig.2). 
 
Fig. 2. Infiltration of connective tissue with inflammatory cells in periodontitis, de novo 
capillaries (Haematoxylin & Eosin staining x 10) 
Using silver impregnation we noticed that the ratio between collagen types was changed, 
the extent of the yellowish coloured areas proving the presence of more type I collagen 
(Fig.3).  
 
Fig. 3. Abundant collagen type I in chronic periodontitis (Gömöri silver impregnation x 4,5) 
Our observations are in agreement with those of Lorencini and coworkers (2009) who, in 
their experimental model of ligature-induced periodontal disease noticed also this 
paradigm. They hypothesized that a kind of “frustrated repair” of the extracellular matrix 
can occur simultaneously with collagen breakdown and that the new configuration of the 
fibers can contribute to periodontal disease progression (Lorencini et al., 2009). Other 
authors postulated that with the developing of inflammatory lesion, the gingival collagens 
become more soluble, with increasing amount of collagen type V and the appearance of a 
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new collagen, type I trimer (Narayanan et al., 1985, as cited by Bartold & Narayanan, 2006). 
Taken together these results prove without doubt that there is a permanent link between 
inflammatory cell populations and extracellular matrix turnover in inflammatory gingival 
overgrowth. Gingival tissues are recognized for their remarkable ability of regeneration and 
healing after wounding. The ability of regeneration of the gingival epithelium is compulsory 
in order to maintain the homeostasis of the gingival mucosa. Lamina propria has also the 
ability to heal very quickly after wounding. Some areas of interest for researchers are the 
biological processes that control how the periodontal tissues respond to wounding, and how 
cells from the different tissues of the periodontium interact when more than one periodontal 
tissue is affected. It is generally agreed that gingival overgrowth results from an increase of 
extracellular matrix macromolecules infiltrated with various numbers of inflammatory cells.  
3. Extracellular matrix homeostasis in periodontal disease 
Connective tissue remodelling is essential for normal growth and development and many 
diseases have long been associated with the imbalance of the breakdown of the collagenous 
matrix of different tissues. Complex pathogenic pathways control the balance 
synthesis/degradation of the extracellular matrix. Macromolecules of interstitial connective 
tissues and basement membranes may be degraded by: i) matrix metalloproteinase (MMP)-
dependent, ii) plasmin-dependent, iii) polymorphonuclear leukocyte serine proteinase-
dependent reactions, and iv) a phagocytic pathway based on intracellular digestion of 
internalized material by lysosomal cathepsins (Birkedal-Hansen et al., 1993). 
Since the early 1990s, interest has focused on works showing that connective tissue cells 
synthesize and secrete a family of proteinases, the MMPs, which can digest extracellular 
matrix macromolecules and play a major role in connective tissue breakdown.  
3.1 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs), or matrixins, are enzymes derived from many types of 
mesenchymal cells, monocytes, macrophages and keratinocytes and can synergistically 
digest most of extracellular matrix (ECM) macromolecules (Reynolds et al., 1994; Whittaker 
& Ayscough, 2001). The MMP gene family encodes more than 20 human metal-dependent 
endopeptidases (Stamenkovic, 2003) divided into major five groups (see Tabel 1).  
As we already mentioned, gingival tissue remodelling involve the balance between 
synthesis and accumulation of matrix components and their breakdown under the catalitic 
action of metalloproteases. Several MMPs have been identified in the inflamed gingival 
tissues: MMP-1, -2, -3, -8, -9, -13, produced by the keratinocytes, macrophages, 
polymorphonuclear leukocytes (Banita et al., 2011; Bartold & Narayanan, 2006; Bildt et al., 
2008; Kubota et al., 2008; Kumar et al., 2006). Their activity could be different depending on 
the severity of disease and the needs for extracellular matrix digestion.  
In a previous study regarding the expression of MMPs in gingival samples of chronic 
periodontitis we observed an enhanced expression of MMP-1 in keratinocytes from diseased 
epithelial layers (Fig.4). In some cases, MMP-1 expression extended to the lamina propria as 
inflammation progressed. MMP-1 increased activity could explain the change of collagen 
quality and quantity, since its preferred substrates are the type I and type III collagens.  
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Type of MMPs Substrates Members 
Collagenases 
Native fibrilar collagens  
(I, II, III, VII, VIII, X) 
Gelatins (limited) 
Other ECM molecules 
MMP-1 (Collagenase 1) 
MMP-8 (Neutrophil collagenase) 
MMP-13 (Collagenase 3) 
Gelatinases 
Denaturated collagens (gelatins) 
Type IV collagen  
Other ECM molecules 
MMP-2 (Gelatinase A) 
MMP-9 (Gelatinase B) 
Stromelysins 
Collagens III-V  
Gelatins (limited) 
Other ECM molecules  
MMPs 
MMP-3 (Stromelysin 1) 
MMP-10 (Stromelysin 2) 
Matrilysins 
Collagen IV and X, gelatins 
Other ECM molecules  
MMPs  
MMP-7 (Matrilysin 1) 
MMP-26 (Matrylisin 2) 
Membrane type - 
MMPs  
Collagen (I, II, III) 
Pro-MMP-2 
Other ECM molecules  
MT1-MMP - MT6-MMP 
(MMP-14, MMP-15, MMP-16, 
MMP-17, MMP-24, MMP-25) 
Table 1. Major types of matrix metalloproteinases (MMPs)  
Several other researchers reported an intense MMP-1 collagenolytic activity in fibroblasts 
and macrophages resident in the periodontal tissue (Beklen et. al., 2007; Kubota et al., 2008) 
and focused on the interrelation between MMP-1 and MMP-3 in order to amplify the 
proteolysis in chronic periodontitis (Beklen et. al., 2007). 
 
 
Fig. 4. Expression of MMP-1 in gingival epithelium in chronic periodontitis (IHCx40) 
Regarding MMP-2, we observed an increased expression of this enzyme in many 
keratinocytes from the basal layer and in some cells from the basement membrane (Fig. 5); 
the active form of MMP-2 increased significantly as inflammation progressed.  
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Fig. 5. Increased expression of MMP-2 in gingival epithelium and basement membrane in 
chronic periodontitis (IHCx20) 
Its expression and distribution is justified by the fact that this gelatinase has an important 
role in the degradation of denatured collagen (predigested with MMP-1) and type IV 
collagen of the basement membrane, and these processes are increased in various stages of 
periodontal disease progression. MMP-2 is also able to increase matrix degradation by 
MMP-13 and neutrophil collagenase (De Souza & Line, 2002). The degenerative process 
causes the loss of attachment apparatus between tooth, epithelium, and connective tissue 
which accelerates inflammation and deepening of periodontal pocket. In the last decade, 
many research groups reported the putative role of other MMPs (MMP-7, MMP-25, MMP-
26, MT1-MMP) as mediators of the alternating sequence inflammation-fibrosis during 
progression of periodontal disease (Emingil et al., 2006a, 2006b; Oyarzun et al., 2010).  
3.2 Tissue inhibitors of matrix metalloproteinases  
MMPs activity is controlled in vivo in three ways: i) these enzymes are synthesized and 
secreted as latent, inactive precursors and conversion to the active form require activation; 
ii) production of MMPs can be regulated by growth factors and cytokines; iii) their activity 
can be inhibited by endogenous serum and tissue inhibitors (Nagase, 1997, as cited by 
Bartold & Narayanan, 2006). Various tissues express one or more of the members of the 
most important group of inhibitors known as tissue inhibitors of MMP (TIMPs). These are 
specific inhibitors that bind MMPs in a 1:1 stoichiometry. All the four currently known 
TIMPs (TIMP-1, TIMP-2, TIMP-3, and TIMP-4) are very well conserved since they have been 
identified in vertebrates, including humans, insects and even in the nematode, Caenoharbditis 
elegans (Brew et al., 2000). Their expression is rigorous regulated during development and 
tissue remodelling under pathological conditions associated with unbalanced MMP 
activities, and changes of TIMP levels are considered to be important because they directly 
affect the level of MMP activity (Visse & Nagase, 2003). TIMP-1 and TIMP-3 expression is 
inducible, whereas TIMP-2 is largely constitutive (Verstappen & Van den Hoff, 2006). TIMPs 
are produced in many tissues, although not every tissue expresses all four inhibitors. Most 
mesenchymal and epidermal cells are able to produce TIMPs in various conditions (Rowe et 
al., 1997, as cited by Verstappen & Van den Hoff, 2006), but TIMP-4 expression is restricted 
to neural tissue, gonads, breast and skeletal muscle (Lambert et al., 2004).  
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Our studies regarding the modulation of MMP/TIMP balance in gingival overgrowth 
associated with periodontitis lead to the following observations related to TIMP activity. We 
noticed that the immune reaction for TIMP-1 was positive in few epithelial cells in 
periodontitis-affected gingival samples assessed (Banita et al., 2011). For TIMP-2 the 
immune response was quite different. We observed extended areas of TIMP-2 intense 
positive cells in the epithelium (Fig.6) and a lot of TIMP-2 positive pro-inflammatory cells 
and few fibroblasts in the lamina propria (Fig.7). 
 
Fig. 6. TIMP-2 expression in gingival epithelium in periodontitis–affected gingiva (IHCx40) 
 
Fig. 7. TIMP-2 expression in periodontitis-affected gingival lamina propria (IHCx20) 
Our results showed increased levels for both MMPs and TIMPs assessed in periodontitis-
affected gingival tissue and are in accordance with other similar studies. Up-regulated MMPs 
and TIMPs expression with a modified MMPs/TIMPs ratio depending on the type of lesion 
(destruction or fibrosis) indicate that the imbalance between degradation and synthesis of the 
extracellular matrix components persists in periodontitis-affected gingiva and is responsible 
for an increased tissue breakdown in periodontitis. The reciprocal regulation of TIMPs and 
MMPs expression may depend on endogenous growth factors and cytokines.  
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4. Growth factors and cytokines in periodontal disease  
The balance between MMPs and TIMPs influence on extracellular matrix homeostasis in 
different types of tissues is tightly controlled by growth factors, a class of polypeptide 
hormones. Other polypeptide mediators that affect matrix synthesis include several 
cytokines - interleukins (IL-1, IL-4, IL-6, IL-10) and tumour necrosis factor-α (TNF-α). By 
binding to specific cell-surface tyrosine kinase receptors, growth factors are able to regulate 
significant cellular events in tissue regeneration and repair, including cell growth, 
proliferation and differentiation, chemotaxis, angiogenesis, and extracellular matrix 
synthesis (Giannobile, 1996). Growth factors are classified as biological mediators that lack 
specificity sequestered in the extracellular matrix and molecules available from the 
circulation (Bartold & Narayanan, 2006). Growth factors demonstrate pleiotropic or multiple 
effects on wound repair in almost all tissues, including the periodontium.  
Some of the most important growth factors exerting functions in healthy and diseased 
periodontium are listed below: 
a. Platelet-Derived Growth Factor (PDGF)  
b. Fibroblast Growth Factors (a-FGF and b-FGF) 
c. Transforming Growth Factors (TGF-α and -β) 
d. Connective Tissue Growth Factor (CTGF) 
e. Vascular Endothelial Growth Factor (VEGF)  
f. Insulin-like Growth Factors (IGF-I, IGF-II)  
g. Epidermal Growth Factor (EGF)  
h. Hepatocyte Growth Factor (HGF) 
After an injury occurs, healing proceeds in a succession of “well orchestrated” cell-cell and 
cell-extracellular matrix interactions. In the process of normal wound healing, the growth 
factors act in conjunction to form a complex arrangement of molecules that regulate cellular 
activity and bordering the wound (Giannobile, 1996). Table 2 lists the sources and the main 
effects of some growth factors and cytokines important for extracellular matrix remodelling.  
The role of growth factors is now recognized in connective tissue homeostasis during 
inflammation and fibrosis. Tissue repair studies conducted on animals provide evidence 
that soft tissue wound healing is enhanced by EGF, TGF-α and β, PDGF, acidic and basic 
FGF. Combinations of different growth factors yield greater repair than can be achieved by 
individual factors alone (Giannobile, 1996). 
Growth factors mediate many events associated with turnover, repair and regeneration of 
periodontal tissues. Gingival epithelial cells, gingival fibroblasts, and periodontal ligament 
fibroblasts are the major cells involved in tissue repair. An appropriate response of these 
target cells to various growth factors depends on the expression of corresponding receptors.  
a) Platelet-Derived Growth Factor. In vitro and in vivo studies suggest PDGF as the most 
thoroughly described growth factor associated with periodontal health. There are different 
isoforms of PDGF (PDGF-AA, -AB, -BB), and all have been shown to have a fibroblast 
proliferative activity in vitro (Giannobile, 1996). PDGF is present in increased levels in the 
human inflamed gingiva and is mainly localized to the pocket epithelium (Pinheiro et al., 
2003).  
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Table 2. Sources and major functions of several growth factors and cytokines  
It is possible that expression of PDGF contributes to the inflammatory changes that occur 
during periodontal diseases. PDGF supports the healing in the periodontal soft tissues in a 
variety of ways. Since PDGF is chemotactic for fibroblasts, it induces collagen synthesis, but 
also stimulates fibroblasts to synthesize the proteoglycans that supply the framework for 
extracellular matrix development. Lipopolysaccharide, the major constituent of the cell 
walls of gram-negative bacteria, inhibits the proliferation of gingival fibroblasts and PDGF 
decreases this inhibitory effect (Bartold & Narayanan, 1992). Reported data suggest that 
there may be cell specific differences in response to PDGF isoforms critical to periodontal 
healing that may be exploited in the development of efficient therapies (Mumford et al., 
2001).  
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b) Transforming Growth Factor-β (TGF-β). TGF-β superfamily consists of several multifunctional 
structurally related growth and differentiation factors associated to the inflammatory 
response, known also to be involved in apoptosis, angiogenesis, wound healing and fibrosis 
(Frank et al., 1996; Lawrence, 1995). There are three TGF-β isoforms important for humans, 
TGF-β1, 2 and 3; their amino acid sequences are 70-80% homologous but they can be 
distinguished by the effects on cell growth, biological interactions and receptor binding 
abilities (Frank et al., 1996). TGF-β1 is expressed in epithelial, hematopoietic, and connective 
tissue cells (Massague, 1998). Because TGF-β1 exhibits both pro-inflammatory and anti-
inflammatory properties besides its ability to stimulate synthesis of ECM molecules and to 
inhibit the breakdown of ECM, it has been intensively evaluated in relation to all types of 
gingival overgrowth.  
Regarding TGF-β1 expression in chronic periodontitis, we noticed a positive reaction in 
some keratinocytes from the gingival basal epithelial layer (Fig.8), and pro-inflammatory 
cells infiltrating lamina propria (Fig.9).  
 
Fig. 8. TGF-β1 expression in gingival epithelium in periodontitis (IHCx20) 
 
Fig. 9. TGF-β1 expression in inflammatory cells infiltrating lamina propria of periodontitis-
affected gingiva (IHCx20) 
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Our results confirm that increased gingival inflammation is associated with high levels of 
TGF-β isoforms. It is well known that TGF-β is one of several cytokines able to regulate 
inflammation and immune responses and the fact that TGF-β mediates leukocyte 
recruitment, adhesion and activation suggests that it play a key role in the host response to 
bacterial and immunological insults (Prime et al., 2004), even there is not a clear evidence for 
its role in the pathogenesis of the periodontal disease. But TGF-β has also a marked effect on 
ECM homeostasis, being an important mediator of fibroblast proliferation and ECM 
synthesis. The inverse relationship between TGF-β1 and MMP-1 expression in the gingival 
epithelium noticed in our studies could be in accordance with TGF- β1 action as inhibitor of 
MMP-1 activity and proves that TGF-β mediates a tight control of the MMP/TIMPs 
equilibrium and synthesis of matrix macromolecules. TGF-β1 pro-fibrotic role could be 
explained also by the stimulation of collagen synthesis in lamina propria. There are 
considerable data supporting the fact that under pathological conditions, TGF-β1 
orchestrates a cross talk between parenchymal, inflammatory and collagen expressing cells 
and have a key role in control inflammation and fibrosis (Buduneli et al., 2001b; Ellis et al., 
2004; Wright et al., 2001). The role of TGF-β1 in gingival overgrowth must be considered in 
line with natural development of the periodontal lesion, as inflammation preceedes fibrosis, 
and with its stadial activity. First, it acts as a pro-inflammatory cytokine that mediate the 
recrutation of monocytes-macrophages, their adhesion and action at site lesion, suggesting a 
key role in the host-response to the presence of the bacterial products. Finally, as the 
inflammation progresses, TGF-β1 overexpression in epithelial and fibroblasts could be a 
response to paracrine stimulation by other cytokines secreted by the pro-inflammatory cells. 
Despite the great interest for this growth factor, the precise role of TGF-β1 in the 
pathogenesis of periodontitis-induced gingival overgrowth is still under debate. 
c) Connective Tissue Growth Factor (CTGF). The CCN family consists of six multifunctional 
members including CCN1 (Cyr61), CCN2 (connective tissue growth factor, CTGF), CCN3 
(Nov), CCN4 (WISP1), CCN5 (WISP2), and CCN6 (WISP3) (Brigstock, 2003). The functions 
of this family include embryogenesis, wound healing, and regulation of ECM production. 
CTGF is a matricellular cysteine-rich peptide that plays a variety of important roles in cell 
development and differentiation and acts to promote fibrosis in many different tissues in 
cooperation with other growth factors and extracellular matrix proteins (Leask & Abraham, 
2003). These findings rise the hypothesis that CTGF could play a role in gingival fibrosis.  
In periodontitis, we observed a different pattern of CTGF distribution in gingival structures. 
Many samples showed an intense positive reaction in basal and parabasal epithelial layers 
but also in structures from the lamina propria (Fig.10). Higher CTGF staining in overgrown 
gingiva was accompanied by an increased number of fibroblasts and collagen fibers, in 
accordance with CTGF contribution to increase fibrosis. Fibrosis, as well as physiological 
wound repair and inflammation, involves the same molecules and cellular events (Bartold & 
Narayanan, 2006). As a consequence of inflammation, fibrosis can be the result of several 
events: abnormal release of mediators and persistence of changes in the abnormal growth 
factor/cytokine profile, and proliferation of cells with an abnormal phenotype responsible 
for the excessive extracellular matrix synthesis that characterize fibrosis. CTGF alone does 
not promote fibrosis. Recent studies indicate that CTGF binds to other factors, resulting in 
either inhibition or stimulation activity (Kantarci et al., 2006, Trackman & Kantarci, 2004). 
CTGF binding to VEGF results in inhibition of VEGF while CTGF binding to TGF-β1 is 
reported to be stimulatory (Trackman & Kantarci, 2004). Therefore simultaneous production 
of both TGF-β1 and CTGF is required to sustain fibrosis in gingival overgrowth.  
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Fig. 10. Intense expression of CTGF in periodontitis-affected gingival epithelium (IHCx20) 
d) Basic Fibroblast Growth Factor (bFGF or FGF-2). FGFs are a family of at least 23 structurally 
related polypeptides known to play a critical role in angiogenesis and mesenchymal cell 
mitogenesis. In periodontium, FGF-2 is present in the extracellular matrix, as well as in the 
cementum and can function as a local factor at the site (Gao et al., 1996). In periodontitis, the 
presence of bFGF was reported in the gingival epithelium, inflammatory cells and 
connective tissue (Laurina et al., 2009). They noted also a more increased expression of FGF 
receptor (FGFR) in hyperplasic gingival tissue compared to normal. One of their conclusions 
was that the expression of growth factors and their receptors in sulcular epithelium was 
lower than into the gingival epithelium and seems to be specific for periodontitis (Laurina et 
al., 2009). 
e) Epidermal Growth Factor (EGF). EGF is a multifunctional cytokine with a variety of 
biological functions including epithelial growth and differentiation, and wound healing. In 
the periodontium, EGF seems to exert only a minor effect on the promotion of mitogenesis, 
chemotaxis, or matrix synthesis in periodontal ligament fibroblasts (Giannobile, 1996). He 
supposed that EGF receptors (EGF-R) localization in periodontal ligament fibroblasts may 
stabilize the periodontal ligament fibroblast phenotype or cellular physical characteristics. 
Buduneli et al. (2001c) evaluated the expression of EGF-receptor (EGFR) in frozen sections of 
cyclosporine (CsA)-induced gingival overgrowth using immunohistochemical and 
semiquantitative techniques. Gingival biopsies were obtained from 12 renal transplant 
patients receiving CsA as well as from 9 systemically and periodontally healthy individuals. 
The authors suggested that CsA affects EGFR metabolism in gingival keratinocytes resulting 
in an increased number of cell surface receptors, which may eventually play a role in the 
pathogenesis of gingival tissue alterations. In chronic periodontitis, EGFR was regionally 
detected in gingival epithelium in some cases (Laurina et al., 2009). Other in vivo studies are 
needed to reveal the precise effects of EGF on soft periodontal tissue healing.  
f) Insulin-Like Growth Factors (IGFs). IGFs are a family of mitogenic proteins that control 
growth, differentiation, and the maintenance of differentiated function in numerous tissues. 
The IGF family includes three ligands (insulin, IGF-I, and IGF-II), their corresponding cell 
surface receptors (IR, IGF-IR, and IGF-IIR), and at least six IGF-binding proteins (IGFBPs) 
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able to bind circulating IGFs and modulate their biological actions. Studies have suggested 
that IGF-I has an important involvement in periodontal wound healing and regeneration. 
IGF-I is chemotactic for cells that come from the periodontal ligament and demonstrates 
significant effects on the mitogenesis of periodontal ligament fibroblasts (Giannobile, 1996). 
IGF-I is able to prevent apoptosis in fibroblasts, to regulate DNA and protein synthesis in 
periodontal ligament fibroblasts in vitro and to enhance soft tissue wound healing in vivo 
(Werner & Katz, 2004). Regarding the IGF-IR expression in chronic periodontitis, Laurina et 
al. (2009) reported only a weak presence in the sulcular epithelium suggesting a potential 
role in regeneration of periodontal tissue. The effect of IGF-II on the metabolism of gingival 
fibroblasts is still uncertain. 
h) Hepatocyte growth factor (HGF). HGF is a multifunctional cytokine involved in the repair 
and regeneration of various tissues and their protection from injury (Matsumoto & 
Nakamura, 1997) and recently, it has been linked also to the development of periodontal 
disease (Ohshima et al., 2001; Ohnishi & Daikuhara, 2003). HGF may be closely involved in 
the pathogenesis and progression of periodontal disease because it stimulates excessive 
proliferation and invasion of gingival epithelial cells and impair the regeneration of deep 
collagenous structures in the periodontium (Ohshima et al., 2001). 
g) Vascular Endothelial Growth Factor (VEGF). Over the last two decades researchers have 
demonstrated that VEGF is a key regulator of physiological and pathological angiogenesis, 
because it induces endothelial cell proliferation, stimulates angiogenesis and increases 
vascular permeability (Ferrara, 2009). In the last decade, many groups focused their research 
on the angiogenic factors that contribute to periodontal healing. In periodontitis patients, 
VEGF was detected within vascular endothelial cells, neutrophils, plasma cells, and 
junctional, pocket and gingival epithelium (Booth et al, 1998). In a previous study on 
biopsies obtained from patients with type 2 diabetes associated gingival overgrowth, we 
detected VEGF expression in keratinocytes from the basal and spinous layers and in many 
de novo capillaries (Pisoschi et al., 2009). Other authors reported increased VEGF expression 
in epithelial cells and endothelial cells in periodontitis-affected gingiva (Guneri et al., 2004; 
Keles et al., 2010; Lucarini et al., 2009). Giannobile et al. (2003) suggested that VEGF could be 
an important growth factor for the onset of gingivitis and its progression to periodontitis. 
Taken together these observations conclude that VEGF expression is related to both 
maintenance of periodontal health and periodontal tissue destruction but the precise 
mechanism of neovascularization remains in debate.  
5. Gingival crevicular fluid and salivary growth factors as potential 
biomarkers of periodontal disease 
Traditional periodontal diagnostic methods include assessment of clinical parameters 
(probing pocket depth, bleeding on probing, clinical attachment loss, plaque index), and 
radiographs but these conventional techniques are of limited usefulness because they are 
not sufficiently accurate to discern between previous periodontal disorders and present 
disease activity. For this reason, development of non-invasive diagnostic tools has presented 
a significant challenge to periodontology. Recently, gingival crevicular fluid (GCF) and 
saliva are in the middle of high-throughput techniques aimed to validate tests for the 
objective diagnosis of disease, monitoring, and prognostic indicators. Oral fluids contain 
locally and systemically derived mediators of periodontal disease, including pathogens, 
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host-response, and bone-specific markers (Kinney et al., 2007). Most biomarkers assessed in 
oral fluids are inflammatory cytokines, but some collagen degradation products and bone 
turnover-related molecules have emerged as possible markers of periodontal disease 
activity, too. Most biomarkers in GCF and saliva are indicators of soft-tissue inflammatory 
events (pathogens infection and host inflammatory response) that precede the destruction of 
the alveolar bone (Buduneli & Kinane, 2011).  
The detection of connective tissue-derived molecules may provide a more precise 
assessment of the breakdown of periodontal tissues, especially in light of the variability in 
the host response of different individuals (Giannobile et al. 2003).  
Among those which are the potential candidates for oral fluid-based diagnostics of 
periodontal disease are included: alkaline phosphatase, MMP-8, MMP-9, MMP-13, 
osteocalcin, osteonectin, osteopontin, and pyridinoline cross-linked carboxyterminal 
telopeptide of type I collagen (Arikan et al., 2008, 2011; Buduneli et al., 2008; Kinney et al., 
2007; Miller et al., 2006; Ozçaka et al., 2011) but the list is still open.  
Extracellular matrix molecules that are derived from the periodontium have been identified 
in GCF and saliva. Although growth factors function as molecular mediators of periodontal 
tissues repair their value as diagnostic biomarkers of periodontal tissue inflammation 
and/or destruction has yet elucidated.  
Research in this area has reported the assessment of GCF and salivary levels of several 
growth factors for their potential to diagnose periodontal disease, including EGF, TGF-β, 
PDGF, HGF, and VEGF (Buduneli et al., 2001b; Chang et al., 1996; Gurkan et al., 2006; 
Hormia et al., 1993; Kamimoto et al., 2002; Sakallioglu et al., 2007; Wilczynska-Borawska et 
al., 2006).  
We were also interested to seek a relationship between salivary levels of growth factors and 
other molecules (MMPs, TIMPs, TNFα) related to host response and morphological and 
clinical changes observed in periodontitis. We compared the salivary concentration of TGF-
β1 and CTGF in patients with periodontal disease and healthy control subjects. We didn’t 
obtain any significant difference for the salivary TGF-β1 levels between healthy subjects and 
those with gingivitis. Only the values obtained for salivary TGF-β1 in chronic periodontitis 
differ significantly from those found for control subjects but even in this case we observed a 
great difference between the smallest and the highest values (Pisoschi et al., 2010). This 
variation could be explained by the duration of the candidate risk factors on TGF-β1 levels, 
being well known that periodontal disease is characterized by periods of active tissue 
destruction and quiescence. Our findings are in accordance with the results reported by 
other researchers for the variation of TGF-β1 levels in patients with aggressive and chronic 
periodontitis (Gurkan et al., 2006). We also obtained a good correlation between salivary 
concentration and gingival expression of TGF-β1. So far, we didn’t find any significant 
differences between salivary CTGF levels of patients with gingivitis, chronic periodontitis 
and controls (unpublished data). However, CTGF concentrations were higher in samples 
obtained from patients with type 2 diabetes associated gingival overgrowth (Pisoschi et al., 
2011). Regarding the level of circulating and oral fluids TGF-β1 and CTGF, we agree with 
other researchers that variation in the analytical technique used in sample assessment might 
influence the values. 
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As we mentioned before, many reports sustained the importance of VEGF in the 
pathogenesis of periodontal disease. Therefore researchers attempted to find a correlation 
between GCF or salivary VEGF levels and its tissue expression in order to link this 
biomarker with the degree of periodontal damage. A recent study of Pradeep et al. (2011) 
that included patients with gingivitis and chronic periodontitis, reported an increase of 
VEGF concentration in GCF and a positive correlation between GCF and serum VEGF 
levels. Moreover a correlation between growth factor levels and clinical periodontal 
parameters before and after nonsurgical periodontal treatment was observed.  
Even the results of much research have confirmed the presence of several growth factors in 
GCF and saliva, for many of them the relation between their variation and the severity of the 
periodontal disease is still unclear. In the future, high-throughput proteomic and 
metabolomic technologies will be critical in establishing whether a biomarker could be 
accurate to diagnose and predict the severity of the periodontal disease.   
6. Growth factors as therapeutic tools in periodontal disease 
Therapeutic approaches for treatment of periodontitis are divided into two categories: i) 
anti-infective treatment, and ii) regenerative therapy. 
Several restoring techniques have been developed to regenerate periodontal tissues 
including guided tissue regeneration, bone grafting, and use of enamel matrix derivatives. 
Principles of guided tissue regeneration dictate that one of the goals of therapy is to 
modulate the repopulation of the wound with cells derived from the periodontal ligament 
rather than from the gingival tissues (Mumford et al., 2001). However, this technique is not 
associated with complete periodontal regeneration and a major complication and limiting 
factor in the achievement of periodontal regeneration is the presence of microbial 
periodontopathogens that contaminate wounds and reside on tooth surfaces as plaque-
associated biofilms.  
For more than a decade, periodontal researchers have been studying the potential of growth 
factors to achieve predictable periodontal regeneration. It is accepted that many growth 
factors are produced as inactive propeptides and stored in the cytoplasm (Anusaksathien & 
Giannobile, 2002). Cleavage of these propeptides and extracellular secretion of the mature 
forms provide the growth factors able to bind on their specific receptors. 
Growth factor therapies are directed to stimulate the specific progenitor cells which are 
responsible for the regeneration of mineralized and nonmineralized tissues in the 
periodontium but also to limit periodontal degradation. Therapeutic application of growth 
factors to restore damaged tissue aims the regeneration through biomimetic processes, or 
mimicking the processes that occur during embryonic and post-natal development 
(Schilephake, 2002). The complexity of these events suggests that creating an optimal 
regenerative environment requires the combination of different growth factors as found in 
natural processes. But also the use of a single recombinant growth factor may induce several 
molecular, biochemical and morphological cascades that will result in tissue regeneration. 
Almost all the growth factors are believed to be potential targets for the periodontal 
regenerative therapy but few strategies are subjected to various phases of clinical trials. 
Growth factors tested for their contribution to periodontal regeneration include PDGF,  
IGF-I, TGF-β1, bFGF and some bone morphogenetic proteins (Giannobile et al., 1996, 2001; 
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Murakami et al., 1999; Taba et al., 2005). Results from the in vivo studies have shown that all 
of the above mentioned bioactive molecules, with the exception of TGF-β1, exhibited ability 
to promote periodontal tissue regeneration and suggest that there may be cell-specific 
differences critical to periodontal wound healing that may be exploited in the development 
of new therapies.  
PDGF was the first growth factor to be evaluated in preclinical periodontal regenerative 
studies. In vitro studies had shown that exogenous application of PDGF at different 
concentrations (between 0,01 and 10 ng/ml) resulted in proliferation, migration and matrix 
synthesis in cultures of periodontal cells, including gingival and periodontal ligament 
fibroblasts, cementoblasts, preosteoblasts and osteoblasts in a time and dose dependence 
(Kaigler et al., 2006). From all its isoforms, PDGF-BB is the most effective on periodontal 
ligament cell mitogenesis and extracellular matrix macromolecules biosynthesis (Bartold, 
1993; Ojima et al., 2003). Even periodontal ligament fibroblasts and gingival fibroblasts have 
been shown to proliferate rapidly, gingival fibroblasts have been shown to fill a wound 
space significantly faster than periodontal ligament cells and this is an unwanted effect 
(Mumford et al., 2001). Studies on combination growth factor therapy involving PDGF and 
IGF-I have consistently promoted the periodontal regeneration (greater osseous and new 
attachment response) in animal models and lead to the first study in humans using growth 
factors for periodontal regeneration. In their human phase I/II clinical trial, PDGF/IGF-I 
were considered safe when applied topically to periodontal osseous lesions, resulting in a 
significant improvement in bone growth and fill of periodontal defects, compared with 
standard therapy (Howell et al., 1997, as cited by Kaigler et al., 2006). 
TGF-β plays a significant role in periodontal regeneration. It is pleiotropic, and can 
stimulate or inhibit cell growth, an action that can interfere with its therapeutic use (Clokie 
& Bell, 2003). TGF-β1 has been used for this application. The results of rhTGF-β1 for 
periodontal regeneration have not been consistent preclinically as shown in dogs and sheeps 
investigations (Mohamed et al., 1998; Tatakis et al, 2000, as cited by Kraigler et al., 2006). 
These studies showed little advantages in new bone formation and no improvement in 
cementum regeneration when treated with rhTGF-β1. Other research demonstrated that 
TGF-β1 increased the amount of bone healing adjacent to dental implants in minipigs 
(Clokie & Bell, 2003). TGF-β can also modulate other growth factors, such as PDGF, EGF, 
and FGF, by altering their cellular response or by inducing their expression.  Combined 
therapies, which involved PDGF and TGF-β, have demonstrated synergistic effects and 
enhanced regeneration. Together, PDGF and TGF-β have stimulated gingival fibroblasts and 
periodontal ligament cells. Some authors reported that TGF-β, both alone and in 
combination with PDGF, led to a greater proliferation of periodontal ligament cells 
compared to the gingival fibroblasts. On the contrary, PDGF stimulated a significantly 
greater proliferation of gingival fibroblasts compared to periodontal ligament cells. Since 
periodontal proliferation at the diseased site is a desired feature in periodontal regeneration 
and because of the limited number of studies and inconsistent results, the use of TGF-β will 
be further emphasized and thoroughly investigated. 
Several studies reported that FGFs can stimulate mitogenesis and chemotaxis in periodontal 
ligament cells (Takayama et al., 1997; Terranova et al., 1989). FGFs increased osteoblast 
proliferation, although they do not directly increase collagen production by differentiated 
osteoblasts. They have shown bFGF stimulates human endothelial and periodontal ligament 
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cell migration and proliferation on the dentin surfaces, and that the combination of bFGF with 
fibronectin can further enhanced periodontal ligament cell chemotaxis. Despite different 
concentrations of bFGF and different delivery systems used in the studies, all showed an 
improvement in the periodontal tissue regeneration. Studies that evaluated more than one 
concentration of bFGF suggested that its effects are dose dependent (Murakami et al., 2003).  
The results from preclinical and initial clinical studies using growth factors are encouraging; 
however, some limitations exist with respect to bone volume and predictability. Trials 
utilizing topical growth factors have revealed difficulties in maintaining therapeutic levels 
of proteins and to obtain optimal outcomes in vivo; of great importance is to enhance the 
half-life of growth factors and their biological stability (Yun et al., 2010). Based on the results 
of studies that support in vitro biological functions of FGFs for tissue regeneration, the 
largest in vivo study in the field of periodontal regenerative therapy was initiated by 
Kitamura’s team. This was a human clinical trial projected to determine the safety and 
efficiency of FGF-2 for clinical application. Their results support that topical application of 
three doses of FGF-2 during periodontal surgery could be efficient for the regeneration of 
periodontal tissue (Kitamura et al., 2008).  
Future clinical application of growth factors in the regeneration of periodontal tissues will 
be achieved when their biological functions are maximized by the appropriate use of 
biomaterials and stem cells.  
7. Conclusions  
The biology of periodontal connective tissues is important to be understood in terms of 
development, pathology, regeneration and interrelationship between periodontitis 
interactions and various systemic diseases. Although growth factors function as molecular 
mediators of periodontal tissues, their value as diagnostic biomarkers for periodontal tissue 
inflammation and/or fibrosis is yet to be elucidated. High-throughput technologies applied 
for assessment of gingival crevicular fluid and saliva will give new promises for the use of 
growth factors as objective biomarkers in periodontal disease.  
In earlier studies, the application of growth factors provided different degrees of success in 
stimulating wound healing in the periodontal areas. There is an imperious need to further 
evaluate the biologic mechanisms that may be responsible for the promotion of tissue 
regeneration by growth factors. Finally, studies on growth factors delivery and improved 
stability seek evidence to conclusively support the addition of growth factors strategy to the 
therapeutic protocol for regeneration of periodontal tissues.  
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1. Introduction 
Periodontitis is one of the most common oral diseases and is characterised by gingival 
inflammation and alveolar bone resorption (Savage et al. 2009). Periodontitis is a 
multifactorial irreversible and cumulative condition, initiated and propagated by bacteria 
and host factors (Kinane 2001). More than 500 different bacterial species are able to colonise 
the oral biofilm and up to 150 different species of bacteria are possible in any individual’s 
subgingival plaque. There are two forms of periodontitis; chronic and aggressive 
periodontitis which differ from each other not only in clinical findings but also age of onset 
and rate of progression. Chronic periodontitis progresses more slowly compared to the 
aggressive forms of periodontitis and responds much better to periodontal treatment. 
According to a report by the World Health Organisation, severe chronic periodontitis 
leading to tooth loss was found in 5% to 15% of most populations worldwide (Armitage 
2004). Hence, it can be considered among the prevalent and important global health 
problems in terms of quality of life. 
The multifactorial nature of periodontitis is based on the complex interactions between 
microorganisms in the microbial dental plaque, namely dental biofilm, host response 
mechanisms and environmental factors. Smoking is well known to be the leading 
environmental factor that is closely related not only with the risk but also the prognosis of 
periodontitis. Indeed, the harmful effects of smoking on numerous organs have been well-
documented for years now. Cigarette smoking is recognised as the major preventable cause 
of death in the United States (Centres for Disease Control 2002 (CDC 2002)). Smoking is the 
second strongest modifiable risk factor for periodontal disease after the first one which is the 
microbial dental plaque. Smokers are more likely to harbour a higher prevalence of potential 
periodontal pathogens, and smoking impairs various aspects of innate and acquired 
immune responses. Numerous molecules in the oral fluids namely; gingival crevicular fluid 
(GCF) and saliva, as well as molecules in blood circulation; serum or plasma have been 
investigated so far in an attempt to provide a sensitive and specific marker for periodontal 
tissue destruction (Buduneli & Kinane 2011). The aim of the present literature review is to 
provide an overview of the evidence for smoking as a risk factor for chronic periodontitis 
and to discuss the possible mechanisms of action and finally the negative effects of smoking 
on the outcomes of periodontal treatment in patients with chronic periodontitis. 
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Smokers are accepted to be more susceptible to advanced and aggressive forms of 
periodontitis than non-smokers (Haber et al. 1993, Calsina et al. 2002) and former smokers 
are at decreased disease risk than current smokers (Bostrom et al. 2001). Tobacco smoking 
modifies the periodontal response to microbial challenge (Barbour et al. 1997, Palmer et al. 
2005). Although, smoker and non-smoker patients exhibit more or less the same periodontal 
pathogens (Preber et al. 1992, Buduneli et al. 2005a) smokers also tend to respond less 
favourably to periodontal treatment (Ah et al. 1994, Renvert et al. 1998). Smoking was 
suggested to influence host cytokine levels (Boström et al. 1999, Buduneli et al. 2005b, 
Buduneli et al. 2006). Furthermore, smoking was reported to reduce salivary osteoprotegerin 
concentrations in untreated and also treated chronic periodontitis patients (Buduneli et al. 
2008). Chronic periodontitis has been associated with various systemic diseases and/or 
conditions such as cardiovascular diseases and preterm low birth weight. Over the last 
decade there have been a number of reviews that have considered the biological 
mechanisms underlying  susceptibility to periodontitis in smokers (Barbour et al. 1997, 
Johnson & Hill 2004, Kinane & Chestnutt 2000, Mullally 2004, Palmer et al. 2005, Scott et al. 
2001). Despite that a clear dose-response relationship between chronic periodontitis and 
smoking was reported (Martinez-Canut et al. 1995) the mechanisms by which smoking 
contributes to the pathogenesis of periodontitis are not yet clearly understood. 
The fundamental mechanisms that lead to the development of chronic periodontitis are 
closely related to the dynamics of the host immune and inflammatory responses to 
periodontal pathogens present in the dental biofilm (Gemmell & Seymour 2004). The 
immune and inflammatory responses are critical to understanding the pathogenesis of 
periodontal diseases and they are orchestrated by a number of host-related factors, either 
intrinsic or induced (Taubman et al. 2005). Under normal circumstances, there is a balance 
between microbial virulence factors and host response. Tissue homeostasis is maintained as 
long as this balance is preserved. In periodontitis, this balance between the microbial 
virulence factors and host response is impaired in favour of microbial challenge. Smoking as 
an environmental factor has been suggested to interact with host cells and affect 
inflammatory responses to this microbial challenge (Palmer et al. 2005). It is also likely that 
the toxic components of tobacco smoke, mainly nicotine, may directly or indirectly 
deteriorate periodontal tissues. Cigarette smoking represents a risk factor for progression of 
periodontitis, the effect of which may be dose related. Heavy smokers should be considered 
as high-risk individuals for progression of periodontitis. The clinical implications for this are 
that smokers should be identified during patient examination and efforts should be made to 
modify this behavioural risk factor. Furthermore, smoking or molecules related to smoking 
such as blood cotinine induced by smoking should be considered as important risk markers 
of periodontal disease that are relevant to the assessment of prognosis (Calsina et al. 2002, 
Tang et al. 2009). 
Smokers are almost four times more likely to have severe periodontitis than non-smokers 
(Haber et al. 1993). Nicotine and lipopolysaccharide (LPS) effects on the expression of 
macrophage colony-stimulating factor (M-CSF), osteoprotegerin (OPG), and prostaglandin E2 
(PGE2) have been evaluated by Tanaka et al. (2006) in osteoblasts and osteoclast-like cells. OPG 
expression was increased in the initial stages of culture with nicotine and LPS but decreased in 
the later stages of culture. Apatzidou et al. (2005) stated that smokers with periodontal disease 
have a suppressed inflammatory response, a significantly less favourable clinical outcome and 
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seem to have an altered host antibody response to antigenic challenge than non-smokers 
although; the subgingival microflora of smokers appears similar to that of non-smokers. 
Lappin et al. (2007) reported decreased serum OPG levels and greater soluble receptor 
activator of nuclear- factor kappa B ligand (sRANKL) sRANKL/OPG ratios in smoker patients 
in the maintenance program than the non-smoker counterparts. Negative correlation between 
pack-years and total OPG amount in peri-implant crevicular fluid was detected in clinically 
healthy implants (Arkan et al. 2008). Our recent finding of higher sRANKL, lower OPG 
concentrations in saliva of untreated/treated smokers than non-smokers (Buduneli et al. 2008) 
confirmed these findings. Furthermore, our saliva data (Buduneli et al. 2008) indicated that 
treated non-smokers had lower sRANKL levels than untreated non-smokers possibly 
indicating a more active inflammatory process in untreated patients. Although the exact GCF 
concentrations of RANKL and OPG varied from study to study, overall RANKL/OPG ratio 
showed a trend to increase in periodontitis compared to healthy controls (Mogi et al. 2004, Lu 
et al. 2006, Bostanc et al. 2007, Crotti et al. 2003). This may either be explained by an increase 
in RANKL or a decrease in OPG levels or both.  
Significantly lower plasma OPG concentrations were detected in smoker chronic 
periodontitis patients than the smoker healthy controls without any significant differences 
between the smoker and non-smoker study groups (Özçaka et al. 2010). That finding 
suggests that smoking alone may not be effective on plasma levels of RANKL/OPG system 
in periodontal disease but when it is coupled with periodontal inflammation the disturbing 
effect on bone homeostasis may become detectable. Moreover, the significant positive 
correlations found in the smoker groups between plasma OPG concentrations and probing 
depth may indicate a tendency towards increased bone metabolism which aims to 
compensate the increased susceptibility to alveolar bone resorption (Özçaka et al. 2010). 
Neither the clinical periodontal measurements nor the laboratory data obtained in plasma 
samples showed significant differences between the smoker and non-smoker chronic 
periodontitis patients (Özçaka et al. 2010). Indeed, the similarity in clinical periodontal 
findings between the smoker and non-smoker chronic periodontitis patient groups may 
explain the lack of significant differences in plasma levels of RANKL and OPG. Darby et al. 
(2005) suggested that the inferior improvement in probing depth following scaling and root 
planing in smoker chronic periodontitis patients may reflect the systemic effects of smoking 
on the host response, the healing process, and the poorer clearance of the microorganisms. 
The plasma data reported by Özçaka et al. (2010) are in line with the recent study by Tang et 
al. (2009) reporting similar sRANKL and OPG levels in GCF samples of never smokers, 
former smokers and current smokers. In that study the only significant difference could be 
found in GCF OPG levels of the high pack-years group and never smokers. 
It has been shown that not only the number of leukocytes is increased but also leukocytes 
particularly polymorphonuclear neutrophils (PMNs) are significantly activated in smokers, 
suggesting a systemic inflammatory state. Nicotine has been shown to activate PMNs. 
Pathogens in microbial dental plaque are capable of stimulating host cells to increase their 
matrix metalloproteinase (MMP) release which is considered among the indirect 
mechanisms of tissue destruction seen during periodontitis (Sorsa et al. 2006). Periodontal 
tissues are infiltrated mainly by neutrophilic granulocytes and PMN which play an 
important role in the development of inflammatory injury. Tobacco-induced degranulation 
events in neutrophils, tobacco-induced alterations to the microbial flora, and tobacco-
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that smokers should be identified during patient examination and efforts should be made to 
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such as blood cotinine induced by smoking should be considered as important risk markers 
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(PGE2) have been evaluated by Tanaka et al. (2006) in osteoblasts and osteoclast-like cells. OPG 
expression was increased in the initial stages of culture with nicotine and LPS but decreased in 
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confirmed these findings. Furthermore, our saliva data (Buduneli et al. 2008) indicated that 
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suggests that smoking alone may not be effective on plasma levels of RANKL/OPG system 
in periodontal disease but when it is coupled with periodontal inflammation the disturbing 
effect on bone homeostasis may become detectable. Moreover, the significant positive 
correlations found in the smoker groups between plasma OPG concentrations and probing 
depth may indicate a tendency towards increased bone metabolism which aims to 
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Neither the clinical periodontal measurements nor the laboratory data obtained in plasma 
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(2005) suggested that the inferior improvement in probing depth following scaling and root 
planing in smoker chronic periodontitis patients may reflect the systemic effects of smoking 
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al. (2009) reporting similar sRANKL and OPG levels in GCF samples of never smokers, 
former smokers and current smokers. In that study the only significant difference could be 
found in GCF OPG levels of the high pack-years group and never smokers. 
It has been shown that not only the number of leukocytes is increased but also leukocytes 
particularly polymorphonuclear neutrophils (PMNs) are significantly activated in smokers, 
suggesting a systemic inflammatory state. Nicotine has been shown to activate PMNs. 
Pathogens in microbial dental plaque are capable of stimulating host cells to increase their 
matrix metalloproteinase (MMP) release which is considered among the indirect 
mechanisms of tissue destruction seen during periodontitis (Sorsa et al. 2006). Periodontal 
tissues are infiltrated mainly by neutrophilic granulocytes and PMN which play an 
important role in the development of inflammatory injury. Tobacco-induced degranulation 
events in neutrophils, tobacco-induced alterations to the microbial flora, and tobacco-
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induced increases in pro-inflammatory cytokine burden could each, theoretically, influence 
MMP-8 levels in the periodontal tissues of smokers. In a recent study (Özçaka et al. 2011), it 
was hypothesised that smoking may affect MMPs and neutrophil degranulation products in 
the systemic level eventually leading more severe periodontal tissue destruction and 
systemic inflammation predisposing to cardiovascular diseases (Pussinen et al. 2007). In that 
exploratory study, the serum concentrations of MMP-8, MMP-9, TIMP-1, NE, and MPO 
were evaluated comparatively in smoker versus non-smoker patients with chronic 
periodontitis as well as periodontally healthy subjects. The clinical periodontal 
measurements were recorded and serum samples were analyzed in 55 patients with the 
clinical diagnosis of chronic periodontitis (16 smoker and 39 non-smoker) and 56 
periodontally healthy subjects (17 smoker and 39 non-smoker). The findings of significantly 
elevated serum MMP-9, MPO, NE together with decreased TIMP-1 in smoker patients with 
chronic periodontitis than non-smoker counterparts support the idea that smoking together 
with periodontal destruction may expose/predispose to cardiovascular diseases. 
MMP-8 activity has been found to be modified in various organs and body fluids in tobacco 
smokers. Knuutinen et al. (2002) noted an increased MMP-8 concentration in the resulting 
fluid infiltrate in smokers compared to that in the non-smokers following the induction of 
suction blisters on the upper arm. Furthermore, Betsuyaku et al. (1999) have shown 
increased MMP-8 and MMP-9 activity in the bronchial alveolar lavage fluids of smokers 
with emphysema compared to those without emphysema. A significant correlation between 
increased MMP-8 levels and periodontal disease severity has been suggested. Liu et al. 
(2006) have reported increased local MMP-8 expression in the periodontal tissues of 
smokers compared to the non-smokers and a slight increase in the serum MMP-8 
concentration, although the difference between the smoker and non-smoker groups did not 
reach the level of significance.  
On the other hand, Söder et al. (2002) found a positive correlation between elastase 
complexed to α1-antitrypsin and MMP-8 concentrations in the gingival crevicular fluid 
(GCF) of smokers in individuals with various persistent periodontal diseases. However, 
they did not observe any difference in GCF MMP-8 levels between smokers and non-
smokers. Persson et al. (2003) reported that GCF MMP-8 levels remained unchanged in the 
smokers following surgical treatment for periodontitis, whereas decreased levels were 
observed in the non-smokers, suggesting a tobacco-induced MMP-8 burden. Liede et al. 
(1999) examined salivary MMP-8 concentrations in 327 smokers and 82 quitters and found 
lower MMP-8 levels in the current smokers than the ex-smokers. According to our recent 
data (Özçaka et al. 2011), serum MMP-8 concentrations did not differ significantly between 
the smokers and non-smokers. It should be kept in mind that self-reports of non-smoking 
people can sometimes be unreliable (Buduneli et al. 2006). Therefore, confirmation of the 
smoking status by serum and/or salivary cotinine analysis may result in changing the 
accurate group of individual subjects which may eventually affect the results. Therefore, 
apart from the relatively small numbers of smokers in some of the studies, lack of cotinine 
analysis may explain the discrepancies between the findings of different clinical studies. 
MPO was suggested as an early marker of systemic inflammation in smokers without severe 
airway symptoms in a study aiming to relate smoking and chronic obstructive pulmonary 
disease (Andelid et al. 2007). The authors reported significant increases in serum MPO 
concentrations in smokers than never smokers at 6th year of follow-up. Enhanced serum 
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levels of MPO indicate increased degranulation of specific granules of neutrophils (Rautelin 
et al. 2009). Accordingly, our recent data indicated significant increases in serum 
concentrations of MPO in smoker chronic periodontitis patients, although the clinical 
periodontal measurements did not differ from those of the non-smoker counterparts 
(Özçaka et al. 2011a). This increase in serum MPO concentration may be regarded as an 
indicator of increased risk for local and systemic inflammation such as periodontal tissue 
destruction or an early sign of atherosclerosis. 
NE, which is a serine protease, can also accelerate MMP-cascades by activating latent 
proMMPs and inactivating TIMP-1 (Sorsa et al. 2006). NE was suggested to be involved in 
the degradation of non-collagenous protein-covered collagen fibrils in the early destructive 
stages of periodontal diseases (Ujiie et al. 2007). To our best of knowledge, serum NE levels 
as a systemic inflammatory parameter reflecting effects of smoking on chronic periodontitis 
has been evaluated only in our recent study (Özçaka et al. 2011) which revealed significantly 
higher serum NE concentrations in smoker chronic periodontitis patients than those of non-
smokers. 
Significantly increased serum concentrations of MMP-9 together with significant decreases 
in TIMP-1 concentrations in smoker chronic periodontitis patients deserve further 
investigation and suggest that chronic periodontitis together with smoking can predispose 
the development of cardiovascular diseases (Pussinen et al. 2007). Persistent smoking and 
periodontal inflammation predispose the patients for enhanced systemic inflammation in 
addition to enhanced periodontal destruction. 
Carboxyterminal-telopeptide pyridinoline cross-links of type I collagen (ICTP) is released 
into the periodontal tissues as a consequence of collagen degradation and alveolar bone 
resorption (Seibel 2003). Type I collagen composes 90 % of the organic matrix of bone and is 
the most abundant collagen in osseous tissue (Narayanan & Page 1983). Studies assessing 
the role of ICTP levels in GCF or peri-implant crevicular fluid as a diagnostic marker of 
periodontal disease activity have reported promising results so far (Oringer et al. 1998, 
2002). ICTP was suggested to predict future bone loss, to correlate with clinical parameters 
and putative periodontal pathogens and also to reduce following periodontal therapy 
(Giannobile 1999). Apart from the direct cigarette smoke-mediated effects, tissue damage 
mediated by impaired balance of bone turnover markers originating from tobacco smoke 
and tobacco-induced inflammation may be a potential mechanism. 
Osteocalcin (OC) is a calcium-binding protein of bone and the most abundant non-
collagenous protein of the mineralized tissue (Lian & Gundberg 1988). Serum level of OC is 
considered as a marker of bone formation (Christenson 1997). Serum levels of OC were 
reported to be lower in periodontitis patients compared with healthy subjects suggesting 
lower osteoblastic activity and bone formation ability (Shi et al. 1996). 
In a recent study, we investigated possible effects of smoking on saliva ICTP and OC 
concentrations comparatively in patients with chronic periodontitis and periodontally 
healthy subjects (Özçaka et al. 2011b). Smoker periodontitis patients revealed similar clinical 
periodontal index values with non-smoker counterparts, whereas salivary OC levels were 
lower in smokers than non-smokers. ICTP levels in non-smoker chronic periodontitis 
patients were higher than non-smoker controls and smoker healthy control group revealed 
higher ICTP levels than non-smoker counterparts. The data suggested that suppression of 
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induced increases in pro-inflammatory cytokine burden could each, theoretically, influence 
MMP-8 levels in the periodontal tissues of smokers. In a recent study (Özçaka et al. 2011), it 
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concentration, although the difference between the smoker and non-smoker groups did not 
reach the level of significance.  
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smoking status by serum and/or salivary cotinine analysis may result in changing the 
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levels of MPO indicate increased degranulation of specific granules of neutrophils (Rautelin 
et al. 2009). Accordingly, our recent data indicated significant increases in serum 
concentrations of MPO in smoker chronic periodontitis patients, although the clinical 
periodontal measurements did not differ from those of the non-smoker counterparts 
(Özçaka et al. 2011a). This increase in serum MPO concentration may be regarded as an 
indicator of increased risk for local and systemic inflammation such as periodontal tissue 
destruction or an early sign of atherosclerosis. 
NE, which is a serine protease, can also accelerate MMP-cascades by activating latent 
proMMPs and inactivating TIMP-1 (Sorsa et al. 2006). NE was suggested to be involved in 
the degradation of non-collagenous protein-covered collagen fibrils in the early destructive 
stages of periodontal diseases (Ujiie et al. 2007). To our best of knowledge, serum NE levels 
as a systemic inflammatory parameter reflecting effects of smoking on chronic periodontitis 
has been evaluated only in our recent study (Özçaka et al. 2011) which revealed significantly 
higher serum NE concentrations in smoker chronic periodontitis patients than those of non-
smokers. 
Significantly increased serum concentrations of MMP-9 together with significant decreases 
in TIMP-1 concentrations in smoker chronic periodontitis patients deserve further 
investigation and suggest that chronic periodontitis together with smoking can predispose 
the development of cardiovascular diseases (Pussinen et al. 2007). Persistent smoking and 
periodontal inflammation predispose the patients for enhanced systemic inflammation in 
addition to enhanced periodontal destruction. 
Carboxyterminal-telopeptide pyridinoline cross-links of type I collagen (ICTP) is released 
into the periodontal tissues as a consequence of collagen degradation and alveolar bone 
resorption (Seibel 2003). Type I collagen composes 90 % of the organic matrix of bone and is 
the most abundant collagen in osseous tissue (Narayanan & Page 1983). Studies assessing 
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periodontal disease activity have reported promising results so far (Oringer et al. 1998, 
2002). ICTP was suggested to predict future bone loss, to correlate with clinical parameters 
and putative periodontal pathogens and also to reduce following periodontal therapy 
(Giannobile 1999). Apart from the direct cigarette smoke-mediated effects, tissue damage 
mediated by impaired balance of bone turnover markers originating from tobacco smoke 
and tobacco-induced inflammation may be a potential mechanism. 
Osteocalcin (OC) is a calcium-binding protein of bone and the most abundant non-
collagenous protein of the mineralized tissue (Lian & Gundberg 1988). Serum level of OC is 
considered as a marker of bone formation (Christenson 1997). Serum levels of OC were 
reported to be lower in periodontitis patients compared with healthy subjects suggesting 
lower osteoblastic activity and bone formation ability (Shi et al. 1996). 
In a recent study, we investigated possible effects of smoking on saliva ICTP and OC 
concentrations comparatively in patients with chronic periodontitis and periodontally 
healthy subjects (Özçaka et al. 2011b). Smoker periodontitis patients revealed similar clinical 
periodontal index values with non-smoker counterparts, whereas salivary OC levels were 
lower in smokers than non-smokers. ICTP levels in non-smoker chronic periodontitis 
patients were higher than non-smoker controls and smoker healthy control group revealed 
higher ICTP levels than non-smoker counterparts. The data suggested that suppression of 
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salivary OC level by smoking may at least partly explain the deleterious effects of smoking 
on periodontal status. In another recent study by our group (Gürlek et al. 2009) similar 
salivary ICTP levels were detected in smoker, non-smoker and ex-smoker patient groups 
with similar clinical periodontal findings. Smoking status was confirmed by salivary 
cotinine analysis but there was no clinically healthy control group in that study and the 
number of teeth present, average probing depths and attachment levels were all similar in 
the three study groups. There were no significant differences in saliva ICTP concentrations 
between the smoker and non-smoker patient groups. It may be suggested that the similarity 
in clinical periodontal disease parameters may explain the similar salivary ICTP levels 
obtained in these studies.  
Significantly lower salivary OC concentrations in both healthy and diseased smokers than 
their non-smoker counterparts were reported by Özçaka et al. (2011b). The detrimental 
effects of smoking may explain these decreases in salivary levels of OC in smokers also 
indicating a deficiency in tissue response to the injuries in smoker subjects. The differences 
in patient numbers and/or the possible differences in the disease activity states may explain 
the differences in findings of the present study and the previous ones. On the other hand, 
significantly lower salivary OC concentrations in the smoker patients than the non-smokers 
as well as the ex-smokers may at least partly explain the mechanisms of negative effects of 
smoking on periodontal health. 
Lymphocyte functions including antibody production may also be affected by smoking. 
However, such affects seem to be complex and some components of cigarette such as 
nicotine are immunosuppressive (Geng et al. 1996) whereas some others are 
immunostimulatory such as tobacco glycoprotein and metals (Francus et al. 1988, Brooks et 
al. 1990). Serum immunoglobulin G (IgG) levels were reduced in smoker patients with 
periodontitis (Quinn et al. 1998). On the other hand, the number of B lymphocytes seemed 
to be similar in smokers and non-smokers but their function in peripheral blood was 
impaired in smokers, as reflected in proliferative response to polyclonal B cell activators and 
antigens (Sopori et al. 1989). 
Interleukin-1 (IL-1), tumour necrosis factor (TNF), and prostaglandin E2 (PGE2) are among 
the major inflammatory mediators that play significant role in alveolar bone resorption. 
Increased GCF levels of TNF-alpha were detected in current and former smokers (Bostrom 
et al. 1998). Moreover, it was reported that the expressions of inflammatory mediators such 
as IL-1, IL-6, IL-8, TNF-α, and cyclooxygenase-2 (COX-2) in response to lipopolysaccharide 
(LPS) of gram negative bacteria were increased in smokers (Bostrom et al. 1999, Tappia et al. 
1995, Kuschner et al. 1996). 
Tobacco smoking mostly in the form of cigarette smoking has been accused of impairing 
microcirculatory system and the relevant changes in vascular formations and functions 
may have a negative influence on the immune and inflammatory reactions in periodontal 
tissues. Smokers were reported to have significantly less number of vessels in inflamed 
gingival tissue compared to non-smokers (Rezavandi et al. 2002). Long-term smoking has 
an established negative effect on the vasculature of periodontal tissues. Acute exposure to 
cigarette smoke induces gingival hyperaemia, which is caused by the concomitant 
increase in blood pressure against a small but significant sympathetically induced 
vasoconstriction in healthy gingiva (Mavropoulos et al. 2003). Smoking even one cigarette 
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has been suggested to have the potential to cause a decrease in gingival blood flow 
(Mavropoulos et al. 2007). Such small but repeated vasoconstrictive attacks and 
impairment of revascularization due to cigarette smoking may contribute to disruption of 
immune response and delay in the healing response, leading to an increased risk of 
periodontal disease (Ojima & Hanioka 2010). Vascular dysfunction may also reduce 
oxygen delivery to gingival tissue. Pocket oxygen tension was reported to be significantly 
lower in smokers than non-smokers providing support for the negative effects of smoking 
on vascular system (Hanioka et al. 2000). Evidence from both human and experimental 
studies suggests that smoking has a long-term chronic effect, and its effect is not simply a 
vasoconstriction. Its suppressive effects on the vascular system of gingiva can be observed 
through less gingival redness, lower bleeding on probing and fewer vessels visible 
clinically and histologically.  
A better understanding of the influence of tobacco smoke on the host response to 
periodontal infection has been the major concern in numerous studies whereas, limited 
research has been published aiming to identify the influence of tobacco smoke on the dental 
biofilm. Tobacco smoke has been shown to cause shifts in the microbial species that 
comprise dental plaque (Haffajee & Socransky 2001, Kamma et al. 1999, Shiloah et al. 2000, 
Umeda et al. 1998, van Winkelhoff et al. 2001, Zambon et al. 1996). In a recent study by our 
group (Buduneli et al. 2011), it was hypothesized that tobacco may induce alterations to the 
molecular structure of lipid A in a manner consistent with reduced inflammatory potential. 
Therefore, the ratios of 3-OH fatty acids in smoking and non-smoking chronic periodontitis 
patients were investigated. The findings suggested that smoking induces specific structural 
alterations to the lipid A-derived 3-OH fatty acid profile in saliva that are consistent with an 
oral microflora of reduced inflammatory potential. Such data may explain increased 
infection with periodontal pathogens but reduced clinical inflammation in smokers. 
However, further studies are warranted to better clarify this issue. 
In a systematic review, Bergstrom (2006) concluded that 100% of 70 cross-sectional studies 
and 100% of 14 case-control studies indicate an association between smoking and an 
impaired periodontal health condition, and 95% of 21 cohort studies indicate a greater 
periodontal health impairment rate in smokers than in non-smokers. Therefore, he 
suggested that there is good evidence to recommend smoking to be specifically considered 
in a periodontal health examination. Indeed, in a review by Hilgers & Kinane (2004) it was 
concluded that smoking cessation is indicated in the promotion of better general health and 
in the improvement of periodontal health. Considering the existing evidences, the authors 
suggested that dentists should offer to refer patients for smoking cessation counselling. 
In conclusion, smoking is accepted as a strong risk factor for destructive periodontal disease. 
Gelskey (1999) stated that smoking meets most of the criteria for causation proposed by Hill 
(1965). This statement is based on the consistency and strength of association between 
smoking and periodontal disease severity demonstrated by multiple cross-sectional as well 
as longitudinal studies. Further evidence comes from the dose effect of smoking on 
periodontal disease severity and a slowing of disease progression in patients who quit 
smoking. Furthermore, smoking has a negative impact on periodontal treatment outcomes. 
Smoking is harmful virtually to every tissue in the body. The basis for these deleterious 
effects is related to the adverse impact of smoking on microbial and host factors. 
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salivary OC level by smoking may at least partly explain the deleterious effects of smoking 
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The proposed mechanisms for the negative effects of smoking on periodontal health were 
summarised by Johnson & Guthmiller (2007) as follows; decreased immunoglobulin G2 
production, chronic reduction in blood flow and vascularity, increased prevalence of 
potential periodontal pathogens, shift in neutrophil function towards destructive activities, 
negative effects on cytokine and growth factor production and inhibition of fibroblast 
growth, attachment and collagen production.  
In addition to be accepted as an important risk factor for destructive periodontal disease, 
smoking has been suggested to interfere with the outcomes of various periodontal therapies. 
Bostrom (2006) systematically reviewed the intervention studies both in terms of non-
surgical and surgical periodontal therapy. It was concluded that the results of the 
intervention studies suggest an inferior therapeutic outcome in smoker patients compared 
to non-smoker counterparts. The author reports that in 80% of studies the results were 
statistically significant. When measured in terms of mean probing depth reduction or mean 
clinical attachment level gain after a maximum of 9 months, the outcome on the average is 
less efficient in smokers than in non-smokers (Bostrom 2006). However, none of the non-
surgical intervention studies has evaluated the effect of smoking in terms of a successful 
versus a non-successful outcome following predetermined criteria. Furthermore, it was 
stated that it is still not known whether or not a negative short-term effect of smoking 
observed in terms of probing depth or clinical attachment level holds true in the long run as 
tooth loss. Most of the intervention studies have a rather short follow-up period and 
therefore unable to provide an answer in terms of the rate of tooth loss. It is quite clear that 
further intervention studies with larger scales and longer follow-ups are required to better 
clarify this issue. Smoking more than 10 cigarettes per day is considered as heavy smoking 
and heavy smokers have a poorer treatment response than non-smokers or ex-smokers 
(Kaldahl et al. 1996, Norderyd 1998).  
A meta-analysis by Labriola et al. (2005) evaluated the impact of smoking on non-surgical 
periodontal therapy and reported that probing depth reduction in sites where probing 
depth was initially equal to or more than 5 mm was significantly greater in non-smokers 
than in smokers in eight studies (Grossi et al. 1997, Mongardini et al. 1999, Palmer et al. 
1999, Preber et al. 1995, Pucher et al. 1997, Renvert et al. 1998, Ryder et al. 1999, Williams et 
al. 2001).  
In a recent intervention study (Buduneli et al. 2009),  effects of initial periodontal treatment 
on GCF levels of interleukin-17 (IL-17), sRANKL, and OPG in smoker versus non-smoker 
patients with chronic periodontitis. All clinical periodontal measurements decreased 
significantly after the initial periodontal treatment in both the smoker and non-smoker 
patient groups. There were no significant differences between the smoker and non-smoker 
patients in regards with the changes in clinical periodontal data following initial periodontal 
treatment. Data indicated that GCF volume, OPG total amount and concentration decreased 
in both smokers and non-smokers after scaling and root planning (SRP), whereas IL-17 
concentration increased. sRANKL levels did not differ between groups or with SRP. 
Significant correlations were found between baseline IL-17 and RANKL levels, baseline 
papilla bleeding on probing and OPG levels. According to the findings, it was suggested 
that neither smoking nor periodontal inflammation appears to influence GCF RANKL levels 
in systemically healthy patients with chronic periodontitis. Smoker and non-smoker patients 
with chronic periodontitis seem to be affected indifferently by the initial periodontal 
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treatment in regards with GCF IL-17 and OPG concentrations. Smoking seems to suppress 
OPG synthesis and might be contributory to increased bone destruction often seen in 
smokers. 
Surgical periodontal therapy aims to eliminate periodontal pockets and obtain 
physiological contours in both soft and hard periodontal tissues. As with the non-surgical 
intervention studies, the primary outcome measures in surgical intervention studies are 
probing depth and clinical attachment level. On the basis of a systematic review, Bostrom 
(2006) reported that 91% of 10 non-surgical and 93% of 14 surgical therapy intervention 
studies indicate an untoward effect of smoking on the therapeutic outcome. The author 
concluded that there is limited but consistent evidence to suggest that smoking negatively 
interferes with the therapy outcomes of nonsurgical as well as surgical periodontal 
interventions. 
Haesman et al. (2006) also reviewed the clinical evidence for the relative clinical responses to 
periodontal treatment in smokers, non-smokers and ex-smokers. The authors concluded that 
data from epidemiological, cross-sectional and case-control studies strongly suggest that 
quitting smoking is beneficial to patients following periodontal treatments. The response of 
ex-smokers to periodontal treatment suggests that quitting smoking helps to improve the 
clinical periodontal status but there are only limited data from long-term longitudinal 
clinical trials to demonstrate unequivocally the periodontal benefit of quitting smoking. It is 
clear that long-term, longitudinal clinical trial that monitors over several years the response 
to treatment in a cohort of smokers with chronic periodontitis will provide valuable data on 
the detrimental effects of smoking. However, such a study is definitely not easy to conduct 
both from the practical and financial points of view. At present, the dental profession can 
rely on the strong evidence base of the epidemiological, cross-sectional, and case-control 
studies concluding that quitting smoking is likely to be beneficial to oral and in particular 
periodontal health.  
Johnson & Guthmiller (2007) suggested that smoking cessation cannot reverse the negative 
past effects of smoking; however, the rate of bone and attachment loss slows after patients 
quit smoking. Periodontal disease severity in former smokers falls between that of current 
smokers and never smokers (Bergstrom et al. 2000, Jansson & Lavstedt 2002, Tomar & Asma 
2000, Torrunggruang et al. 2005). Preshaw et al. (2005) evaluated the effect of smoking 
cessation on non-surgical periodontal treatment in 49 smokers who wanted to quit smoking. 
Therapy included individualised cessation interventions, scaling and root planning and oral 
hygiene instructions followed by maintenance phase of periodontal treatment. Only 26 
patients completed the study; 10 successfully stopped smoking, 10 continued smoking, and 
six stopped but relapsed during the study period. The authors reported that the patients 
who successfully quit smoking had the best response to therapy; the “oscillators” had an 
intermediate response to the non-smokers and quitters. These results underscore the 
challenges of cessation of tobacco smoking. Counselling on the benefits of smoking cessation 
by dentists may encourage the patients to seek periodontal therapy and eventually lead to 
improved periodontal health. Likewise, Borrell & Papapanou (2005) suggested that smoking 
cessation is a key in the prevention and control of periodontal disease because it affects both 
the bacterial and host etiological components in the disease process.  
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In conclusion, the data from both cross-sectional and epidemiological studies over the past 15 
years evaluating the relationship between smoking and periodontal diseases suggest that there 
is strong evidence of a positive association between smoking and clinical and biochemical 
signs of periodontitis, as well as an increased risk of periodontitis in smokers. Furthermore, the 
evidence for smoking having a deleterious effect on periodontal treatment outcomes is quite 
convincing but still needs more data from longitudinal intervention studies. 
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1. Introduction 
At a planetary scale, the Metabolic Syndrome (MetS) is the third cause of inability after 
malnutrition and nicotinism, even higher than water shortage and sedentariness. In the 
USA, the prevalence is estimated at over 25% of the population; in Italy, it involves 
approximately 25% of men and even 27% of women (Ford et al. 2002). These are very high 
figures, corresponding to approximately 14 million affected individuals. The prevalence is 
alarming and must not be underestimated, particularly in the dental field, where more than 
one patient out of four sitting in a dentist’s chair is affected. The aetiology of periodontal 
disease has not been clarified yet, and recently the idea to consider it as a multifactor 
pathology has been developed. Cofactors such as the formation of reactive oxygen species 
(ROS), oxidative stress, lipid peroxidation, and formation of glycation end-products (AGEs) 
probably play an important role in the onset of periodontal disease (Pietropaoli et al. 2010). 
The AGEs are compounds physiologically produced by all metabolically active cells. 
However, they accumulate and cause pro-inflammatory statuses, when the cellular 
clearance fails, or in hyperglycaemic and oxidative statuses (Peppa et al. 2008). All these 
conditions can be clinically summarized as Metabolic Syndrome. 
The purpose of this literature review is to establish a relationship between two pathologies 
with very high prevalence: Metabolic Syndrome and Periodontal Diseases. 
The literature seems to have clarified that the Metabolic Syndrome involves a pro-oxidation 
status, which induces AGE formation. AGEs play a very important role in the course and 
severity of periodontal diseases.  
2. The Metabolic Syndrome 
The Metabolic Syndrome (MetS) (also known as X-syndrome, insulin-resistance syndrome, or 
Reaven’s syndrome) refers to a clinical condition involving a high cardio- cerebrovascular 
(CVD) risk, which includes a number of risk factors and symptoms of simultaneous 
appearance in individuals. These are often related to the individual’s life style (overweight, 
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appearance in individuals. These are often related to the individual’s life style (overweight, 
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sedentary habits), or existing pathological conditions (e.g. obesity and hypercholesterolemia) 
(Lakka et al. 2002). 
The studies confirm that individuals affected by Metabolic Syndrome, who do not 
dramatically change their life style, have a high mortality related to CVD (Lakka et al. 2002). 
The accepted definition of MetS, which is broadly applied at the international level, is given 
by the Third Report of the National Cholesterol Education Program (NCEP-III). According 
to the NCEP-III, a diagnosis of Metabolic Syndrome is applicable when at least 3 out of 5 of 
the following elements are identified: 
• Abdominal Obesity (abdomen circumference >102 cm in Men, >88 cm in Women)  
• Triglyceridemia ≥ 150 mg/dl  
• Plasma HDL cholesterol <40 mg/dl in Men, <50 mg/dl in Women  
• Arterial blood pressure ≥130 and/or ≥85 mm Hg  
• Fasting plasmatic glycaemia ≥110 mg/dl Expert Panel on Detection and of High Blood 
Cholesterol in Adults (2001).  
More recently (2005), the International Diabetes Federation has reviewed the diagnostic 
criteria, proposing the presence of two of the following disorders in the same patient as a 
method to identify the disease: 
• Triglyceridemia ≥150 mg/dl  
• Plasma HDL cholesterol <40 mg/dl in Men, <50 mg/dl in Women, or hypolipemizing 
treatment  
• Arterial blood pressure ≥130 and/or ≥85 mm Hg, or anti-hypertension treatment  
• Fasting plasmatic glycaemia ≥110 mg/dl (IFG stage),  
associated with waist circumference of more than 94 cm in men and 80 cm in women for 
Caucasian patients (the parameters vary, based on the patient’s ethnic group) (Alberti et al. 
2005). 
Substantially, these two definitions are the same. However, in the most recent review, the 
International Diabetes Federation associated the diagnostic factors with above-normal waist 
circumference and classified it as a required condition for diagnosis. 
Despres et al. (2000) assessed the lipid profile (total cholesterol, HDL cholesterol, triglycerides, 
plasmatic values of apolipoprotein B) and glucide profile (fasting insulin haematic values) of 
2103 male patients, aged 45-76 years, representative as a sample population of Québec. The 
analysis was carried out to determine the association between cardiovascular risk factors and 
ischemic cardiopathy during a five-year period (Després et al. 2000). During the study, 
significantly higher fasting insulinemia (p < 0.001) was observed in patients affected by 
ischemic events. The hyperinsulinemia-artherosclerotic cardiopathy association kept this high 
rate also after a correction of triglycerides, apolipoprotein B, LDL cholesterol, and HDL 
cholesterol levels. Therefore, high insulin plasmatic concentrations in non-diabetic individuals 
– who can be classified as ‘insulin-resistant’ – were associated with an ischemic cardiopathy 
increase, independently from the lipid profile (although a lipid profile alteration in pro-
atherogen sense has a synergic effect with hyperinsulinemia) (Després et al. 2000). 
In addition to the role played in glucidic metabolism, insulin contributes to regulating lipid 
and protein metabolism and arterial blood pressure, interfering with platelet function and 
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the balance between pro-thrombotic factors and endogenous fibrinolysis modulators. It also 
regulates the proliferative stimuli on smooth muscle cells of vascular walls and influences 
the endothelial function: all this explains the possible role played by insulin- resistance in 
determining the Metabolic Syndrome (Harano et al. 2002). 
The mechanisms of insulin resistance, or the insulin-cell surface-intracellular compartment 
interaction sites, in which the chain of signals produced by the hormones stops, preventing 
an appropriate use of circulating glucose, are not known yet. Insulin-resistance almost 
certainly develops much before the Metabolic Syndrome and other more advanced clinical 
diseases, such as type-2 diabetes mellitus and atherosclerosis, appearing in all contexts as a 
multifactor reality in terms of both its onset and potential harm (Harano et al. 2002). 
It is clear that, in a person affected by MetS, a hyperglycaemia status triggers cellular 
damage with repercussions at the systemic level and also on periodontal tissue. Periodontal 
diseases of diabetic origin are a clear example of this (Bensley et al. 2011). 
New studies focus on the aetiology of periodontal diseases and the role of oxidative stress, 
starting a cascade of molecular signals from inflammation mediators, which cause loss of 
attachment, reabsorption of alveolar bone, and, ultimately, tooth loss, through activation of 
osteoclasts (Pietropaoli et al. 2010). As a source of oxidative stress, the MetS could provide 
an alternative etiological explanation to the development of periodontal disease, as 
suggested by Bullon et al. (2009). 
The purpose of this study is to extend this vision, which includes the residual products of 
non-enzymatic glycosylation, originated from oxidative metabolism conditions, as factors 
promoting periodontal disease. 
3. Metabolic Syndrome and oxidative stress 
It is known that all MetS triggering factors play a clear role in the onset of oxidative stress, in 
the subsequent formation of Reactive Oxygen Species (ROS), and probably also in the 
activation of the pro-oxidising, pro-inflammatory AGE-RAGE system (Koyama et al. 2005). 
Many inflammatory pathways are activated by these conditions. The excess of visceral fat 
(high waist circumference) is certainly one of the most important factors in activating these 
signalling molecular cascades through the TNF-alfa pathway (Boden 2006). 
Visceral fat, unlike subcutaneous fat, induces lipolysis increase, when stimulated, with 
release of Free Fatty Acids (FFA) in the blood circulation. Excess FFAs significantly 
contribute to inducing hyperinsulinemia, as they reduce insulin clearance, increase hepatic 
gluconeogenesis, reduce glucose uptake in the muscle tissues, and facilitate a pro-
inflammatory status (Liu et al. 2011). 
TNF-alfa increase, in turn, contributes to triggering the molecular processes that lead to the 
development of insulin-resistance, which would apparently play a key pathogenetic role in 
all MetS conditions (Odrowaz-Sypniewska 2007). When calorie intake is higher than body 
consumption, ROS excess is created, due to hyper-activity of the citric acid cycle, hence 
oxidative stress (Maddux et al. 2001). This oxidative stress alters intracellular signalling and 
contributes to the development of insulin-resistance (Evans et al. 2003). On the other hand, 
Ceriello et al. (2000) showed that insulin-sensitivity improves after administration of anti-
oxidizing substances (Ceriello and Motz 2004). 
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Soory et al. (2009) claim that ROS increase causes a hyper-inflammation status in its most 
aggressive forms of periodontal disease and causes an unbalance of redox status, outcome of 
which is damage. In accordance with this vision, the hyper-inflammation status associated 
with periodontal disorder could overload the body with Reactive Oxygen Species, which are 
in turn able to contribute to the development of other pathologies, such as metabolic, articular, 
neoplastic, or geriatric diseases (Soory, 2009). In addition to lipid peroxidation, the AGEs are 
another emerging marker of oxidative stress. The AGEs are a set of heterogeneous products 
constantly formed in physiological conditions, but significantly increasing in the presence of 
hyperglycaemia and excessive oxidative stress (Peppa et al., 2008). The recent literature 
suggests that the AGEs are the cause of a large number of adverse conditions established in 
systemic diseases, where the oxidative component is strong, as in diabetes (Xue et al., 2011). 
The activation of these pathways is not restricted to limited areas of the body, but their 
signalling triggers systemic responses, which are also visible at the level of teeth supporting 
tissues. Since the 1970s, it is known that obesity and hypertension increase the severity of 
the periodontal disease (Perlstein and Bissada, 1977). It is also suggested that overweight 
individuals have a worse periodontal status than individuals with a normal body weight, 
with evident histological changes on dental tissues (Suvan et al., 2011). To support this 
suggestion, Pischon et al. (2007) clearly emphasised that inflammation caused by obesity 
markedly affects the status of periodontal tissues. In these cases, the activation of pro-
inflammatory cytokines has been broadly supported by scientific literature. In fact, TNF-
alfa, Interleukin-6 and -10 (IL-6, IL-10), and C-Reactive Protein (CRP) are certainly involved 
in individuals with high Body Mass Index (BMI) (Pischon et al., 2007). 
The activation of these complexes leads to the interaction between AGEs and RAGE cellular 
receptors (found in many cell populations), which amplify the release of cytokines, 
metalloproteinases (MMPs), and ROS. 
It is worth stressing that the nature of an individual’s diet certainly contributes to the action 
of inflammatory cytokines. Obese individuals eat several times during the day, without 
caring too much for oral hygiene, thus facilitating accumulation of dental plaque and dental 
calculus. This condition is the basis of periodontal problems in these subjects. 
4. Advanced Glycation End-Products (AGEs) 
The AGEs are a heterogeneous group of physiologically formed compounds, which 
accumulate when cellular clearance fails, and in hyperglycaemia and oxidative stress 
conditions (Peppa et al., 2008). 
The accumulation of AGEs may also be dependent on environmental sources, such as 
tobacco smoking (Yamagishi et al., 2008), vegetarian diet (Sebeková et al., 2006), alcohol 
(Kalousová et al., 2004), consumption of browned foods, and high lipid/glucide quantities 
(Krajcovicová-Kudlácková et al., 2002). Approximately one third of AGEs intake through 
diet is excreted with urine, whereas the remaining part is supposedly incorporated in tissues 
(Bohlender et al., 2005). 
These compounds are produced through enzymatic pathway from monosaccharide 
substances, such as glucose and fructose, but also dicarbonyls originating from Maillard’s 
reaction, sugar self-oxidation, and other molecular pathways, such as glycolysis, which 
involves the formation of glyoxal and methylglyoxal (Fu et al., 1996).The non-enzymatic 
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post-translational glycosilations of proteins occur through reductive amination reaction 
between the non-reducing end of a carbohydrate and primary amino groups located on 
macromolecules containing lysine or arginine residues (amino acids, proteins, 
phospholipids, lipids, and nucleic acids). These reactions lead to the formation of a number 
of reversible intermediate products called Schiff’s bases and Amadori products (e.g. 
Glycated haemoglobin; HbA1C). Any subsequent rearrangement of these complexes lead to 
the formation of much more stable products, the AGEs, which affect the functionality and 
properties of proteins, lipids, and DNA (Thornalley, 2005; Fu et al., 1996).A key role in the 
formation of these adducts can be referred to oxidative stress and aging (Baynes, 2001). 
Oxidising conditions and Reactive Oxygen Species (ROS) facilitate the formation of AGEs, 
which in turn increase the production of free radicals (Wen et al., 2002; Yin et al., 2001). 
Schiff’s bases and Amadori products increase ROS production, and hyperglycaemia 
promotes glucose self-oxidation, which involves OH radicals (Noiri and Tsukahara, 2005). 
Several studies clearly show that the AGEs are involved in the development of diabetes 
problems, andin CVD and renal and neurodegenerative disease pathogenesis (Goldin et al., 
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Throughout life, AGEs produced accumulate in the tissues and can be found in plasma 
(Ulrich and Cerami, 2001). The pathogenetic action of these compounds performs directly, 
damaging the tissues, or indirectly, binding a specific receptor, called RAGE, which belongs 
to the family of immunoglobulins (Ramasamy et al., 2005). 
This receptor is physiologically found in small quantities in many cells, but it is over-
expressed in conditions such as diabetes, vasculopathy, and cancer (Ramasamy et al., 2005). 
The AGE-RAGE bond involves a cascade of pro-inflammatory signalling with subsequent 
activation of redox-sensitive transcription factors, such as nuclear factor kappa B (NF-κB) 
(Schmidt and Stern, 2000). This interaction involves hyper-permeability, at the level of 
endothelial cells, and activates the vascular cell adhesion molecule-1 (VCAM-1) molecule, 
whereas on monocytes it involves chemotaxis and cytokine increase, such as the tumour 
necrosis factor (TNF), and interleukins IL-1 and IL-6 (Vlassara et al., 1988). Collagen 
synthesis by fibroblasts is also reduced (Hollá et al., 2001). 
In addition to persistent hyperglycaemia statuses, transient hyperglycaemia is also a risk 
condition, as it induces pro-inflammatory signalling and activates the long-lasting 
expression of p65, which is a fraction of the above-mentioned NF-κB (Siebel et al., 2010). 
Recently, the interest in this condition has grown, as a few studies report that the ‘cell 
memory’ – thus, pro-inflammatory signalling – continues up to 16 hours after the end of the 
hyperglycaemic condition (El-Osta et al., 2008). 
Long-survival proteins, such as collagen, are the most vulnerable molecules exposed to 
cross-links and forming AGEs, with subsequent subtraction to proteolysis and tissue 
remodelling (Verzijl et al., 2000). Collagen irreversibly modified by the AGEs is also the 
vascular collagen, which contributes to the formation of atherosclerosis and development of 
kidney failure (Bohlender et al., 2005). The AGEs have a higher predictive value of 
microvascular complication development than the value of other risk predictors, such as the 
duration of diabetes and HbA1c. 
On the other hand, reduced clearance of serum AGEs can further increase the accumulation 
of AGEs in tissues and their new formation, which worsens kidney failure (Miyata et al., 
1997). 
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5. Aetiology and pathogenesis of periodontitis 
The aetiology of periodontitis has not been fully clarified yet. However, it is commonly 
accepted that it may result from an opportunistic infection. The bacteria cross the epithelial 
barrier and invade the sub-epithelial connective tissue. A crucial role is played by the 
increase in the number of dental plaque microorganisms, their capacity to penetrate the 
tissues, and the host’s immunological status. The damage is only partially reversible, even 
after professional treatment (Needleman et al., 2006). 
The hyper-inflammation following these events determines the failure of the immunological 
response: it does not only remove the pathogens, but it also involves the prolonged release 
of proteolytic enzymes by the neutrophils, pro-inflammatory mediators, and ROS (Sheikhi 
et al., 2000). These elements determine periodontal attachment destruction (Chapple and 
Matthews, 2007). Fusobacterium nucleatum and the other oral pathogens induce an increase in 
intracellular production and ROS release in neutrophils (Sheikhi et al., 2000). Higher ROS 
levels are, in fact, found in saliva and gingival crevicular fluid of patients with chronic 
periodontitis as compared with healthy controls (Tsai et al., 2005). 
Lee et al. (2008) suggest that hydrogen peroxide (oxygenated water) deposited in 
periodontal tissues to reduce the inflammation caused by bacteria accelerates their 
destruction by activating the IL-8 pathway in periodontal cells (Lee et al., 2008). This event 
should not be underestimated and should be taken into consideration during periodontal 
surgery. 
Soory et al. (2009) proposed that during periodontal disease, increased ROS production may 
worsen an inflammatory condition, causing an alteration of the redox status and inducing 
damage from oxidative stress, which involves a more rapid evolution of the disease (Soory, 
2008). A broad body of literature documenting a link between periodontal diseases and 
other pro-oxidative inflammatory diseases support this hypothesis. In fact, it has been 
confirmed that diseases inducing oxidative metabolic changes, such as diabetes, arthritis, 
neoplasias, and aging, are associated with periodontal disease, increasing its severity (Soory, 
2009). 
Based on these observations, it is clear that many conditions may worsen periodon- tal 
disorders or promote new onset. Contemporary literature supports the assumption that, in 
addition to inflammation and oxidative stress, other conditions such as cigarette smoking 
(Bagaitkar et al., 2009), vitamin deficits, alcohol abuse, diet (Dye, 2010; Hujoel, 2009), and 
other pro-oxidation conditions, such as MetS, play a key role in the activation of signalling 
pathways, which act in promoting ROS development and probably also in worsening or 
producing new onset of a periodontal disease (Liu et al., 2011; Soory, 2009; Boden, 2006). 
SO, WHY IS METS INVOLVED IN PERIODONTAL DISEASES? 
Certainly this is because a pathological range including all pro-oxidation conditions 
(hyperglycaemia, hyperlipaemia, obesity, and hypertension), which coexist in a vicious 
circle, and establish and support the onset of free radicals and products from non-enzymatic 
glycosilation. As yet, there is not much in literature to support this assumption, except for a 
note- worthy epidemiological analysis, which helps to provide the background on the 
relationship between MetS and periodontal diseases, i.e. the analysis of the American study 
NHANES III (D’Aiuto et al., 2008). NHANES III (Third National Health and Nutrition 
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Examination Survey) analysed 13,994 individuals (men and women) aged over 17. The 
study assessed their periodontal condition through plaque and bleeding indexes, and 
testing depth, as well as the Metabolic Syndrome parameters. The patients aged over 45 
affected by MetS had a risk 2.31 times higher than healthy individuals of being affected by 
periodontal diseases. The study authors concluded that serious periodontal disease is 
associated with middle-aged individuals affected by MetS (D’Aiuto et al., 2008). Further 
investigations are required to support and extend this hypothesis. However, it is clear 
enough that the MetS negatively influences the health of tissues supporting the teeth. 
6. Metabolic Syndrome, AGEs, and periodontal diseases 
Hypertension, obesity, dyslipidemia, and hyperglycaemia, which coexist in MetS, play an 
incremental role in ROS and AGEs production (Turco et al., 2011). This is probably on the 
basis of a potential MetS role in the destruction of periodontal tissues. In fact, the AGEs 
create damage by directly modifying proteins (Verzijl et al., 2000), or indirectly, activating 
signalling through its RAGE receptors (Schmidt et al., 2000). The interaction AGE-RAGE 
results in pro-inflammatory signalling and in generation of intracellular oxidative stress and 
subsequent activation of the redox-sensitive transcription factors such as NF-κB (Schmidt 
and Stern, 2000). Formation of AGEs is a way to maintain the signal of a short oxidative 
burst in a much longer-lived post translational modified proteins (Andrassy et al., 2006). 
Interaction of RAGE with AGEs in endothelial cells results in hyperpermeability and 
enhanced expression of adhesion molecules such as vascular cell adhesion molecule-1 
(VCAM-1). This interaction on monocytes induces chemotaxis, as well as an increased 
generation of cytokines such as tumour necrosis factor (TNF), interleukin-1 (IL-1), or IL-6 
(Vlassara et al., 1988). 
Furthermore, the engagement of RAGE results in diminished collagen synthesis in 
fibroblasts (Hollá et al., 2001). Recent observations suggest that RAGE is a central cell-
surface receptor also for EN-RAGE (extracellular newly identified RAGE binding proteins) 
and other members of the S100/calgranulin family of pro-inflammatory cytokines 
(Hofmann et al., 1999). These intracellular proteins may gain access to extracellular space in 
the inflammatory milieu. Upon release, their ability to interact with cellular RAGE appears 
to be an important means by which to propagate inflammatory cellular perturbation and 
chronic tissue injury (Schaefer and Heizmann, 1996). It is important to note that a study with 
diabetic rats shows that RAGE inhibition prevents the progression of periodontal disease, 
improving the prognosis, and reduces the formation of pro-inflammatory cytokines, such as 
IL-6, TNF-alfa, and metalloproteinases, significantly reducing the loss of alveolar bone 
(Schmidt et al., 1996). The authors have also observed that the beneficial effect of the RAGE 
block is independent from glycaemic control, thus supporting the importance of signalling 
RAGE in periodontal disease. Observations based on the involvement of RAGEs in 
periodontal disease are not valid to support the hypothesis that the AGEs are involved in 
the onset of periodontal disease. However, this aspect has been recently studied by Murillo 
et al. (2008) and Ren et al. (2009), who assessed the in vitro effect of AGEs on human 
gingival and periodontal fibroblasts. Both of these studies started from the premise that an 
important role in periodontal physiology is played by cell interaction with molecules of the 
extracellular matrix (Steffensen et al., 2001). In an in vitro model of periodontal cells, the 
behaviour of human gingival fibroblasts (hGFs) and human periodontal fibroblasts (hPDLs) 
is deeply influenced by changes in the surrounding environment (Lackler et al., 2000). The 
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glycated proteins of the extracellular matrix can also have their pathogenic effects 
interacting with RAGE. The observation that the AGEs can regulate the cellular function and 
hGFs’ collagen metabolism supports this assumption. It was also found that the AGEs 
reduce the mobility of these cells and significantly inhibit the expression of type I and III 
collagen (Ren et al., 2009). The importance of these mechanisms in the pathogenesis of 
periodontal disease is emphasised by the observation according to which the reduction of 
periodontal integrity, which occurs physiologically with age, could be referred to a reduced 
expression of type I collagen caused by age-dependent hypermethylation in the gene-
promoting area (Ohi et al., 2006). 
In concurrence with the above-mentioned data, it seems that the AGEs participate in the 
pathogenesis of periodontal disease, independently from the mechanisms provoking their 
accumulation. This hypothesis is supported by a recent study, which has investigated the 
existing relationship between the development of periodontal disease and glycosylated 
haemoglobin (HbA1c) levels in non-diabetic individuals. The periodontal health status, 
analysed in these patients using modified CPI (Community Periodontal Index), was 
significantly correlated with HbA1c levels. After the normalisation of data, the authors 
observed that mean HbA1c was significantly increased in the case of periodontal 
deterioration (Hayashida et al., 2009). 
7. Final considerations and future developments 
The literature analysed clearly shows that all the conditions and pathologies causing 
oxidative stress, production of AGEs, and activation of RAGE, are potentially involved in 
the aetiology and severity of periodontal diseases, and particularly in the development of 
chronic periodontitis. 
As the MetS is defined by the presence of hyperglycaemia, dyslipidemia, obesity, 
hypertension – all these conditions determine ROS increase and AGEs production – it is 
clear that the MetS may worsen an existing state, or cause a new periodontal pathology, 
with mechanisms like those described for diabetes, where the AGEs play a key role in the 
onset of microangiopathy, retinopathy, nephropathy, neuropathy, and general tissue 
degeneration conditions (Ramasamy et al., 2005). Considered individually, the conditions 
defining the MetS play an important role. However, their role is certainly at a lower level as 
compared with synergic action. It is now described by clinical evidence and scientific 
literature that neglecting a high BMI involves a cascade of other compensatory and 
dysfunctional conditions promoted by humoral signalling; whose sum defines the MetS 
(Martin-Cordero et al., 2011; Martínez-Clemente et al., 2011). 
The AGEs that may irreversibly accumulate in periodontal tissue with age, prolonged 
hyperglycaemia and/or chronic inflammation statuses, such as those that may be observed 
in the MetS, can damage the tissues and affect the functional status of collagen fibres and 
increase ROS and inflammation mediator levels through the interaction with RAGE. The 
formation of AGEs in the extracellular matrix may contribute to increasing ROS production 
and release from phagocytes and periodontal ligament cells, with subsequent induction of 
pro-inflammatory cytokines and metalloproteinases, leading to osteoclast activation and 
bone loss. 
Since AGEs are products of accumulation, all these conditions have more significance in a 
condition which needs long time to develop, just as chronic periodontitis.  
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Therefore, we believe periodontal diseases , and particularly chronic periodontitis, should 
be considered by a multidisciplinary approach, bearing in mind that the periodontal tissues 
exposed not only to local bacterial onslaught, but also to systemic conditions damaging 
them through the same mechanisms provoking damage in other tissues. 
 
Fig. 1. In this figure has been represented the hypothesis supported in this article. MetS 
promote a self supporting ROS and AGEs accumulation that result in chronic inflammation 
signalling. This condition also promotes the osteoclast activation that result in alveolar bone 
loss.  
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1. Introduction 
Gingival embrasures are defined as the embrasure cervical to the interproximal contact.1  If 
the embrasure space is not completely filled by the gingiva, it is considered open. Open 
gingival embrasures contribute to retention of food debris and can adversely affect the 
health of the periodontium. They are more common in adult patients with bone loss.2 Black 
triangles occur in more than 1/3 of all adults and should be discussed with patients prior to 
initiating dental treatment.1,3 Key considerations in restorative and orthodontic treatment 
are preserving papilla and avoiding black triangles in the gingival embrasures of the esthetic 
zone (Figure 1). Open embrasures are best managed with a team work involving restorative, 
orthodontic and periodontal parts (Figure 2). 
 
 
Fig. 1. Open gingival embrasure between the maxillary central incisors. 
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Open gingival embrasures are visibly unesthetic and negatively affect a person’s smile. In a 
study by Kokich et al.,4 orthodontists considered a 2 mm open gingival embrasure as 
noticeably less attractive than an ideal smile with normal gingival embrasure. Open gingival 
embrasures slightly greater than 3 mm were considered less attractive by both general 
dentists and the general population.  
 
Fig. 2. Interdisciplinary approach to overcome black triangles. 
To better manage open gingival embrasures, the dental clinician must be aware of the 
underlying etiology and make an individualized treatment plan for each patient. Many 
embrasures may be corrected with restorative procedures, but if the underlying etiology is 
not addressed correctly, the result may not be as esthetic as expected.5 Open gingival 
embrasures are more frequently encountered in adults undergoing orthodontic treatment 
(38%) than adolescents in treatment (15%).3 However, 41.9% of adolescent patients who are 
treated for maxillary incisor crowding have gingival embrasures.6 The higher prevalence in 
adults is related to periodontal disease and periodontal or orthognathic surgery.1,7 Gingival 
embrasures change over time, and once filled, embrasures may become open again.8,9 
2. Etiology and prevalence of open gingival embrasures 
Etiologic factors for open gingival embrasures include; dimensional changes of papilla 
during orthodontic treatment, long lasting orthodontic treatment, loss of periodontal 
attachment resulting in recession, loss of height of the alveolar bone relative to 
interproximal contact, length of embrasure area, root angulations, age, contact position, and 
triangular-shaped crowns.10-12 Patients may present with one or more etiologic factor; thus, 
managing each patient requires an individual assessment and treatment plan. 
 
Clinical Considerations of Open Gingival Embrasures 
 
115 
The occurrence of open gingival embrasures is found to be age related. Studies1,13 have 
demonstrated that patients over 20 are more susceptible than those under 20. Open gingival 
embrasures were reported in 67% of the population over 20 compared with 18% in the 
population under 20.1 This is due to the thinning of oral epithelium, a decrease in 
keratinization, and a reduction in papilla height as a result of the aging process. Therefore, age 
is a significant factor leading to wide and long embrasure spaces in adults. Embrasure and 
tooth morphology also is another etiologic factor. Open embrasures occur more frequently in 
short narrow, long narrow, long wide, and short wide embrasure morphologies.11,13 
3. Periodontal disease and open gingival embrasures 
Periodontal disease leads to loss of alveolar bone which also affects the interdental papilla. If the 
distance from the alveolar crest to interdental contact point exceeds 5 mm, it is more likely that 
the papilla is insufficient to fill the embrasure.2 The distance between the contact point and the 
alveolar crest is less than 5 mm in healthy periodontium whereas, pocket depths greater than 3 
mm will lead to increased plaque retention, inflammation, and possibly gingival recession.14 For 
those with periodontal diseases, it is the bone loss that increases the distance between the 
contact points and alveolar crest and eventually creates open gingival embrasures. 
The distance from the base of the contact point to the alveolar crest in central incisors is a 
strong indicator of the presence of open gingival embrasures (Figure 3a). Tarnow et al.2 
reported an association between black triangles and the distance from the contact point to 
the alveolar crest of the bone. Another study found that a distance of 5, 6, and 7 mm resulted 
in an open embrasure in 2, 44, and 73% of the cases, respectively.15 These observations 
indicated that papilla was present in almost 100% of the cases if the distance from the 
alveolar crest to the contact point was 5 mm or less. When the distance was more than 7 
mm, most cases had an open gingival embrasure. At 6 mm, the papilla was present in half of 
the cases.15 Other studies14,16 have reported similar results (Figure 3b).  
 
Fig. 3. (a) The distance between the alveolar crest to contact point (red) is critical in determining 
the extent of an open embrasure. A distance greater than 5 mm is considered to be a black 
triangle. (b) Summary of several studies measuring the distance from the alveolar crest to the 
contact point. Increasing the distance will increase the likelihood of an open embrasure. 
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The prevalence of plaque accumulation and gingivitis is probably higher in people with 
crowding, but host susceptibility and other factors may also play a role in the occurrence of 
open gingival embrasures, especially in patients who have been previously treated for 
periodontal disease.17 For these patients, there needs to be an increased effort to enhance 
periodontal maintenance and oral hygiene to prevent bone loss and recession.  
Adult patients with open gingival embrasures have an increased alveolar bone crest- 
interproximal contact distance of 5.5 mm or more.3 An increase of 1 mm in the distance 
between the alveolar bone crest and interproximal contact increases the possibility of an 
open gingival embrasure from 78 to 97%. As a rule, 5-6 mm distance from the contact point 
to the alveolar crest is the most critical in determining the presence or absence of an open 
gingival embrasure.15  
Chronic periodontitis and tooth brush trauma are other factors that may cause open 
embrasures. If tooth brushing is causing gingival recession, interproximal tooth brushing 
should be discontinued until the tissue can recover if it causes loss of interdental papilla.18 
At present, there are no surgical procedures to augment papilla with a predictable 
outcome.19-25 Surgical papillary reconstruction often results in contraction and necrosis of 
the grafted tissue due to tissue fragility and the low blood supply to interdental papilla.15 
However, case studies26,27 have reported some degree of success with subepithelial 
connective tissue grafts and orthodontic therapy. Pedicle flaps have provided better results 
than free gingival grafts.15 
Presence of a thick biotype gingiva and no loss of insertion at the periodontal attachment are 
important for the successful outcome of the surgery.18 Patients with a thin biotype of gingiva 
are more susceptible to recession and consequently, to open gingival embrasures. Patients 
with thin periodontium are shown to have long narrow maxillary central incisors, whereas 
patients with a thick biotype have short and wide central incisors.28 In addition, the thick 
periodontal biotype has a thick osseous structure with flat morphology and a thick gingival 
tissue with short wide papilla. Thick biotype is associated with less open embrasures 
especially around implants.29 In contrast, thin biotype is characterized by a scalloped 
appearance with long interdental papilla.30 Typically thick biotype has a better vascular 
supply and biological tissue memory that helps the tissue to rebound, whereas the thin 
biotype usually results in permanent recession.24 Once interdental gingival recession has 
occurred, there is a reduced height and thickness of free gingiva that results in a long clinical 
crown. This recession is aggravated by plaque and toothbrush trauma. Atraumatic plaque 
control is highly recommended for patients susceptible to black triangles.31 
4. Orthodontic correction of open gingival embrasures 
Root divergency of adjacent teeth is strongly associated with open gingival embrasures. This 
either occurs naturally or is caused by improper bracket placement during orthodontic 
treatment. Kurth et al.3 showed that the mean root angulation in normal gingival 
embrasures converge at 3.65° and an increase in root divergence by just 1° increases the 
probability of an open gingival embrasure from 14 to 21%. Orthodontic treatment can be 
performed to converge maxillary incisor roots to reduce or eliminate open gingival 
embrasures (Figure 4).  
 




(a) (b) (c) 
Fig. 4. Paralleling divergent roots will decrease the severity of a black triangle. (a) Divergent 
roots with an open black triangle. (b) Bracket positioning to follow the long axis of the tooth 
and correct for black triangle. (c) Converged roots with a closed black triangle after 
orthodontic treatment. 
The bracket slots must be perpendicular to the long axis of the tooth and not parallel to the 
incisal edges during bracket placement, especially in adults with worn incisal edges. It is 
important to evaluate the periapical radiograph prior to bracket placement, especially in 
patients with attrition.15 If brackets are placed based on incisal edges, greater root 
divergence may cause an open gingival embrasure. Bonding brackets with slots 
perpendicular to the long axis of the teeth will allow roots to converge, and may require the 
worn distoincisal edges to be restored or contoured. As roots become more parallel, the 
contact point will lengthen and move apically toward the papilla, thus reducing open 
gingival embrasures.15 The crowns of each incisor will move closer, causing the stretched 
transseptal fibers to relax and fill in the gingival embrasure.2  
Patients with triangular crown morphology are more susceptible to open gingival 
embrasures (Figure 5a). In this case, the crowns of the central incisors are much wider 
incisally than cervically, resulting in a high contact point. Interproximal reduction (IPR) of 
enamel between triangular crowns will broaden the point contact area which will reduce 
open gingival embrasures. Reduction of interproximal enamel with a reducing diamond 
strip is one way to correct the black triangle. Typically, 0.5 - 0.75 mm of enamel is removed 
with IPR.15  Orthodontic space closure after IPR will lengthen the contact point and move 
the contact gingivally, thus reducing open gingival embrasures (Figures 5b-5d). 
 
(a) (b) (c) (d) 
Fig. 5. (a) Pre-treatment with triangular crowns. Minimizing a black triangle by changing 
point contact (b) to a broader surface (c) through interproximal reduction (IPR). (d) Post-
treatment. 
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After orthodontic treatment, the direction of orthodontic tooth movement and labiolingual 
thickness of the supporting bone and soft tissue determines whether gingival embrasures 
will be present. Interestingly, maxillary incisor imbrication and rotation have a controversial 
association with open gingival embrasure spaces.3,6,31 It would be wise to inform patients 
with imbricated maxillary incisors that they may be predisposed to an open gingival 
embrasure following orthodontic treatment.  
The amount of crowding plays only a limited role in the prevalence of open gingival 
embrasures. Ko-Kimura et al.1 reported that open embrasures occur in a similar percentage 
of patients with incisor crowding of less than 4 mm and those with 4 - 8 mm of incisor 
crowding. When crowding was more than 8 mm, the occurrence of open gingival 
embrasures increased by 7%. However, these results revealed no statistically significant 
differences. The authors also found that the length of orthodontic treatment had 
insignificant effect on occurrence of open gingival embrasures. 
The volume of soft tissue in the gingival embrasure depends on the existing tissue, bone levels, 
and the severity of diastema. Closing a diastema by orthodontic treatment compresses the soft 
tissue, making it fill the embrasure area. Minor diastema closure can be simplified with a 
removable orthodontic appliance (Figure 6). However, large diastema closure may require 
more complex treatment with additional orthodontic and/or restorative measures. 
 
(a) (b) (c) 
Fig. 6. Limited orthodontic treatment to close a diastema. (a) Pre-treatment of diastema. (b) 
A modified maxillary Hawley retainer with extended arms. 3/8”, 3.5 oz elastics (3M Unitek, 
Monrovia, CA, USA) are worn across the teeth from the right arm to the  left arm of the 
retainer. (c) Post-treatment after 4 weeks of treatment. 
5. Restorative correction of open gingival embrasures 
Prosthetic alterations of crown forms by mesiocervical restorations or full veneers will reduce 
the unaesthetic appearance of open gingival embrasures. To guide the shape of the interdental 
papilla, composite resin can be extended into the gingival sulcus, much like a provisional 
crown for an implant.5 When restorative measures are used, care must be taken not to impinge 
on the interdental tissue or harbor plaque. Typically, maxillary central incisors have 80% width 
to height ratio, which is considered to be ideal. Simply using a restorative treatment to reduce 
a large space may cause a divergence of this ratio, resulting in an unaesthetic crown 
appearance. In this case, an interdisciplinary approach may be necessary.  
A connector is the point where teeth appear to contact, and the contact point is the place 
where they actually do. For restorative treatment to be successful, an appropriate ratio of 
crown height between the connector and central incisor is required. The connector of 
maxillary anterior teeth has a proportional relationship to the height of the central incisors. 
The ratio of connector to tooth height for the central, lateral, and canine is 50, 40, and 30%, 
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respectively.32 Teeth with longer crown height will have longer connectors (Figure 7). 
Furthermore, embrasures are smaller between the central incisors and increase progressively 
toward the posterior region. The application of pink-colored porcelain or a removable 
appliance is recommended to hide severe tissue defects.2 A comprehensive understanding 
of anterior esthetics is critical in determining the appropriate treatment for any individual 
patient.33-37 
 
Fig. 7. Connectors and interproximal contact. Connectors (red) are where teeth appear to 
meet. Contact (blue) between teeth is where they actually meet. The appropriate ratio for a 
connector between maxillary central incisors is 50% of the central incisor height. The ratio 
between central–lateral connectors is 40% of the central incisor height, and ratio between 
lateral-canine connectors is 30% of central incisor height. 
6. Considerations for open gingival embrasures with single tooth implants 
Currently, the single tooth implant is one of the most common treatment alternatives for the 
replacement of missing teeth. During the treatment planning of single tooth implants to 
replace congenitally missing lateral incisors, an interdisciplinary approach is preferred to 
provide the most predictable treatment outcome. Studies have documented successful 
osseointegration and long term function of restorations supported by single tooth 
implants.38-41 One of the main advantages of this type of restoration is the ability to keep the 
adjacent teeth intact. However, orthodontic treatment is often necessary to provide adequate 
room both in the coronal and apical areas.  
The biological width of  periimplant mucosa is about 2-3 mm; and a similar amount of 
supracrestal soft tissue is required to allow for the formation of a stable soft tissue 
attachment and to prevent bone resorption.39 Orthodontic treatment should be designed to 
minimize extrusion of the adjacent teeth because any such movement will have the effect of 
an apical migration of the implant.38 To preserve the interdental papilla and allow for 
adequate oral hygiene, 1.5 - 2.0 mm of space is needed between the implant and the tooth on 
each side. Therefore, 7 mm of mesiodistal space must be created between the adjacent 
teeth.41 After the appropriate amount of coronal space has been determined, it is necessary 
to evaluate the interradicular spacing. The minimum interradicular distance required is 
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generally 5-7 mm for a single implant placement. Problems with inadequate space between 
the root apices are generally due to improper mesiodistal root angulation. When patients 
with a missing tooth undergo orthodontic treatment, it is important to take a periapical 
radiograph of the edentulous area prior to removing orthodontic appliances to confirm the 
ideal root position of the adjacent teeth and adequate spacing for a future implant 
placement.38 
A provisional restoration should be placed on the implant to prosthetically guide the soft 
tissue into its final position.41 When a provisional restoration is placed, the subgingival 
contours and shape of this provisional will influence the position of the soft tissue.42 Adding 
more contour to the facial aspect of the provisional causes the facial free gingival margin to 
move apically, whereas adding interproximal contour to the provisional helps create a more 
ideal papillary form. The provisional restoration is generally allowed to remain in place for 
4-6 weeks. 
The correct buccolingual position of an anterior implant is another important esthetic factor. 
The head of the implant should be placed inside an imaginary line connecting the incisal 
margins of the adjacent teeth, so the longitudinal axis of the implant should be 4 mm from a 
line tangent to the adjacent occlusal surfaces (Figure 8). In the horizontal plane, the center of 
the crown placed on the implant should be no farther than half of the abutment radius from the 
center of the implant — that is approximately 1 mm in the case of a standard abutment. This 
location may help to prevent resorption of the thinner cortical buccal bone and consequent 
recession.43 Vertically, the implant platform should be 3-5 mm apical to the gingival margins 
of the adjacent teeth to provide a harmonious smile line (Figure 9). An adequate band of 
attached gingiva also helps reduce the risk of gingival recession.  
 
 
Fig. 8. The longitudinal axis of the implant should be approximately  4 mm away from an 
imaginary line connecting the incisal surfaces of the adjacent teeth.  
 




Fig. 9. The implant platform should be 3-5 mm apical to the gingival margins of the adjacent 
teeth to provide a harmonious smile line. 
Single tooth implants have a significant possibility of papilla loss because of an increase in 
the distance between the contact point and the alveolar crest.44-46 It is important to keep the 
distance between the contact point and bone level as 5 mm or less to preserve papilla 
around implants. The distance of the adjacent natural teeth to the alveolar crests is the most 
critical factor, whereas the height of the implant contact to the bone is less important.44 
Choquet et al.45 showed the presence of papilla at 100% and 50% level in healthy teeth when 
the distance from the alveolar crest to the contact point of single implant in the maxillary 
anterior region was 5 and 6 mm, respectively. A significant increase in black triangles was 
observed at distances above 7 mm.28 Some clinicians believe that tissue healing around an 
immediate provisional abutment helps in proper tissue contouring. However, Ryser et al.44 
stated that there was no difference in papilla loss even if an implant had a provisional 
placed immediately. Extrusion of a tooth prior to implant placement allows the bone to 
extrude with the tooth, resulting in an increase in soft tissue dimensions. Tooth extrusion 
can be performed with intermaxillary elastics and a clear removable appliance such as an 
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Essix.47 However, existing tissue loss prior to implant placement  usually results in an open 
embrasure following final restoration. Grunder et al.48 reported a 0.375 mm increase in soft 
tissue volume after 1 year, although 0.6 mm of soft tissue shrinkage occurred on the buccal 
side of the implant crown. Jemt49 also suggested that the volume of soft tissue around 
anterior single tooth implants can be expected to undergo soft tissue shrinkage on the 
buccal; whereas, an increase in soft tissue volume occurs in 80% of cases after 1.5 years. 
7. Considerations for open gingival embrasure with adjacent implants 
In cases where two implants are placed adjacent to each other, open gingival embrasures are 
more pronounced. Up to 4 mm of vertical alveolar bone may be lost in such cases.50 Fibers 
are stretched vertically instead of perpendicularly from the implant surface and there is 
reduced blood supply, further complicating papilla restoration.51 A soft tissue deficiency of 
1-2 mm occurs because the biological width around an implant is apical to the platform for 
the abutment.52 As a result, the biological width of implants is located subcrestally rather 
than the supracrestal location with natural teeth.43 The distance between the implant 
shoulder and alveolar crest should be at least 4 mm in the maxillary anterior region. To 
prevent bone loss and subsequent papilla loss, it is important that the distance between two 
adjacent implants exceeds 3 mm.44 This helps to maintain interproximal bone above the 
implant shoulder. In the anterior region, it is usually difficult to achieve this ideal 
mesiodistal distance between implants. One way to compensate for the loss of interproximal 
bone is to augment the buccal bone in the papillary area,53,54 but it is not possible to ensure a 
complete papilla with distances greater than 3 mm. There are several procedures that may 
help to prevent additional interproximal bone loss but they won’t allow papilla 
regeneration. When placing and restoring adjacent immediate implants, papilla is better 
preserved if the distance is 2-4 mm.55 To prevent unaesthetic open embrasures in the esthetic 
zone, adjacent implants should better be avoided. Options for two missing teeth in the 
esthetic zone include orthodontic movement of teeth, placing an implant with a cantilever 
pontic and performing a soft tissue graft, interproximal bone augmentation, or a three unit 
bridge involving one implant.46   
8. Summary 
The distance between the alveolar crest and interproximal contact point together with 
periodontal bone loss appear to be the most significant factors contributing to occurrence of 
open gingival embrasures. The etiology of open gingival embrasures is multifactorial, so to 
determine the ideal treatment for the patient, the clinician should first evaluate whether the 
problem is caused by soft or hard tissue problem. An interdisciplinary team approach 
including a general dentist, an orthodontist, a periodontist, and a prosthodontist should be 
considered for the optimum restoration of open gingival embrasures. 
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1. Introduction  
Periodontitis is characterized by an inflammatory reaction that affects tooth attachment 
tissues and can be classified as chronic periodontitis or aggressive periodontitis (AgP) 
according to clinical characteristics and rate of progression. The current classification of 
periodontal disease describes two clinically distinct forms of periodontitis. AgP is 
characterized by rapid progression and severe periodontal destruction, mainly seen in 
younger individuals (Meng et al., 2007). Chronic periodontitis is characterized by a lower 
rate of progression (Schätzle et al., 2009). AgP constitutes a group of rare and rapidly 
progressing forms of periodontitis that are frequently characterized by an early age of 
clinical onset (Genco et al., 1986). AgP is defined as a destructive periodontal disease 
affecting more than 14 teeth in young individuals. Its etiology has been linked to the 
presence of Aggregatibacter actinomycetemcomitans (Fine et al., 2007; Haraszthy et al., 2000; 
Di Rienzo et al., 1994), host response defects (Page et al., 1984, 1985; Lavine et al., 1979), 
and possibly to genetic inheritance (Hart & Kornman, 1997; Kinane et al., 2000; 
Boleghman et al., 1992; Beaty et al., 1987; Hart et al., 1992; Melnick et al., 1976; Page et al., 
1985). In contrast, chronic periodontitis is characterized by a lower rate of progression 
(Schätzle et al., 2009), although like AgP it can reach a severe stage, leading to tooth loss 
and edentualism. Many clinicians report difficulty in establishing a differential diagnosis 
for AgP and chronic periodontitis due to an overlapping “gray area” that often negates a 
clear-cut diagnosis. Such issues raise the question of whether these are actually two 
distinct clinical entities. 
In AgP, comprehensive mechanical/surgical and antimicrobial therapy is usually 
required for long-term stabilization of periodontal health (Buchmann et al., 2002). Enamel 
matrix proteins have been proposed to promote regeneration of the lost periodontal 
tissues when used during periodontal surgery (Gestrelius et al., 2000; Hammarström, 
1997). Indeed, clinical studies showed that applying the commercially available enamel 
matrix derivative (EMD) to deep intrabony defects during periodontal flap surgery 
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promotes a favorable clinical outcome in terms of clinical attachment gain and probing 
depth reduction (Heijl et al., 1997; Heden & Wennström, 2006). Other treatment 
alternatives for bone defects include grafting or extraction of the affected teeth, with 
possible orthodontic movement into the involved sites (McLain et al., 1983). AgP has the 
potential to cause tooth mobility and pathological tooth movement, and thus orthodontic 
treatment might become necessary. It is well established that despite bone loss, teeth can 
be moved orthodontically if the remaining bone and the periodontium can be brought 
back to a healthy state (Boyd et al., 1989). 
Although the use of conventional computed tomography (CT) is well established in oral 
surgery (Gold et al., 2003), three-dimensional (3D) CT imaging can provide particularly 
useful information that may assist in diagnosis and planning of treatment strategies 
(Ferrario et al., 1996). Furthermore, computational simulations that include 3D image 
processing and biomechanical calculations show promise as useful tools for orthodontic 
research and assist in clinical decision-making (Maki et al., 2003). 
This report describes the multidisciplinary treatment of AgP patient with progressing full-
mouth bone resorption. Orthodontic treatment was performed after completion of 
periodontal treatment including regenerative surgery using EMD. 
2. Diagnosis and etiology 
An 18-year-old female patient was referred by a general practitioner to the Department of 
Periodontology at Showa University Dental Hospital for treatment of AgP (Fig. 1A).  
A review of her medical history did not reveal any systemic disease. Familial aggregation of 
AgP was denied. An initial examination revealed probing depths of 7 to 10 mm at teeth 
numbers 16, 15, 14, 13, 11, 21, 23, 24, 25, 26, 36, 35, 42, 43, 44, and 46, with bleeding on 
probing (Table 1A). Suppuration was registered at teeth numbers 15, 14, and 21. Full-mouth 
periapical radiographs revealed an overall pattern of severe horizontal bone loss with 
localized cratering (Fig. 1B).  
 
Table 1. (A-C). Probing depths (PD) and bleeding on probing (BOP) in the patient before, 
during, and after periodontal treatment. 
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Fig. 1. Oral photographs at initial presentation (A) and dental X-rays at initial presentation 
(B). 
Prior to commencing orthodontic treatment, the patient underwent periodontal treatment. 
Periodontal treatment involved oral hygiene instructions, scaling, root planing, temporary 
fixation using 4-META/MMA-TBB resin, occlusal adjustment, and periodontal surgery. 
After periodontal treatment the patient was introduced to the Department of Orthodontics 
at Showa University School of Dentistry for tooth alignment. She presented with a Class II 
malocclusion. Cone-beam CT (CBCT) imaging confirmed aggressive horizontal and vertical 
alveolar bone resorption throughout the whole area. Facial photographs before orthodontic 
treatment are presented in Fig. 2A. The maxillary central incisors were crowded (Fig. 2B). 
The patient’s chief concerns for orthodontic treatment were the longevity of her front teeth 
and the possibility of enhancing aesthetics.  
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Fig. 1. Oral photographs at initial presentation (A) and dental X-rays at initial presentation 
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Fig. 2. Facial photographs before orthodontic treatment (A) and oral photographs before 
orthodontic treatment (B). 
3. Treatment objectives 
The clinical objectives of treatment were as follows: (1) to achieve adequate daily plaque 
control and clinically healthy gingiva, (2) to avoid occlusal trauma, and (3) to correct the 
planarization of the alveolar bone level. Furthermore, orthodontic treatment was also 
planned with the patient’s expectations regarding with the longevity of her teeth and 
enhanced aesthetics. 
4. Treatment results 
Prior to commencing orthodontic treatment, the patient underwent periodontal treatment 
by a periodontist for 20 months. The primary goal in the treatment of this patient  
was to control her periodontal infection. Periodontal treatment was started by oral 
hygiene instruction and subsequent scaling and root planing under local anesthesia. 
Manual and ultrasonic instruments were used for scaling and root planing. Then, 
temporary fixation using 4-META/MMA-TBB resin (teeth numbers 16, 15, 14, 13, 23, 24, 
25, 26, 33, 34, 35, 36, and 37) and occlusal adjustment were performed with the goals of 
reducing occlusal interferences in lateral excursions and improving canine guidance. 
Following the reevaluation after this initial treatment phase, periodontal surgery  
was performed. The bone defects at the maxillary right second premolar were subjected  
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to regenerative periodontal surgery. Intrabony defects and root surfaces were 
degranulated and cleaned with curettes, rinsed with saline, and dried with cotton  
swabs. The exposed root surfaces were demineralized using EDTA for 2 minutes. After 
thorough rinsing with saline, EMD (Emdogain; Institut Straumann, Basel, Switzerland) 
was applied to the root surfaces. The autogenous bone was then blended with EMD, and 
the osseous defect was grafted. The autogenous bone was harvested using a trephine bar 
from the extraction fossa around the right third molar in the mandible and crushed using 
a bone mill (Fig. 3A, B). Radiographs obtained 3 years after surgery showed marked 
filling of the defects and sharp contours of the hard tissue that had developed (Fig. 4A, B).  
 
 
Fig. 3. Buccal view of the surgical wound after a full-thickness flap was reflected, 
granulation tissue was removed, and the root surfaces and bone defect were conditioned 
with EDTA. After thorough rinsing with saline, EMD was applied (A). The autogenous bone 
was harvested using a trephine bar from the extraction fossa around the right third molar in 
the mandible and crushed using a bone mill (B). 
 
 
Fig. 4. Radiographs obtained 3 years after surgery showing a marked filling of the defects 
and sharp contours of hard tissues gained through therapy. 
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a bone mill (Fig. 3A, B). Radiographs obtained 3 years after surgery showed marked 
filling of the defects and sharp contours of the hard tissue that had developed (Fig. 4A, B).  
 
 
Fig. 3. Buccal view of the surgical wound after a full-thickness flap was reflected, 
granulation tissue was removed, and the root surfaces and bone defect were conditioned 
with EDTA. After thorough rinsing with saline, EMD was applied (A). The autogenous bone 
was harvested using a trephine bar from the extraction fossa around the right third molar in 
the mandible and crushed using a bone mill (B). 
 
 
Fig. 4. Radiographs obtained 3 years after surgery showing a marked filling of the defects 
and sharp contours of hard tissues gained through therapy. 
 
Pathogenesis and Treatment of Periodontitis 
 
132 
The right first molar in the mandible had class I furcation involvement at the lingual sites. 
The furcation involvement was treated by a flap operation with furcation plasty 
(odontoplasty and osteoplasty) (Fig. 5). Clinical examination showed improved probing 
depths after periodontal treatment (Table 1B). 
 
 
Fig. 5. The mandibular right first molar had class I furcation lesion at the lingual site. The 
furcation lesion was treated with furcation plasty. 
All teeth were sequentially bonded or banded with 0.018- × 0.025-in standard edgewise 
brackets. For the upper teeth, a 0.012-in round stainless steel archwire was initially placed, 
followed by a 0.014-in round stainless steel archwire. By 6 months, the incisors were leveled 
by the use of a 0.016-in round stainless steel archwire. The alignment proceeded until a 
0.016- × 0.016-in rectangular archwire was placed. For the lower teeth, the initial archwires 
consisted of the following: 0.012-in round stainless steel, 0.013- and 0.014-in nickel titanium, 
followed by 0.016- × 0.016-in nickel titanium archwires by the 9th month of treatment. The 
alignment proceeded until a 0.016- × 0.016-in rectangular archwire was placed. The patient 
was instructed to carefully clean around the orthodontic appliances and was monitored for 
gingival and tooth mobility changes at every orthodontic visit. The patient compliance was 
good throughout the orthodontic treatment period with regular periodontal maintenance 
appointments. Scaling, localized root planing, polishing, and follow-up examinations of 
plaque control were performed at each maintenance visit. After 12 months of orthodontic 
treatment, a removable Hawley retainer for the maxilla and mandible was recommended for 
nighttime use over the course of a year.  
Post-treatment facial photographs are shown in Fig. 6A. Intraoral views (Fig. 6B) showed an 
acceptable occlusion in which a normal overbite and overjet were achieved. However, the 
intraoral view also showed that the midlines of the incisors were not coincident. We avoided 
aggressive tooth movement concerning to the damage of tooth root and periodontal tissue. 
This resulted in dis-coincident of midline. Cephalometric superimpositions (Fig. 7, Table 2) 
showed that the incisors were retracted 2 to 3 mm with a slight reduction in protrusion. 
After full orthodontic treatment, the left central incisor and canine in the maxilla were 
treated with a connective tissue graft (Fig. 8). 
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Fig. 6. Facial photographs (A) intraoral photographs (B) after orthodontic treatment. 
 
 
Fig. 7. Superimposed cephalometric tracings, pretreatment (solid line) and post-treatment 
(dotted line). (A) Superimposed on the SN plane registered at S. (B) Superimposed on the 
palatal plane registered at ANS. (C) Superimposed on the mandibular plane registered at 
Me. 
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Angular (°)  
  PRE-Tx   POST-Tx  
  Mean SD  Mean SD
SNA  83.1  +1  82.9  +1 
SNB  78.1  −1  78.2  −1 
ANB  5.0  +1  4.7  +1 
Mandibular plane 
angle  33.4  −1  33.5  −1 
Gonial angle  121.4 +1  121.7 +1 
Ramus inclination  85.2  −1  85.3  −1 
U1 to FH plane 
angle  121.5 +2  117.1 −1 
L1 to Mandibular 
plane angle  102.8 +2  106.1 +2 
FMIA   50.7  −1  54.0  −1 
The data indicate mean and standard deviation (SD).  
Table 2. Cephalometric analysis of patient pre- and post-treatment. 
 
Fig. 8. Connective tissue graft for root coverage. 
The satisfactory clinical results including the reduction in mean pocket depth from 3.9 ± 2.3 
mm to 2.1 ± 0.6 mm and flattening of the alveolar bone level were achieved. Clinical 
examination showed appreciable gains in clinical attachment levels and improved probing 
depths from 1 to 4 mm at all sites after periodontal and orthodontic treatment (Table 1C). 
Radiographic analysis showed improvement in bone height at all sites. Overall, full mouth 
radiographs showed significant changes in the crater-like bone defects on teeth numbers 21, 
23, 35, and 46 (Fig. 9A), and intraoral views showed aesthetic improvement by prosthetic 
treatment of the central incisor on the upper right side. Tooth mobility was also significantly 
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reduced compared with pretreatment values. A complete blood count including differential 
blood counts also improved compared with pretreatment levels.  
3D CT allows for precise assessment of bone defects caused by periodontal disease (Naito et 
al., 1998). In this study, CBCT (CB MercuRay; Hitachi Medical Technology, Tokyo, Japan) 
was performed prior to orthodontic treatment (Fig. 10, Fig. 12A) and during retention 
phases (Fig. 11, Fig. 12B). It was confirmed that all teeth were positioned appropriately in 







Fig. 9. Oral photographs after prosthetic treatment (A) and dental X-rays at  
retention (B). 
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Fig. 9. Oral photographs after prosthetic treatment (A) and dental X-rays at  
retention (B). 
 





Fig. 10. Cone-beam X-ray computed tomography (CBCT) images of the upper arch in pre-
orthodontic treatment (A) and CBCT images of the lower arch in pre-orthodontic treatment 
(B). 
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Fig. 11. Cone-beam X-ray computed tomography (CBCT) images of the upper arch during 
retention phases (A) and CBCT images of the lower arch during retention phases (B). 
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orthodontic treatment (A) and CBCT images of the lower arch in pre-orthodontic treatment 
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Fig. 12. Volumetric rendering in pre-orthodontic treatment (A) and in pre-orthodontic 
treatment (B) 
5. Discussion 
Rescala et al. (2010) reported similar microbiological and immunological parameters for 
subjects with chronic periodontitis and AgP who showed comparable periodontal disease 
severity. Herein we report  dental management of an otherwise healthy patient diagnosed 
with generalized AgP and rapidly progressing bone loss throughout the mouth. Generalized 
AgP features  loss of supporting tissues in addition to changes in tooth mobility and 
pathological tooth movement that are associated with sustained periodontal tissue 
destruction. In such cases, a comprehensive and effective treatment plan often includes 
periodontal therapy to relieve inflammation and orthodontic treatment to correct 
malocclusion. Comprehensive periodontal therapy is also often necessary in severe chronic 
periodontitis. The present patient showed a successful periodontal response with no 
progressive bone loss during or after treatment. 
The strategy of treatment planning for periodontitis patients with aggressive or chronic 
periodontitis is well established. For patients with aggressive or chronic periodontitis, 
phases of treatment - systemic, initial, re-evaluation, surgical, maintenance, and restorative –
are generally accepted. The amount of active planning required at each step may be greater 
for the patient with aggressive periodontal disease. To retain teeth cannot help but 
complicate the treatment-planning process. Therefore, the patient with aggressive 
periodontitis to have experienced attachment loss would be expected at a younger age, at a 
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faster rate and to a greater extent than the patient with chronic periodontitis (Deas et al., 
2010). 
Some authors reported that tooth intrusion might deepen the defect and improve blood 
circulation (Vandevska-Radunovic et al., 1994; Ericsson et al., 1977), suggesting that this 
provides a better environment for guided tissue regeneration procedures (Rabie et al., 1996). 
In the presence of osteoinductive factors, mesenchymal cells differentiate into cells capable 
of regenerating the periodontal structures. This procedure is an alternative to rebuilding the 
bone and the original periodontal architecture. It therefore seems reasonable to manage a 
patient with compromised periodontal dentition using an interdisciplinary approach 
consisting of both orthodontic and periodontal treatment strategies. 
In this study, the initial periodontal treatment was followed by periodontal regeneration 
therapy using EMD for the maxillary right second premolar. The bone defect involved one 
to two wall defects and the radiographic bone gain was 4-5 mm in the 3 year follow-up 
evaluationafter surgery. In prospective controlled clinical trials using EMD therapy, clinical 
attachment gains of 2.2-3.4 mm have been observed in addition to bone growth (Pontoriero 
et al., 1999; Sculean et al., 2001; Heijl et al., 1997). Thus, the clinical findings presented herein 
are equal to or better than those in previous reports, and there are a number of clinical 
scenarios associated with this therapy: (1) EMD only, if the defect is well contained, i.e., two- 
and three-walled intrabony defects and craters; (2) a combination of EMD and graft 
material, as in cases of moderate to deep, non-contained intraosseous defects; and (3) a 
combination of EMD, graft material, and barrier membrane, as in supracrestal cases with 
shallow intraosseous defects. In each case, a coronally advanced flap procedure must be 
performed (Froum et al., 2001). Because the patient in this report presented with a non-
contained intraosseous bone defect of the maxillary right second premolar, we performed 
combination therapy of EMD and autogenous grafting, which resulted in a satisfactory and 
uneventful treatment outcome. 
Meticulous initial therapy and good oral hygiene are considered prerequisites for successful 
regenerative periodontal surgery (Cortellini et al., 1994). In studies reporting the best 
regenerative outcomes, patients with chronic periodontitis were carefully selected regarding 
oral hygiene performance, the proportion of bleeding sites remaining after initial 
periodontal therapy, as well as smoking habits (Cortellini & Tonetti, 2005; Wachtel et al., 
2003). In agreement with these reports, the present patient with AgP qualified for 
periodontal regeneration therapy using EMD as a nonsmoker with low plaque levels and 
minimal bleeding scores. 
Early comparisons of imaging techniques have shown that CT yields more detailed 
information than conventional radiography for visualizing bone (Sarikaya et al., 2002; 
Ericson & Kurol, 1988). Consequently, CT is now frequently used to qualitatively and 
quantitatively assess potential implant sites (Fuhrmann et al., 1995), instead of conventional 
dental radiographs, which do not allow for the evaluation of dehiscence at the implant site. 
Cone Beam CT (CBCT) and other such 3D technologies compare well with traditional 
methods, with the additional advantage that periodontal defects can be observed in all 
directions (Misch et al., 2006). It is clinically important to determine the direction of 
orthodontic movement and the groups of teeth with higher risks of dehiscence and 
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fenestration. In the present case, all teeth were appropriately maintained in alveolar bone, 
and the recovery of such bone in molar regions was also investigated using CBCT. 
An important factor underlying the successful periodontal outcome and lack of progressive 
bone loss during and after treatment in the present case was the patient’s strict adherence to 
regular periodontal maintenance at 3-monthly intervals. A recent longitudinal study 
indicated that patients with reduced, but healthy periodontal tissues (after successful 
periodontal treatment) undertook a full course of orthodontic treatment with fixed 
appliances without the occurrence of additional bone loss, provided that plaque removal 
was effective and a 3-monthly periodontal maintenance schedule was followed (Boyd et al., 
1989). Periodontal disease progression was successfully arrested in 95% of the initially 
compromised lesions, while 2-5% of patients experienced discrete or recurrent episodes of 
loss of periodontal support (Buchmann et al., 2002). It is therefore clear that periodontal 
follow-up is crucial for successful treatment. In many patients with a periodontally involved 
dentition, pathological tooth migration can create serious functional and aesthetic problems. 
The coordination of proper orthodontic and periodontal therapies has proven to be effective 
in such situations, with long-term stability of the results obtained. A key point for achieving 
therapeutic success is therefore the patient’s periodontal health status prior to and during 
the orthodontic treatment. Because periodontal health is essential for any form of dental 
treatment, good oral hygiene at home and professional maintenance care are important 
during and after active orthodontic treatment. 
6. Conclusion  
Prior to the commencement of orthodontic treatment, periodontal inflammation should be 
appropriately addressed by eliminating calculus and overhanging restorations, scaling, root 
planing, and instructing patients on proper oral hygiene. Deep pockets must be eliminated 
before orthodontic treatment to avoid apical displacement of plaque to avoid establishing 
progressive periodontal lesions. 
Unlike other imaging methods, CBCT allows detailed imaging of periodontal defects to be 
gathered from a number of directions. The application of this technology is highly relevant 
for oral health professionals because it potentially provides the necessary information on 
tooth movement to the treating orthodontist and allows the periodontist to make treatment 
plans for periodontal disease. 
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1. Introduction 
A lot of fruits contain nutrient substances that can prevent, cure or suppress various 
diseases. They are nature’s true medicines, and diets rich in fruits are consistently 
associated with a decreased risk of cancer and other chronic diseases. Apricot “Prunus 
armeniaca” is the fruit of a rosaceous tree (rosaceae), which is produced in most parts of the 
world (Gur, 1985). The name Prunus armeniaca is thought to be a misnomer based upon 
the long-held view that apricots initially originated in Armenia. It is known that apricots 
originated in the Far East, most likely in the Himalayas, the Northern and Western 
regions of China from where they spread to Armenia and Russia (Gu, 1979; Gulcan, 1988). 
Apricot is found semi-wild and wild in the northern hills of China and in a broad belt 
across the hills, mountains, and plateaus of Central Asia as far as the Caucasus 
Mountains. The first record of the domestication of apricots is an account of their 
cultivation in China, about 4000 years ago. It is likely that tribe people of Central Asia 
established traditional rights to harvest their parts of the apricot forests for millennia 
before this time. 
The apricot variety found in Japan is “Prunus mume Sieb. et Zucc’’ widely known as Ume 
(Figure 1). The Japanese people started to grow Ume trees more than 2000 years ago, most 
likely imported from China. Soon they discovered the health enhancing effects of apricot 
fruits, and over many centuries, through cultivation, they have improved their apricot tree 
variety to produce healthier fruits. Accordingly, there is a long-standing view that the 
Japanese apricot juice can suppress cancer in tumour bearing hosts and inhibit the growth of 
bacteria. 
This article reviews the current knowledge on Ume, including its correlation with some 
diseases and periodontitis. 
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Fig. 1. MK615 is made from Japanese apricot (Ume). 
2. Anti-cancer effects of an extract from Ume  
MK615 is an extract mixture containing hydrophobic substances from Ume (AdaBio, 
Gunma, Japan) (Figure 1). It contains several triterpenoids and has been shown to exert an 
anti-neoplastic effect against human cancers, such as breast cancer, stomach cancer, 
hepatocellular carcinoma, colon cancer and malignant melanoma. The mechanisms 
responsible for the anti-neoplastic effects of MK615 include induction of apoptosis and 
autophagy, and suppression of Aurora A kinase in cancer cells (Nakagawa et al., 2007; 
Adachi et al., 2007; Okada et al., 2007; Mori et al., 2007; Matsushita et al., 2010). 
3. Inhibitory effects of an extract from Ume on Helicobacter pylori 
Helicobacter pylori infection is an important factor in human gastric disorders, including 
chronic active gastritis, peptic ulcers, intestinal metaplasia and cancer. 
In the in vitro study, Ume extract had an immediate bactericidal effects on H. pylori 
(Miyazawa et al., 2006; Enomoto et al., 2010). In the in vivo study, Ume extract suppress 
chronic active gastritis in the glandular stomachs of H. pylori-infected Mongolian gerbils 
(Otsuka et al., 2005). H. pylori-inoculated gerbils were given Ume extract in their drinking 
water for 10 weeks. The microscopic scores for gastritis and mucosal hyperplasia in the Ume 
extract groups were significantly lower than in the H. pylori-inoculated control group, with 
dose-dependence. Additionally, it was reported that Ume extract showed the antibacterial 
effect on H. pylori in the human stomach in vivo pilot study (Nakajima et al., 2006). 
Therefore, Ume extract may have potential as a safe and inexpensive agent to control H. 
pylori-associated gastric disorders, including gastric neoplasia. 
4. Anti-inflammatory effects of an extract from Ume 
The high mobility group box 1 protein (HMGB1), a nuclear protein, has two distinct 
functions in cellular systems. In the nucleus, HMGB1 acts as an intracellular regulator of the 
transcription process with a crucial role in the maintenance of DNA functions (Lu et al., 
1996). In the extracellular space, HMGB1 is released by all eukaryotic cells upon necrosis or 
by various cells in response to inflammatory stimuli such as endotoxins, tumor necrosis 
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factor (TNF)- α, and C-reactive protein (Wang et al., 1999; Taniguchi et al., 2003; Kawahara 
et al., 2008). Extracellular HMGB1 can act as a potent inducer of proinflammatory cytokines 
including TNF- α, interleukin (IL)-6, and IL-1s from a wide variety of cells, thus playing a 
major role in various inflammatory diseases such as sepsis, rheumatoid arthritis, 
disseminated intravascular coagulation, periodontitis, xenotransplantation and 
atherosclerosis (Wang et al., 1999; Taniguchi et al., 2003; Kawahara et al., 2008; Ito et al., 
2007; Morimoto et al., 2008; Kawahara et al., 2007; Porto et al., 2006). Therefore, agents 
capable of inhibiting HMGB1 can be considered to possess therapeutic potential. 
It was reported that an extract of Ume, an abundant source of triterpenoids, strongly 
inhibited HMGB1 release from lipopolysaccharide (LPS)-stimulated macrophage-like 
RAW264.7 cells (Kawahara et al., 2009). The inhibitory effect on HMGB1 release was 
enhanced by authentic oleanolic acid (OA), a naturally occurring triterpenoid. Similarly, the 
HMGB1 release inhibitor in Ume extract was found to be OA. Regarding the mechanisms of 
the inhibition of HMGB1 release, the OA or Ume extract was found to activate the 
transcription factor Nrf2, which binds to the antioxidative responsive element, and 
subsequently the heme oxygenase (HO)-1 protein was induced, indicating that the 
inhibition of HMGB1 release from LPS-stimulated RAW264.7 cells was mediated via the 
Nrf2/HO-1 system; an essentially antioxidant effect. These results suggested that natural 
sources of triterpenoids warrant further evaluation as ‘rescue’ therapeutics for sepsis and 
other potentially fatal systemic inflammatory disorders. 
5. Periodontal disease 
5.1 Symptoms 
Periodontal disease, which includes gingivitis and periodontitis, is the most common 
chronic disorder of infectious origin known in humans, with a prevalence of 10–60% in 
adults depending on the diagnostic criteria used (Papapanou, 1996). Periodontitis is a 
chronic inflammatory disease of which the primary etiological factor is microbial dental 
plaque which causes an inflammatory response (Loe et al., 1965). Periodontitis destroys the 
periodontal tissue and eventually causes loss of teeth . Chronic and progressive bacterial 
infection leads to gingival connective tissue destruction and irreversible alveolar bone 
resorption (Ranny, 1993). Periodontal disease has various states and stages, ranging from 
easily treatable gingivitis to irreversible severe periodontitis and is increased by several risk 
factors such as systemic disease, medications (hypotensors, anti-epilepsy drugs and anti-
cancer drugs), cigarette smoking, ill-fitting bridges, and trauma caused by occlusion 
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factor (TNF)- α, and C-reactive protein (Wang et al., 1999; Taniguchi et al., 2003; Kawahara 
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For diagnosing the extent of periodontal disease, probing depth is a good indicator of how 
far the disease has advanced (Greenstein, 1997). In clinically healthy periodontium, there is 
no apical migration of epithelial attachment or pocket formation and the probing depth is 1-
3 mm . Patients with probing depths of 4 mm or more are diagnosed with periodontitis. 
Patients with probing depths of 6 mm or more are diagnosed with advanced, or severe 
periodontitis. Due to mild nature of symptoms, such as gingival bleeding and attachment 
loss many individuals neglect to treat their disease which, if left untreated, may progress to 
irreversible periodontitis and eventually tooth loss. 
5.2 Pathogenesis of periodontal disease 
The presence of large numbers of oral bacteria can induce tissue destruction indirectly by 
activating host defense cells, which in turn, release mediators that stimulate the effectors of 
connective tissue destruction. The components of microbial plaques have the capacity to 
induce an initial infiltrate of inflammatory cells that includes lymphocytes, macrophages, 
and polymorphonuclear leukocytes (PMNs) (Kowashi et al., 1980; Zappa et al., 1991). 
Microbial components, especially LPS, activate macrophages, which synthesize and secrete 
a variety of proinflammatory mediators including IL-1, IL-6, IL-8, TNF-α, prostaglandin E2 
(PGE2) and hydrolytic enzymes (Birkedal-Hansen, 1993). Similarly, bacterial substances 
induce T lymphocytes to produce IL-1 and lymphotoxin (LT), a molecule with similar 
properties to TNF-α. These cytokines play a key role in periodontal tissue destruction 
through the induction of collagenolytic enzymes such as matrix metalloproteinases (MMPs) 
(Sorsa et al., 1992). These latent collagenolytic enzymes are activated by reactive oxygen 
species in the inflammatory environment, leading to elevated levels of interstitial 
collagenase in inflamed gingival tissue.  
5.3 Periodontal disease and systemic disease 
In the last decade, many studies have been published indicating a positive relationship 
between periodontal disease and various systemic diseases. Significant associations between 
periodontal disease and cardiovascular disease, diabetes mellitus, preterm low birth weight 
and osteoporosis have been reported (Jemin, & Salomon, 2006), bridging the once wide gap 
between medicine and dentistry. Researchers have hypothesized the etiologic role of 
periodontitis in the pathogenesis of these systemic diseases. Therefore, patients diagnosed 
with periodontal disease may be at a higher risk due to a compromised immune system as 
infectious and opportunistic microbes responsible for periodontal infection may prove a 
burden to the rest of the body. Furthermore, these microbes can release products that elicit an 
inflammatory response. Periodontal lesions are recognized as continually renewing reservoirs 
for the systemic spread of bacterial antigens, Gram-negative bacteria, cytokines and other 
proinflammatory mediators. Therefore,  development of new treatment modalities for 
periodontitis may contribute to the effective inhibition of systemic inflammatory diseases. 
5.4 Treatment of periodontal disease 
Once diagnosed, most periodontal diseases can be treated successfully. Therapeutic goals 
are to eliminate bacteria and other contributing risk factors, thereby preventing  progression 
of the disease and maintaining healthy state of  periodontal tissues. The recurrence of 
periodontitis must also be prevented. In severe cases, regeneration of the periodontal 
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attachment must be attempted. The nonsurgical step involves a special cleaning technique 
called scaling and root planing. Supplemental treatment tools may include an antiseptic 
mouth rinse and other medications, either to aid the healing process, to suppress 
inflammation, or to further control the bacterial infection. Often, antibiotics are 
administered. Tetracyclines, or a combination of amoxicillin and metronidazole, may be 
used to kill a broad range of bacteria in microbial dental plaque(Hayes et al., 1992; Van 
Winkelhoff et al., 1992). However, if overused, these agents may become uneffective. 
Another drawback to antibiotic therapy lies in the difficulty of identifying and targeting a 
specific pathogen due to the numerous species residing in the plaque.  
6. Possible new treatments for periodontitis 
6.1 Anti-inflammatory effects of an extract from Ume  
Natural compounds such as catechins in green tea, naringenin, a major flavanone, in 
grapefruits, and polyphenols in cranberries may be useful for the prevention and treatment of 
inflammatory periodontal diseases (Makimura et al., 1993; Bodet et al., 2008; Bodet et al., 2008). 
Consequently, natural compounds with the capacity to modulate host inflammatory responses 
have received considerable attention, with the suggestion that they may be potential new 
therapeutic agents for the treatment of periodontal disease (Paquette & Williams, 2000). Some 
studies indicate that MK615 extracted from Ume may have not only anti-cancer effects, but also 
strong anti-inflammatory effects. MK615 contains several triterpenoids, including oleanolic 
acid and ursolic acid, and may have anti-inflammatory effects. Recent studies have suggested 
that triterpenoids have both anti-tumor and anti-inflammatory effects (Nakagawa et al., 2007; 
Adachi et al., 2007; Okada et al., 2007; Okada et al., 2008; Kawahara et al., 2009). MK615 
inhibits the release of HMGB1, a novel inflammatory mediator, by LPS-stimulated RAW264.7 
cells (Kawahara et al., 2009). The inhibitory mechanism is mediated via the antioxidant 
compounds heme oxygenase-1, NQO-1 and glutathione-s transferase, which are induced by 
oleanolic acid. This strongly suggests that MK615 may suppress inflammation. 
In the periodontal field, MK615 inhibits cytokine release, including that of TNF-α and IL-6, 
by P. gingivalis LPS-stimulated cells in dose-dependent manners (Morimoto et al., 2009). It is 
clearly indicating that MK615 contains an inhibitor of cytokine release. The continuous high 
secretion of various cytokines including TNF-α and IL-6 by host cells following stimulation 
with periodontal pathogens and their products is a critical determinant of periodontal tissue 
destruction. Therefore, blockade of TNF-α and IL-6 secreted by periodontal pathogens or 
other cytokines may suppress pro-inflammatory responses, and inhibit the development 
and progression of periodontal disease. It has been reported that LPS possibly induces TNF-
α and IL-6 expressions through transient phosphorylation of ERK1/2, JNK, and p38MAPK 
(Matsuzaki et al., 2004; Kim et al., 2007; Son et al., 2008; Neuder et al., 2009; Xiao et al., 2007). 
Additionally, it has been also reported that the production of inflammatory cytokines 
requires nuclear factor kappaB (NF-κB) activation (D’Acquisto et al., 1997). The inhibitory 
mechanism of MK615 is mediated by the attenuation of MAPK phosphorylation (Figure 2) 
and subsequent inactivation of NF-κB to suppress LPS-induced translocation and 
phosphorylation of the p65 subunit (Figure 3 &4). These results support the notion that 
MK615 has anti-inflammatory effects, and MK615 may represent a key molecule with 
therapeutic potential for periodontitis. Therapeutic approaches that inhibit cytokine 
production are receiving increasing attention as options for managing chronic periodontitis.  
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Fig. 2. MK615 inhibits phosphorylation of MAPKs. 
 
Fig. 3. MK615 suppresses NF-κB activation but not degradation of IκB. 
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Fig. 4. MK615 suppresses P. gingivalis LPS-induced nuclear translocation of NF-κB p65 in 
RAW264.7 cells. Cells were left untreated or pretreated with MK615 and stimulated with 
LPS. (A) In untreated cells, NF-κB p65 is limited to the cytoplasm. (B) LPS-stimulated cells 
show NF-κB p65 (green) translocation into the nucleus. (C) LPS-stimulated cells pretreated 
with MK615 show a significant reduction in p65 nuclear translocation. (D) Cells treated with 
MK615 alone show no effect. Cells stained with DAPI were used to verify the nuclear 
localization (blue). Original magnification: ×400. 
6.2 Anti-microbial effects of an extract from Ume  
Periodontitis and dental caries are major oral diseases. The formation of dental plaque, 
which plays an important role in the development of periodontal disease and caries in 
humans, can be initiated by several strains of oral streptococci (Freedman & Tanzer, 1974; 
Tanzer et al., 1974). Streptococcus mutans is the main pathogen for dental caries, although 
other acidogenic microorganisms can also be involved (Murata, 2008). S. mutans produces 
three types of glucosyltransferase (GTFB, GTFC and GTFD), and synthesizes an adherent 
and water-insoluble glucan from sucrose that allows adherence of S. mutans to the tooth 
surface and dental plaque formation (Edwardsson, 1968; Hamilton-Miller, 2001). 
There is great interest in the use of antimicrobial agents for the prevention and treatment of 
periodontitis and caries. The prevention of periodontal disease and dental caries requires 
control of the pathogens that exist in the oral dental plaque biofilm. Chlorhexidine is a 
potent antiplaque chemical agent. However, it has some side effects, such as altered taste 
sensation, desquamation and soreness of the oral mucosa (Makimura et al., 1993). Thus, it is 
important to develop alternative antiplaque agents from natural sources that have no side 
effects. 
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It is reported that MK615 has not only anti-inflammatory effects for periodontal tissues but 
also antimicrobial activity against periodontal bacteria, such as A. actinomycetemcomitans and 
P. gingivalis (Table 1). In addition, MK615 exerted antibacterial activity against cariogenic 
bacteria, such as S. mutans, S. gordonii and S. sanguinis, with an expected anti-caries effect 
(Table 1). Moreover, it was found that MK615 exhibited an inhibitory effect on S. mutans 
biofilm formation. The most effective treatment against dental caries and periodontitis 
would be one that prevents early biofilm formation (Wei et al., 2006). MK615 is known to 
contain active components with anti-inflammatory and anti-oxidative properties, such as 
oleanolic acid (Kawahara et al., 2009). A previous study suggested that oleanolic acid has 
antimicrobial actions against S. mutans (Kozai et al., 1999), while another study showed that 
oleanolic acid markedly inhibits water-insoluble glucan synthesis from sucrose by the crude 
glucosyltransferase of S. mutans (Kozai et al., 1987). Therefore, MK615 has potential as a 
therapeutic agent for treating and preventing oral diseases such as periodontitis and dental 
caries. Further studies will focus on the active antimicrobial components in MK615, which 
should be identified and investigated for their mechanisms of action. Additionally, further 
studies are required to investigate the effects of local application of MK615 as an adjunctive 
treatment to conventional therapy for patients with periodontitis. Such studies may lead to 
the development of novel periodontal therapies and improved strategies for public oral 
health. 
 
MICs of MK615 against oral 
microorganisms.  
   
Species (mg/ml)  
A. actinomycetemcomitans 57 6.5  
A. actinomycetemcomitans IDH 6.5  
P. gingivalis 1.6  
S. mutans UA159 13  
S. mutans MT403R 13  
S. mutans RIMD 13  
S. gordonii 13  
S. salivarius (-)  
S. sanguinis 13  
Table 1. 
7. Conclusion  
With the growing recognition of their benefits for public health in recent years, natural 
foods are now being highlighted with special reference to their effects on human health in 
addition to their pharmacological actions. Japanese Ume has been used as a herbal medicine 
with several biological activities, including anticancer, antioxidant and anti-inflammation 
effects (Nakagawa et al., 2007; Adachi et al., 2007; Okada et al., 2007; Mori et al.,2007; 
Kawahara et al., 2009). 
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MK615, an extract of compounds from Japanese Ume, has not only anti-inflammatory effects 
for periodontal tissues but also antimicrobial activity against periodontal bacteria, such as A. 
actinomycetemcomitans and P. gingivalis. In addition, MK615 exerted antibacterial activity 
against cariogenic bacteria, such as S. mutans, S. gordonii and S. sanguinis, with an expected 
anti-caries effect. Moreover, it was found that MK615 exhibited an inhibitory effect on S. 
mutans biofilm formation. MK615 has potential as a therapeutic agent for treating and 
preventing oral diseases such as periodontitis and dental caries. Further studies will focus 
on the active anti-inflammatory and antimicrobial components in MK615, which should be 
identified and investigated for their mechanisms. 
MK615 is safe in food for providing health benefits, and this remains unquestioned even 
when it is prescribed for oral therapy. Moreover, it is also used as a treatment for patients 
with liver cancer. In the future, it may be added to toothpastes, mouth rinses and other oral 
products that can be used easily by the majority of the populationranging from youngsters 
to the elderly. In addition, MK615 may be applicable to the total body through examining its 
possible effects on not only oral bacteria but also Staphylococcus aureus and Candida albicans. 
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biofilm formation. The most effective treatment against dental caries and periodontitis 
would be one that prevents early biofilm formation (Wei et al., 2006). MK615 is known to 
contain active components with anti-inflammatory and anti-oxidative properties, such as 
oleanolic acid (Kawahara et al., 2009). A previous study suggested that oleanolic acid has 
antimicrobial actions against S. mutans (Kozai et al., 1999), while another study showed that 
oleanolic acid markedly inhibits water-insoluble glucan synthesis from sucrose by the crude 
glucosyltransferase of S. mutans (Kozai et al., 1987). Therefore, MK615 has potential as a 
therapeutic agent for treating and preventing oral diseases such as periodontitis and dental 
caries. Further studies will focus on the active antimicrobial components in MK615, which 
should be identified and investigated for their mechanisms of action. Additionally, further 
studies are required to investigate the effects of local application of MK615 as an adjunctive 
treatment to conventional therapy for patients with periodontitis. Such studies may lead to 
the development of novel periodontal therapies and improved strategies for public oral 
health. 
 
MICs of MK615 against oral 
microorganisms.  
   
Species (mg/ml)  
A. actinomycetemcomitans 57 6.5  
A. actinomycetemcomitans IDH 6.5  
P. gingivalis 1.6  
S. mutans UA159 13  
S. mutans MT403R 13  
S. mutans RIMD 13  
S. gordonii 13  
S. salivarius (-)  
S. sanguinis 13  
Table 1. 
7. Conclusion  
With the growing recognition of their benefits for public health in recent years, natural 
foods are now being highlighted with special reference to their effects on human health in 
addition to their pharmacological actions. Japanese Ume has been used as a herbal medicine 
with several biological activities, including anticancer, antioxidant and anti-inflammation 
effects (Nakagawa et al., 2007; Adachi et al., 2007; Okada et al., 2007; Mori et al.,2007; 
Kawahara et al., 2009). 
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MK615, an extract of compounds from Japanese Ume, has not only anti-inflammatory effects 
for periodontal tissues but also antimicrobial activity against periodontal bacteria, such as A. 
actinomycetemcomitans and P. gingivalis. In addition, MK615 exerted antibacterial activity 
against cariogenic bacteria, such as S. mutans, S. gordonii and S. sanguinis, with an expected 
anti-caries effect. Moreover, it was found that MK615 exhibited an inhibitory effect on S. 
mutans biofilm formation. MK615 has potential as a therapeutic agent for treating and 
preventing oral diseases such as periodontitis and dental caries. Further studies will focus 
on the active anti-inflammatory and antimicrobial components in MK615, which should be 
identified and investigated for their mechanisms. 
MK615 is safe in food for providing health benefits, and this remains unquestioned even 
when it is prescribed for oral therapy. Moreover, it is also used as a treatment for patients 
with liver cancer. In the future, it may be added to toothpastes, mouth rinses and other oral 
products that can be used easily by the majority of the populationranging from youngsters 
to the elderly. In addition, MK615 may be applicable to the total body through examining its 
possible effects on not only oral bacteria but also Staphylococcus aureus and Candida albicans. 
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features that warrant its examination in this context. First, this theory has strong 
relationships with numerous health behavioural theories. Second, it has been demonstrated 
within a theoretical framework that enhancing self-efficacy leads to behaviour modification. 
Last, due to the simplicity of the self-efficacy theory, it can easily be applied in the daily 
clinical setting. 
2. Self-efficacy theory   
Bandura (1977) observed that the actions of individuals are associated with both outcome 
and efficacy expectations. The former is outcome expectancy related to achieving a desirable 
outcome by taking an action, whereas the latter is related to the confidence an individual 
has for performing an action necessary to produce the desired outcome and is termed self-
efficacy (Bandura, 1977, 1997; Kakudate et al., 2010a). The existence of both types of 
expectations is needed for an individual to act (Figure 1). Thus, self-efficacy is an important 
factor for predicting individual action and controlling subsequent emotional responses.  
Self-efficacy relates to the belief in one’s general confidence to accomplish the actions 
necessary to reach a goal. When applied to the clinical setting, self-efficacy refers to a 
patient’s perception of his or her ability to perform the actions needed to improve and 
maintain their health. Two levels of self-efficacy have been described: general self-efficacy, 
which reflects an individual’s general and stable tendencies, and task-specific self-efficacy, 
which are beliefs related to a certain task (Sherer et al., 1982; Woodruff and Cashman, 1993; 
Stanley and Murphy, 1997).  
 
 
Fig. 1. Relationship between self-efficacy and outcome expectations  
Self-efficacy is the belief in the capacity to perform a specific behaviour, whereas outcome 
expectations are the beliefs that carrying out a specific behaviour will lead to a desired 
outcome. 
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3. Self-efficacy in the clinical practice 
In the clinical practice, the enhancement of self-efficacy has been shown to improve 
symptoms of chronic disease, such as diabetes, indicating that self-efficacy represents an 
antecedent to behaviour modification (Smarr et al., 1997; Wattana et al., 2007). For 
example, Smarr et al. (1997) examined the relationship between induced changes in self-
efficacy following a stress management programme and outcome measures of depression, 
pain, health status, and disease status in rheumatoid arthritis patients, and found a 
significant association between self-efficacy modification and the clinically relevant 
outcome measures.  
In the dental field, the relationship between self-efficacy and oral hygiene behaviour, such 
as toothbrushing or flossing, has been examined in several studies (McCaul et al., 1985; 
Tedesco et al., 1991, 1992; Stewart et al., 1997; Syrjälä et al., 1999, 2004). McCaul et al. (1985) 
analysed self-efficacy among college students with respect to brushing and flossing to 
predict task-related behaviours, and found that the retrospectively self-reported and 
prospective frequency of the two examined oral care factors were significantly associated 
with self-efficacy. Subsequently, Tedesco et al. (1991) reported that the addition of self-
efficacy variables to the theory of reasoned action variables markedly increased the 
observed variance in brushing and flossing behaviours. Furthermore, it was demonstrated 
that cognitive behavioural intervention resulted in a delayed relapse in protective oral self-
care behaviour and improved self-efficacy towards flossing (Tedesco et al., 1991). These 
researchers further analysed the associations between oral health behaviour and self-efficacy 
and the TRA, and found that linking the variables of the two theories significantly increased 
the variance in the brushing and flossing behaviours (Tedesco et al., 1992). Syrjälä et al. 
(2004) performed a comparative analysis to examine the relationships of psychological 
characteristics related to health behaviours, including intention, self-efficacy, locus of 
control, and self-esteem, and oral health-care habits, diabetes treatment adherence, number 
of dental caries and deepened periodontal pockets, and HbA1c (glycosylated haemoglobin) 
levels. Based on this analysis, only self-efficacy was found to be associated with both oral 
health-care habits and diabetes adherence.  
Several cross-sectional studies have also examined self-efficacy and oral hygiene behaviour. 
For example, Stewart et al. (1997) measured self-efficacy with respect to toothbrushing and 
flossing using questionnaires, and demonstrated that self-efficacy scale scores are 
significantly associated with the frequency of brushing, flossing frequency, and dental visits, 
in addition to general dental knowledge. Notably, however, clinical periodontal parameters 
were not surveyed, nor is it clear whether the study participants suffered from periodontal 
disease. Syrjälä et al. (1999) conducted a cross-sectional survey for 149 insulin-dependent 
diabetic patients using a self-efficacy scale, which consisted of items related to the self-
efficacies of toothbrushing, approximal tooth cleaning, and dental visits, and examined the 
associations of self-efficacy with oral health behaviour and dental plaque levels. The results 
of their analyses showed that the scores for all three examined items in the self-efficacy scale 
were related to self-reported oral health behaviours, and that visible plaque index values 
inversely correlated with the self-efficacies of toothbrushing and dental visits. However, 
again, it is unclear whether the study participants, who consisted of only diabetic patients, 
had periodontal disease.  
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4. Development of a self-efficacy scale for self-care (SESS) for  patients with 
chronic periodontitis   
In the context of periodontal disease, the efficacy of regular professional and patient self-
care has been examined in detail (Kressin et al., 2003; Axelsson et al., 2004; Douglass, 2006). 
The adherence of periodontal disease patients to health-promoting behaviour is considered 
critical for the prevention and successful treatment of periodontal disease. In an effort to 
improve oral health-care behaviour, we previously conducted a cross-sectional study 
consisting of a questionnaire and a clinical assessment to develope a task-specific SESS for 
periodontal disease patients (Kakudate et al., 2007, 2008). The subjects of the study were 140 
patients (64 females and 76 males, 19 to 86 years of age, mean age 51.7 ± 15.7) with mild to 
moderate chronic periodontitis.  
The SESS consists of 15 items that are divided into three sub-scales: (i) self-efficacy for 
dentist consultations (SE-DC; five items), which relates to treatment adherence and regular 
dental check-ups (e.g., “I go to the dentist for treatment of periodontal disease”); (ii) self-
efficacy for brushing of the teeth (SE-B; five items), which concerns the careful and thorough 
brushing of teeth (e.g., “I brush my teeth as instructed”); and (iii) self-efficacy for dietary 
habits (SE-DH; five items), which relates to adopting well-balanced eating and drinking 
habits (e.g., “I eat my meals at fixed times during the day”). All answers are scored using a 
five-point Likert scale (Tarini et al., 2007) ranging from 1 (not confident) to 5 (completely 
confident), and the scores for all 15 items are then summed to give total SESS scores ranging 
from 15 to 75 for each participant.  
The reliability of the SESS was preliminarily verified using conventional methods (Carmines 
and Zeller, 1980; Syrjälä et al., 1999; Resnick et al., 2000; Travess et al., 2004; Champion et al., 
2005; George et al., 2007; Rossen and Gruber, 2007) for both internal consistency (Cronbach’s 
alpha = 0.86) and test-retest stability (Spearman’s rank correlation coefficient = 0.73;  
P < 0.001). Based on Spearman’s rank correlation coefficient analysis, the test-retest stability 
scores of the SE-DC, SE-B, and SE-DH components of the SESS were 0.57 (P < 0.01), 0.39  
(P < 0.05), and 0.53 (P < 0.01), respectively. Construct validity of the scale was also 
demonstrated in a cross-sectional study that found periodontal patients with successful 
maintenance therapy had significantly higher SESS scores (mean value, 60.90 ± 6.64; n = 60) 
than those of initial-visit patients who had not received periodontal treatment (mean value, 
56.86 ± 7.56; n = 129) (P < 0.001).  
5. Predicting loss to follow-up in long-term periodontal treatment using the 
SESS  
As described in Section 3, self-efficacy can be divided into general and task-specific self-
efficacy. To compare these two types of efficacy with respect to oral care behaviour, we 
examined whether our developed SESS and a general self-efficacy scale (GSES) (Sakano and 
Tohjoh, 1986) could predict short-term compliance (within one year) for active periodontal 
treatment (Kakudate et al., 2008). The results of our pilot study revealed that only the SESS, 
particularly the SE-DC subscale, accurately predicted loss to follow-up from active 
periodontal treatment (Kakudate et al., 2008). As the continued maintenance of periodontal 
health care is considered critical for preventing relapse after active periodontal treatment, 
we further evaluated the hypothesis that SESS can predict loss to long-term follow-up 
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during periodontal treatment by performing a 30-month longitudinal prospective cohort 
study for patients with mild to moderate chronic periodontitis. In our study, the odds ratios 
of the loss to follow-up for the middle- (54–59) and low-scoring (15–53) SESS groups were 
1.05 (95% confidence interval: 0.36–3.07) and 4.56 (95% confidence interval: 1.11–18.74), 
respectively, compared to the high-scoring group (60-75) (Kakudate et al., 2010b). We 
therefore concluded that the assessment of self-efficacy specific to oral health care may allow 
prediction of loss to follow-up in long-term periodontal treatment. In addition, enhancing 
self-efficacy through psychoeducational intervention may reduce the number of patients lost 
to follow-up.  
6. The four principal self-efficacy information sources 
Self-efficacy beliefs are constructed from four principal sources of information: enactive 
mastery experience, vicarious experience, verbal persuasion, and physiological and affective 
states (Bandura, 1977, 1978, 1997). The first information source, enactive mastery experience, 
relates to an individual’s accomplishments, with previous successes increasing expectations 
of mastery in subsequent tasks and repeated failures serving to lower them. The second 
source, vicarious experience, is obtained through the learning associated with observing a 
task or activity being successfully performed by others, and is often referred to as 
modelling. The third element, verbal persuasion, refers to the use of suggestive language to 
convince an individual that he or she can successfully perform a specific task. Common 
forms of verbal persuasion include coaching and evaluative feedback for performance, and 
help to support (persuade) an individual’s belief that he or she possesses a certain 
capability. The fourth element, physiological and affective states, represents the 
physiological and emotional states, respectively, which influence an individual’s assessment 
of self-efficacy. Through the effective exploitation of these four sources of information, it is 
therefore possible to enhance self-efficacy, which may have significant impacts with respect 
to oral health care in the field of dentistry. For example, Syrjälä et al. (2001) reported 
qualitative evidence that the sources of self-efficacy proposed by Bandura (1977), namely 
personal experience, emotional arousal, and modelling, are also supported in the context of 
oral health behaviour.  
7. Enhancement of self-efficacy for self-care through six step method  
The six-step method is a systematic approach that was designed to facilitate lifestyle 
changes in patients including principal self-efficacy information sources (Farquhar, 1987; 
Albright and Farquhar, 1992) and consists of the following six steps: (i) problem 
identification; (ii) instilling confidence and commitment; (iii) increasing behavioural 
awareness; (iv) developing and implementing an action plan; (v) plan evaluation; and (vi) 
maintaining the behavioural change and preventing relapse. Six-step method has been 
applied to periodontal dental practice as following steps (Kakudate et al., 2009). 
Step 1. Identifying the problem 
Knowledge, belief, and the barrier to periodontal self-care were clarified by person-to-
person interviews. This information was obtained by asking the patient the following 
questions: 
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of self-efficacy. Through the effective exploitation of these four sources of information, it is 
therefore possible to enhance self-efficacy, which may have significant impacts with respect 
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Step 1. Identifying the problem 
Knowledge, belief, and the barrier to periodontal self-care were clarified by person-to-
person interviews. This information was obtained by asking the patient the following 
questions: 
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1. What do you do about self-care?  
a. How many times and how long do you brush?  
b. How many times do you perform inter-dental cleaning per week? 
c. When do you brush?  
2. What do you know about self-care?  
3. Have you tried to change your behavior in the past?  
4. What inhibits the change in your belief? or What are your major barriers to change?  
The patients are clearly told what the problems are, and the patients are told that their 
behaviors are harmful to their health and that modification of this behavior must be made.  
Step 2. Creating confidence and commitment 
There are many patients who have the conviction that changing their self-care behavior is 
not possible. Step 2 involves establishing commitment and confidence by conducting the 
clinical interview to incorporate counseling that assesses the patient’s barrier to change 
his/her behavior. A story of a person who seems to be a model in a similar situation was 
introduced to raise the patient become aware of his/her assumption. In order to confirm 
intention and to promote motivation, the patient and the dentist signed a contract to begin 
working on a particular behavior change after face-to-face counseling.  
Step 3. Increasing awareness of behavior 
This step leads to increase in the patient’s awareness of his or her behavior patterns through 
self-monitoring. The patients were asked to keep a diary of brushing and inter-dental 
cleaning every day until the next consultation and to describe their feelings at that time of 
brushing. The diary is used to determine the internal and external precursors to the 
behavior that often act as behavioral cues. The diary also helps to identify barriers to 
behavioral change in oral self-care. 
Step 4. Developing and implementing the action plan  
Based on the patient’s behavior, description in the diary of oral hygiene measures, and oral 
hygiene states, a short-term action plan is set up by the principle of gradualism. The action 
plan was concrete, realistic, and achievable. For instance, the action plan includes ‘‘Brush 
twice a day’’, ‘‘Brush for more than three minutes’’, and ‘‘Use dental floss once a day at 
night’’ Then an incentive that a patient gives himself/herself when succeeding was decided. 
Small incentives such as beauty treatment, going to the movie, and shopping are selected. In 
the setting of the goal and the incentive, the dentist only supported the decision by the 
patient.  
Step 5. Evaluating the plan  
Whether or not the patient achieved the action plan is evaluated. Success is acknowledged 
and supported. When the plan succeeded, the success experience is acknowledged, and the 
subject is praised. If the patient fail, this is attributed to a failure of the plan, and a new plan 
that can be achieved is set up.  
Step 6. Maintaining change and preventing relapse 
Each patient has high-risk situations that might result in relapse. Unexpected long working 
hours, social events such as parties, and alcohol consumption often make it difficult to 
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maintain newly acquired behaviors. Therefore, it is important for dentists and dental 
hygienists to help and encourage the patient to safeguard and reinforce the new behaviors. 
As in Step 4, incentives might be effective. Incentives can apply to a particular longer period 
of maintenance. 
8. Evidence of behavioural approaches for self-care  
According to a systematic review by the Cochrane Collaboration, several studies have 
suggested that psychological approaches to behavioral management can improve 
behaviours related to oral hygiene (Renz et al., 2007). This finding supports the use of 
psychological models in studies aimed at establishing intervention approaches for 
modifying oral health-related behaviour. In the review, four studies that applied 
psychological models were selected based on the Cochrane Oral Health Group methods 
(Renz et al., 2007). However, the reviewers concluded that overall quality of the included 
trials was low, thus limiting the conclusions that could be drawn, and in addition, the 
applied intervention was weakly designed and lacked key aspects of the major behavioural 
theories.  
Since 2007, two randomized controlled trials (RCTs) have been conducted to evaluate 
intervention based on key aspects of the self-efficacy theory. Clarkson et al. (2009) 
conducted a RCT that was randomized by either patient (Patient) or dentist (Cluster) and 
included 87 dental practices and 778 adult patients (Patient RCT = 37 dentists  300 patients; 
Cluster RCT = 50 dentists  478 patients). The study patients were subjected to evidence-
based intervention that targeted oral hygiene self-efficacy and action plans. After 
adjustment for baseline differences, patients who received the intervention exhibited 
improved behavioural (timing, duration, and method), cognitive (self-efficacy and 
planning), and clinical (plaque and gingival bleeding) outcomes. However, on comparison 
of the Patient and Cluster RCTs, the clinical outcomes were only significantly improved in 
the latter, suggesting that the trial design may have influenced the results. 
In the second RCT, our group compared the efficacy of a six-step method to enhance self-
efficacy with that of conventional oral hygiene instruction (Kakudate et al., 2009; Morita et 
al., 2010). Our RCT consisted of 38 patients with mild to moderate chronic periodontitis 
(Control group : Intervention group = 20 : 18) who were receiving periodontal treatment at a 
private dental clinic located in Sapporo, Japan. In both study groups, all examined variables, 
including Plaque Control Record (PCR) scores (O’Leary et al., 1972), tooth brushing 
duration, weekly frequency of interdental cleaning, and self-efficacy scores, significantly 
improved from the initial to the third clinic visit. Notably, we found that the intervention 
group, who received oral hygiene instruction using the six-step method, displayed higher 
self-efficacy than the control group, who were only provided with conventional oral hygiene 
instructions. In addition, PCR scores, toothbrushing duration, and weekly frequency of 
interdental cleaning also improved in the intervention group as compared with the control 
group.  
In the two RCTs presented here, the enhancement of self-efficacy and ability to promote 
behavioural change through behavioural intervention was clearly observed; however, the 
methodology of intervention has yet to be fully established. Thus, further studies are needed 
to evaluate the suitability of these intervention methods with respect to oral health care in 
the clinical setting. 
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methodology of intervention has yet to be fully established. Thus, further studies are needed 
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9. Conclusion  
The assessment of self-efficacy towards oral health care is effective for the prediction of oral 
self-care behaviour in periodontal treatment. Therefore, by addressing low self-efficacy early 
and providing patient support to enhance self-efficacy in the clinical setting, loss to long-
term follow-up during periodontal treatment can be minimized. Although behavioural 
approaches may enhance the self-efficacy for self-care habits and result in improved oral 
hygiene status, further research to evaluate the suitability of the specific intervention 
methodology is required. In addition, it is also important to determine whether applying 
methods developed based on past research results might provide any disadvantages to 
periodontal patients. 
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(Edwards et al., 1987; Page, 1991) and inhibition of the release of procollagenase. Moreover, 
it increases the synthesis of extracellular matrix molecules by stimulating numerous cell 
types including fibroblasts and osteoblasts (Chen et al., 1987; Hakkinen et al., 1996; Matsuda 
et al., 1992). Expression and production of this growth factor both at periodontally healthy 
and diseased sites suggest that it contributes to maintenance of tissue integrity (Buduneli et 
al., 2001; Kuru et al., 2004a; Kuru et al., 2004b; Steinsvoll et al., 1999; Wright et al., 2003). 
Thus, these properties of TGF-β1 show its important role in the pathogenesis of periodontal 
disease and wound healing. 
Since β-glucan affects immune function with quickened macrophage activation and 
establishment of T helper 1 dominance, the tissue destruction seen in periodontal disease 
may be inhibited by the usage of this immunomodulating agent.  Chaple et al. (1998) have 
reported that there was a failure of the recruitment and activation of macrophages in the 
gingival samples obtained from untreated advanced periodontitis patients, compared with 
those of patients with gingivitis. Thus, the ability of β-glucan to stimulate macrophages 
seems to be very crucial. Breivik et al. (2005) evaluated the effect of β-1,3/1,6 glucan on the 
progression of ligature-induced periodontal disease in animals. Their findings showed that 
orally administrated β-glucan significantly reduced periodontal bone loss as measured on 
digital x-rays.  Stashenko et al. (1995) tested the effect of this biological response modifier on 
infection-stimulated alveolar bone resorption in an in vivo model.  Their findings supported 
the concept that β-glucan can decrease hard and soft tissue destruction in animals. Although 
β-glucan has been suggested to enhance endogenous antibacterial mechanisms in 
neutrophils and to increase the healing potential of damaged tissues (Bedirli et al., 2003; 
Browder et al., 1988, Browder et al., 1990, Stashenko et al., 1995), so far, its effect on 
periodontal tissue healing as an adjunct to nonsurgical periodontal therapy (NPT) has never 
been investigated in humans. 
The aim of this chapter is to present the results of a controlled study investigating the effects 
of NPT with an adjunctive use of systemic β-glucan on clinical, microbiological parameters 
and gingival crevicular fluid (GCF) TGF-β1 levels in chronic periodontitis patients over a 3-
month period. 
2. Materials and methods 
2.1 Study population 
Twenty subjects between 30-56 years of age were selected among chronic periodontitis 
patients who applied to the clinics of Department of Periodontology, Dental Faculty, 
Marmara University, Istanbul, Turkey. Medical and dental histories were obtained and 
intraoral examinations were carried out at pre-screening visit. Patients were diagnosed to 
have chronic periodontitis according to the clinical and radiographic findings (Armitage 
1999). Inclusion criteria were as follows: to be systemically healthy, have at least two sites 
with a probing depth ≥ 5 mm in each quadrant and radiographic evidence of moderate to 
advanced chronic periodontitis. None of the patients had received antibiotics or periodontal 
treatment within the 6 months preceeding the study. Women who were pregnant, breast-
feeding or using oral contraceptives were excluded. In addition, 10 systemically and 
periodontally healthy subjects were selected as the healthy control group. None of these 
subjects had bleeding on probing or a history of medication in the past 6 months. All 
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patients were non-smokers. The protocol of the study was approved by the Ethics Commitee 
of Marmara University (Number: B.30.2.MAR.0.01.00.02/AEK-232). Patients who fulfilled 
the inclusion criteria provided written informed consent and participated in the study. 
2.2 Study design 
This study was a randomized, controlled, parallel group clinical trial of 3-month duration. 
With the purpose of evaluating the adjunctive effect of β-glucan, 20 chronic periodontitis 
patients were randomly divided into 2 groups: group 1 (n=10) received NPT only, group 2 
received NPT and adjunctive β-glucan (n=10). A total of two sessions of NPT were applied 
to all patients and group 2 patients used systemic β-glucan (10 mg, 1x1) for 40 days (Fig. 1).  
 
 
SRP=scaling and root planing 
GCF= gingival crevicular fluid 
Fig. 1. Study design. 
As shown in Fig. 1, this study was consisted of four main stages including pre-screening, 
screening, baseline (Day 0) and re-evaluation (3 month - day 91). Screening examination was 
conducted to assess the patient’s eligibility for participation. The periodontal status of each 
patient was assessed by a single blinded examiner (N.N.A.). The periodontal clinical 
measurements included gingival index (Löe & Sillness, 1963), plaque index (Sillness & Löe, 
1964) and bleeding on probing. Additionally, probing depth and relative attachment level 
were measured to the nearest mm with a periodontal probe using an individual occlusal 
stent as a reference point for probe placement.  Sampling was performed from sites with a 
probing depth ≥ 5 mm and subgingival microbiological and GCF samples were collected 
from different periodontal sites.  
Patients who were eligible for the study, returned to our clinic at baseline visit for sampling 
and application of NPT. At baseline, oral hygiene instructions including brushing and 
flossing were given. Then, full mouth scaling and root planing (SRP) was performed in all 
patients using an ultrasonic scaler (Cavitron® EMZ, Switzerland) and Gracey curettes (Hu-
Friedy Ins. Co, USA) until smooth root surfaces were achieved. The group 2 patients were 
further instructed to take one capsule of β-glucan (10 mg, 1x1) in the morning for 40 days. 
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At day 7, full mouth SRP was applied again in all patients. GCF samples were obtained at 
day 14. Clinical measurements and sampling procedures were repeated at 3-month re-
evaluation stage. 
2.3 Collection of GCF samples 
GCF samples were obtained at days 0 and 14, and 3 months after therapy. Two GCF samples 
from each chronic periodontitis patient were collected from mesio- and disto-buccal aspects 
of single rooted teeth exhibiting probing depth ≥ 5 mm. In the healthy control group, two 
GCF samples were collected from mesio- or disto-buccal aspect of single rooted matching 
teeth exhibiting probing depth ≤ 3 mm without any clinical sign of gingival inflammation 
and alveolar bone loss. 
Prior to GCF sampling, the selected sites were isolated with cotton rolls, saliva was removed 
using a high-power suction tip and supragingival plaque was removed using a periodontal 
probe to prevent saliva and/or plaque contamination (Griffiths et al., 1992). Paper strips 
(Periopaper; ProFlow, Inc., Amityville, NY, USA) were placed at the entrance of the crevice 
until mild resistance was felt and left in position for 30 seconds (Lamster et al., 1985). Strips 
contaminated with blood or saliva were discarded. The volumes of GCF collected were 
measured by weighing the papers, before and after sample collection, using a micro balance 
(AND 200-HM, Japan) (Kuru et al., 2004b). The weight of the fluid was converted to volume 
by assuming that the density of GCF was 1.0 (Cimasoni & Giannopoulou, 1988). The GCF 
samples were stored at -80°C until the day of laboratory analysis.  
2.4 TGF-β1 analysis in GCF 
The paper strips were allowed to thaw at room temperature for 30 minutes. GCF samples 
were eluted from the strips by placing them in 100 µl of phosphate-buffered saline (PBS) and 
stored at 4°C for up to 24 h prior to the laboratory procedures (Kuru et al., 2004a). 
GCF TGF-β1 levels were analysed by enzyme linked immunosorbent assay, using a 
commercially available Colorimetric Sandwich enzyme linked immunosorbent assay Kit 
(Quantikine DB100, R&D Systems, Minneapolis, MN, USA). In order to measure biological 
active TGF-β1, GCF samples were acidified using 20 µl 1 N HCL at room temperature for 10 
minutes. Then, the samples were neutralized by adding 20 µl 1.2 NaOH/0.5 M HEPES. The 
activated GCF samples were further analysed as described previously (Kuru et al., 2004a). 
Briefly, an aliquot of 200 μl of known concentrations (0, 31.2, 62.5, 125, 250, 500, 1000 and 
2000 pg/ml) of the activated recombinant human TGF-β1 standard and of the activated 
samples of GCF were added to the plate, which had been pre-coated with a recombinant 
human soluble receptor II which specifically binds human TGF-β1. The plate was covered 
with an adhesive strip and incubated at room temperature for 3 hours. Each well was 
aspirated and washed 3 times with 400 μl of the wash buffer provided, after which 200 μl of 
the detecting antibody (horseradish peroxidase-conjugated polyclonal antibody against 
TGF-β1) was added. The plate was again covered with an adhesive strip and incubated at 
room temperature for 1.5 hour. After washing 3 times, 200 μl of the substrate solution 
(tetramethylbenzidine containing H2O2) was added to each well and incubated at room 
temperature for 20 minutes. Following the addition of 50 μl of 2 M H2SO4 to stop the 
reaction, the absorbance at 450 nm was measured using a spectrophotometer. The 
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absorbance was also measured at 570 nm to determine any optical imperfections between 
the wells, and this value was subtracted from the absorbance at 450. A standard curve was 
prepared for each experiment and concentrations of TGF-β1 in samples were then calculated 
from this curve. The minimum detection limit of the assay kit was 4.61 pg/ml.   
2.5 Subgingival microbiological sampling 
Subgingival microbiological samples were collected at baseline and 3 months after therapy. 
The mesio- or disto-buccal site of a single-rooted tooth in the upper right quadrant 
exhibiting probing depth ≥ 5 mm was selected as the microbiological sampling site. 
Supragingival plaque was removed from the sampling site with a sterile curette followed by 
isolation using a cotton roll.  Subgingival plaque sample was collected with a standardized 
30# sterile paper point by inserting it into the crevice, and leaving in place for 10 seconds. 
Paper points contaminated with saliva or blood were discarded.  
2.6 Microbiological analysis 
The proportion of anaerobic microorganisms in the total flora was determined by 
microbiological culture method as described previously (Kuru et al., 1999; Noyan et al., 
1997; Yilmaz et al., 2002). Immediately after obtaining subgingival plaque, each sample was 
aseptically transferred into 4.5 ml of PBS and dispersed using a vortex mixer at maximal 
setting for 60 s. The dispersed samples were serially diluted and 0.2 ml portion of 10-1,  
10-2,….10-5 dilutions were spread on a solid agar medium using sterile bent glass rods. 
Trypticase soy agar plate (Oxoid, Oxoid Ltd., England) enriched with 0.0005 % hemin 
(Sigma, Sigma Chemical Co., USA), 0.00005 % menadione (Sigma), and 5 % defibrinated 
sheep blood, was inoculated for non-selective bacterial growth (Wolff et al., 1985). 
Furthermore, trypticase soy agar plate enriched with 5 % defibrinated sheep blood was used 
for cultivation for facultative anaerobic microorganisms.  
After 7 days of incubation of the supplemented trypticase soy agar plates in Gas Pak jars 
(Gas generating kit, Oxoid) in an atmosphere of 95 % H2 and 5 % CO2 at 370C, the total 
viable count was determined from the dilution giving 30-300 colonies. After 5 days of 
incubation of trypticase soy agar plate in air and 10 % CO2 at 370C, the total number of 
facultative anaerobes was determined. 
All the microbiological data were expressed as colony forming units/ml (CFU/ml). Obligate 
anaerobic bacteria was calculated as the total counts of anaerobically cultivable bacteria 
minus the total counts of facultatively anaerobic bacteria and expressed as a percentage of 
total viable count. 
2.7 Statistical analysis 
SPSS for Windows (Release 10.0, SPSS Inc., USA) was used for statistical analyses. The mean 
values for each periodontal measurement was calculated as the mean of whole mouth for 
each patient.  The mean for each periodontal parameter was also calculated separately for 
periodontal sites selected for microbial sampling with initial probing depth ≥5 mm for each 
patient.  Comparisons between the groups were carried out using the Mann-Whitney U test, 
and multiple comparisons within each group were performed using the Friedman test 
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absorbance was also measured at 570 nm to determine any optical imperfections between 
the wells, and this value was subtracted from the absorbance at 450. A standard curve was 
prepared for each experiment and concentrations of TGF-β1 in samples were then calculated 
from this curve. The minimum detection limit of the assay kit was 4.61 pg/ml.   
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isolation using a cotton roll.  Subgingival plaque sample was collected with a standardized 
30# sterile paper point by inserting it into the crevice, and leaving in place for 10 seconds. 
Paper points contaminated with saliva or blood were discarded.  
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10-2,….10-5 dilutions were spread on a solid agar medium using sterile bent glass rods. 
Trypticase soy agar plate (Oxoid, Oxoid Ltd., England) enriched with 0.0005 % hemin 
(Sigma, Sigma Chemical Co., USA), 0.00005 % menadione (Sigma), and 5 % defibrinated 
sheep blood, was inoculated for non-selective bacterial growth (Wolff et al., 1985). 
Furthermore, trypticase soy agar plate enriched with 5 % defibrinated sheep blood was used 
for cultivation for facultative anaerobic microorganisms.  
After 7 days of incubation of the supplemented trypticase soy agar plates in Gas Pak jars 
(Gas generating kit, Oxoid) in an atmosphere of 95 % H2 and 5 % CO2 at 370C, the total 
viable count was determined from the dilution giving 30-300 colonies. After 5 days of 
incubation of trypticase soy agar plate in air and 10 % CO2 at 370C, the total number of 
facultative anaerobes was determined. 
All the microbiological data were expressed as colony forming units/ml (CFU/ml). Obligate 
anaerobic bacteria was calculated as the total counts of anaerobically cultivable bacteria 
minus the total counts of facultatively anaerobic bacteria and expressed as a percentage of 
total viable count. 
2.7 Statistical analysis 
SPSS for Windows (Release 10.0, SPSS Inc., USA) was used for statistical analyses. The mean 
values for each periodontal measurement was calculated as the mean of whole mouth for 
each patient.  The mean for each periodontal parameter was also calculated separately for 
periodontal sites selected for microbial sampling with initial probing depth ≥5 mm for each 
patient.  Comparisons between the groups were carried out using the Mann-Whitney U test, 
and multiple comparisons within each group were performed using the Friedman test 
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followed by the Wilcoxon Sign test for comparisons of values between different time points. 
P values <0.05 were considered statistically significant. Lack of significance is indicated by 
not significant (NS). 
3. Results 
All of patients enrolled in this study completed the study protocol. None of the patients in 
group 2 complained of any adverse effects due to the systemic usage of β-glucan. Patient 
demographics are outlined in Table 1.  
 
 Group 1 Group 2 
n 10 10 
Age (mean years ± SD) 44.5 ± 9.4 42.4 ± 7.7 
Age range 30-56 33-52 
Gender (male:female) 8:2 4:6 
Table 1. Demographic characteristics of patients participated in the study. 
3.1 Clinical findings 
The self-performed plaque control program resulted in improved oral hygiene in all patients 
supported by the finding of significant reductions in full mouth plaque index scores in both 
groups (p<0.01) (Table 2). No significant difference was found between the groups 
regarding the plaque index values (p>0.05). Significant reductions were detected in full 
mouth gingival index and bleeding on probing parameters after therapy in both groups 
(p<0.01). However, the changes in mean gingival index and bleeding on probing values of 
the group 1 were not different than those of the group 2 (p>0.05). Probing depth 
measurements at sampling sites demonstrated significant reductions from baseline to 3 
month in both groups (p<0.01). When the probing depth reduction between the groups was 
compared, there was no significant difference (p>0.05). Significant attachment gain at 
sampling sites was achieved in both groups (p<0.01) (Table 2), but intergroup comparison 
yielded no significant difference between the groups (p>0.05) (data not shown).  
 
 Group 1 Group 2 
Parameter Baseline 3 Months Baseline 3 Months 
PI(Full mouth) 2.17 ± 0.38 0.36 ± 0.23* 2.28 ± 0.31 0.44 ± 0.31* 
GI(Full mouth) 2.36 ± 0.37 0.33 ± 0.21* 2.16 ± 0.47 0.45 ± 0.42* 
BOP(%)(Full mouth) 88 ± 11 9 ± 4* 84 ± 14 10 ± 6* 
PD (mm)(Sampling sites) 5.28 ± 0.16 3.35 ± 0.33* 5.38 ± 0.14 3.49 ± 0.15* 
RAL (mm)(Sampling sites) 9.40 ± 1.14 8.18 ± 1.23* 9.56 ± 0.80 8.44 ± 0.72* 
All values are expressed as mean ± standard deviation. 
* (p<0.01), Wilcoxon Sign test 
PI=Plaque index, GI= gingival index, BOP= bleeding on probing, PD= probing depth,  
RAL= relative attachment level  
Table 2. Clinical parameters of the study groups at baseline and 3 months after treatment. 
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3.2 Biochemical findings 
GCF volume of the groups 1 and 2 showed significant decreases during the experimental 
period (p<0.05) and intragroup comparisons revealed that the decreases between days 0-14, 
14-91 and 0-91 were significant in both groups (p<0.05) (Fig. 2). However, there were no 
significant differences in the changes of GCF volume between the groups (p>0.05).  
 
* p<0.05, between days 0-14, Wilcoxon Sign test, § p<0.05, between days 0-91, Wilcoxon Sign test. 
† p<0.05, between days 14-91, Wilcoxon Sign test. 
Fig. 2. Mean GCF volume of sampling sites in study groups.  
 
¤ p<0.01, compared to groups 1 and 2, Mann-Whitney U test 
* p<0.05, respective baseline value, Wilcoxon Sign test. 
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When baseline GCF TGF-β1 concentrations of the groups 1 and 2 and the healthy group 
were compared, healthy group showed a significantly higher level of TGF-β1 than that of 
the groups 1 and 2 (p<0.01) (Fig. 3). At day 91, TGF-β1 concentration in GCF increased in the 
groups 1 and 2 when compared to their respective baseline values, but only the increase in 
the group 2 was found to be significant (p<0.05) (Fig. 3). However, no significant difference 
was found between the groups in the GCF TGF-β1 concentration level. 
3.3 Microbiological findings 
Total anaerobically grown microorganisms expressed as total viable counts in subgingival 
plaque samples before and 3 month after different treatment modalities, are given in Table 
3. NPT applied to the group 1 resulted in a decrease in total viable counts. A similar 
decrease was also noted when the group 2 patients received adjunctive β-glucan. However, 
these reductions were not significant (p>0.05). Furthermore, intergroup comparisons 
revealed no significant differences between the two groups (p>0.05). Fig. 4 demonstrates the 
proportions of obligate and facultative anaerobes of the study groups. Significant reductions 
were detected in the percentage of obligate anaerobic bacteria along with significant 
increases in the percentage of facultative anaerobic bacteria in both groups after therapy 
(p<0.01). However, no differences were found between the groups (p>0.05).  
 
Group 1 Group 2 p¥
Baseline mean 49 88 NSrange 0.51-178 0.43-260
3 Month mean 2 14 NSrange 0.05-6 0.06-130
pΩ NS NS
¥ Mann-Whitney U test,  ΩWilcoxon Sign test, NS=not significant 
Table 3. Total viable counts (x104 CFU/ml) of subgingival samples at baseline and after 3 months. 
 
* p<0.01, respective baseline value, Wilcoxon Sign test. 
Fig. 4. Proportions of obligate and facultative anaerobes in subgingival plaque samples of 
the groups 1 and 2.  
 




This chapter presented a randomized, controlled, parallel group clinical study which was 
designed to evaluate the effects of NPT with or without adjunctive use of systemic β-glucan 
on clinical, microbiological and biochemical parameters in chronic periodontitis patients 
over a 3-month period. NPT is the first stage of periodontal therapy that aims to reduce the 
number of pathogen microorganisms in periodontal pocket leading to the resolution of 
inflammatory response and arresting the progression of disease, resulting in probing depth 
reduction and attachment gain (Greenstein, 1992; Cobb, 1996; Noyan et al., 1997, Yilmaz et 
al., 2002). It is well known that the efficacy of nonsurgical therapy is related to the baseline 
probing depth, and inflammatory changes are more pronounced in deeper pockets. 
Therefore, the effectiveness of NPT and adjunctive β-glucan in this study was evaluated for 
only periodontal sites with baseline probing depth ≥5 mm. Significant improvements in all 
measured clinical parameters (plaque index, gingival index, bleeding on probing, probing 
depth, relative attachment level) were observed 3 months following SRP procedure, as 
expected. Moreover, SRP supplemented with β-glucan resulted in significant clinical 
outcome. However, β-glucan appears to have no additional effect on clinical parameters 
recorded in the present study, as evidenced by insignificant difference between the groups. 
β-glucan acts as an immunostimulant agent enhancing host-mediated immune responses to 
pathogens, especially by activating macrophages (Brown & Gordon 2001, Suzuki et al., 
2001). β-glucan stimulates macrophage phagocytosis (Lee et al., 2002) and changes the 
balance from immunglobulin G1 antibodies (T helper 2 dependent antibody subclasses) 
towards a T helper 1 dependent immunglobulin G2a response (Suzuki et al., 2001). It also 
stimulates the production of T helper 1-stimulating cytokine interferon-γ but suppresses 
interleukin-4 which induces T helper 2 responses (Inoue et al., 2002). Therefore, β-glucan 
skew the T helper 1/T helper 2 balance towards a T helper 1-dominated response (Suzuki et 
al., 2001). The presence of a T helper 2-biased response to the periodontopathogens is 
supported by the observation that peripheral blood cells of patients release more T helper 2 
cytokines in response to periodontopathogens in vitro (Bartova et al., 2000, Wassenaar et al., 
1998). In the present study, concentration of GCF TGF-β1 increased following both therapies 
but the increase was significant only in the group 2 which received β-glucan. As TGF-β1 is a 
T helper 1 stimulating cytokine, the increase of this cytokine can be explained by this 
mechanism. 
In the present study, the level of TGF-β1 in GCF samples obtained from chronic 
periodontitis patients was investigated and compared with periodontally healthy 
individuals. TGF-β1 has a very important role in the pathogenesis of periodontal diseases 
and also in wound healing. To the best of our knowledge, no data is available on 
periodontal treatment with adjunctive use of β-glucan. Hence this is the first study to 
explore any effect of this immunomodulator agent on the treatment of chronic periodontitis 
patients. 
In the present study we have demonstrated that the healthy group had higher GCF TGF-β1 
concentration than the groups 1 and 2. This finding is in agreement with previous reports 
which found lower GCF TGF-β1 concentrations at inflamed sites when compared with 
healthy sites (Buduneli et al., 2001, Gürkan et al., 2005; Kuru et al., 2004a). Expression of 
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GCF constituents as concentration could result in higher levels at healthy sites where GCF 
volume is very low (Curtis et al., 1988, Emingil et al., 2000). Therefore, in healthy sites, high 
levels of TGF-β1 in GCF may be related to low GCF volume.  
TGF-β1 is a key mediator in resolution of inflammation (Sodek & Overall, 1992, Steinsvoll et 
al., 1999). This multifunctional growth factor has both pro-inflammatory and anti-
inflammatory properties (Wahl et al., 1993). Its effects on cell proliferation and 
differentiation suggest a key role for this cytokine in wound healing, tissue remodeling and 
regeneration (Sporn & Roberts, 1993). Thus, these properties of TGF-β1 indicate its 
important role in inflammatory wound healing. In the present study, concentration of GCF 
TGF-β1 increased following both therapies. After the elimination of microbial factors, as 
shown by decrease in the preposition of anaerobic species, there will be a rapid restoration 
of the periodontium; this might be the reason why the cytokine levels increased in our 
study. This increase was significant only in β-glucan group between day 0 and day 91. Since 
systemic β-glucan usage activates macrophages and neutrophils which produce TGF-β1 
when activated (Igarasi et al., 1993), the significant increase in group 2 might have occurred 
due the effect of β-glucan. In the study of Gürkan et al. (2005), only GCF TGF-β1 levels of 
subantimicrobial dose doxycycline group was significantly higher than baseline and placebo 
group at 3 months. On the other hand, the GCF TGF-β1 concentration in the 
subantimicrobial dose doxycycline group decreased while it increased in the placebo group 
at the end of 6-month period. The authors concluded that the drug efficacy at the 
biochemical level may continue as long as the agent is used. In accordance with our results, 
Gürkan et al. (2005), have demonstrated that the level of this growth factor increased after 
resolution of inflammation. Thus, it could be hypothesized that antiinflammatory role of 
TGF-β1 may be more potent than its proinflammatory properties during healing after NPT. 
However, the levels of this cytokine at different stages of healing process needs to be 
clarified with further studies. 
The demonstration of bacterial specificity in periodontal disease allows the clinician to 
direct therapy toward the elimination or suppression of the periodontopathogens in terms 
of antimicrobial treatment. As antibiotics have important disadvantages including side 
effects, drug resistance etc., recent researches have focused on new therapeutic agents 
alternative to antibiotics. Since β-glucan has been suggested to possess antimicrobial activity 
(Bedirli et al., 2003, Di Luzio et al., 1980, Nicoletti et al., 1992), we evaluated the 
microbiological effect of β-glucan as an adjunct to NPT. In this study, a reduction in the 
proportion of obligate anaerobic bacteria occurred in both groups. A decrease in the number 
of anaerobic bacteria is synonimous with a successful treatment of periodontal infections 
and reflects the antimicrobial effect following NPT, as expected (Greenstein, 1992; Noyan et 
al., 1997; Yilmaz et al., 2002). But as there are no significant differences between the two 
groups, we can assume that β-glucan has no additional antimicrobial effect when used 
systemically as an adjunct to NPT in patients with chronic periodontitis.  
Regarding the duration of systemic β-glucan usage, no data is available so far on its systemic 
usage in the periodontal diseases. Treatment duration with β-glucan varies from 39 days to 
90 days in animal and human studies according to the type and severity of the problem 
(Breivik et al.,2005; Kabasakal et al., 2011; Lin et al., 2011; Sarinho et al., 2009; Turunen et al., 
2011). Biagini et al. (1988) documented soft tissue healing after NPT and found precisely 
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oriented collagen bundle fibres by 30 days to 60 days. Furthermore, Magnusson et al. (1984) 
reported that repopulation of subgingival microbiota occurred between 30 to 60 days. 
Therefore, our patients in this study were put on β-glucan medication for 40 days according 
to the combination of the aforementioned data. 
5. Conclusion 
This is the first preliminary report investigating the effects of NPT plus β-glucan on clinical 
parameters, subgingival microflora and GCF TGF-β1 level in patients with chronic 
periodontitis. Within its limits, systemic β-glucan used as an adjunct to NPT did not provide 
additional clinical and microbiological effects.  However, β-glucan might increase the 
concentration of TGF-β1 thereby augmenting periodontal healing potential. As β-glucans 
are inexpensive and have a good margin of safety (Chan et al., 2009), their potential 
therapeutic value deserves further detailed investigations for clarifying the paucity of 
information in the literature in order to design a strategy for their possible use in clinical 
periodontal practice.  
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of anaerobic bacteria is synonimous with a successful treatment of periodontal infections 
and reflects the antimicrobial effect following NPT, as expected (Greenstein, 1992; Noyan et 
al., 1997; Yilmaz et al., 2002). But as there are no significant differences between the two 
groups, we can assume that β-glucan has no additional antimicrobial effect when used 
systemically as an adjunct to NPT in patients with chronic periodontitis.  
Regarding the duration of systemic β-glucan usage, no data is available so far on its systemic 
usage in the periodontal diseases. Treatment duration with β-glucan varies from 39 days to 
90 days in animal and human studies according to the type and severity of the problem 
(Breivik et al.,2005; Kabasakal et al., 2011; Lin et al., 2011; Sarinho et al., 2009; Turunen et al., 
2011). Biagini et al. (1988) documented soft tissue healing after NPT and found precisely 
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oriented collagen bundle fibres by 30 days to 60 days. Furthermore, Magnusson et al. (1984) 
reported that repopulation of subgingival microbiota occurred between 30 to 60 days. 
Therefore, our patients in this study were put on β-glucan medication for 40 days according 
to the combination of the aforementioned data. 
5. Conclusion 
This is the first preliminary report investigating the effects of NPT plus β-glucan on clinical 
parameters, subgingival microflora and GCF TGF-β1 level in patients with chronic 
periodontitis. Within its limits, systemic β-glucan used as an adjunct to NPT did not provide 
additional clinical and microbiological effects.  However, β-glucan might increase the 
concentration of TGF-β1 thereby augmenting periodontal healing potential. As β-glucans 
are inexpensive and have a good margin of safety (Chan et al., 2009), their potential 
therapeutic value deserves further detailed investigations for clarifying the paucity of 
information in the literature in order to design a strategy for their possible use in clinical 
periodontal practice.  
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1. Introduction 
Periodontal disease is initiated by pathogenic plaque biofilm and characterized by bacteria-
induced inflammatory destruction of tooth-supporting structures and alveolar bone (Lui & 
Corbet, 2011). With a constant bacterial challenge, the periodontal tissues are continuously  
exposed to specific bacterial components that have the ability to alter many local functions. 
The role of the inflammatory process is to protect the host and limit the pathogenic effect of 
biofilm, thus determining some tissue destruction as a collateral effect of the defence. The 
extent and severity of damage vary among individuals and over time (Offenbacher, 
1996;Kinane et al., 2005; Karlsson et al., 2008), mainly influenced by individual’s immune 
and inflammatory responses to microbial challenge. In some patients gingivitis progresses 
to periodontitis, with a slower or faster progression, that is characterized by the destruction 
of the supporting structures of the teeth, including periodontal ligament and  bone, and 
cementum alterations, that may in turn ultimately cause tooth loss (Kinane, 2001). 
Unfortunately, little and still uncertain is the possibility to interfere with individual 
response, to redirect inflammatory and immune defences or, as it is commonly defined, to 
perform a “host modulation”. The rationale behind this approach is to aid the host in its 
fight against infectious agents by supplementing the natural defence mechanism or to 
modify its responses by changing the course of inflammatory systems. Therefore, 
pharmaceutical inhibition of host response with an anti-inflammatory mechanism may 
prove to be an effective strategy for treating periodontal diseases. Current research has 
focused on the use of subantimicrobial dose of doxycycline (SDD) as a treatment modality, 
and SDD is the only systemically used host modulatory drug approved by the United States 
Food and Drug Administration. (Deo et al., 2010) (Figure 1).  
At present state, an effective and widely accepted treatment approach for periodontal 
disease is the mechanical removal of the bacterial biofilm and their toxins from the tooth 
surface by scaling and root planing, making it compatible with biologic reattachment that is 
the basis of any eventual adjunctive therapy (Sigusch et al., 2010). Traditionally, scaling and 
root planing procedures can be performed by hand and/or powered instruments. However, 
complete removal of bacterial deposits within the periodontal pockets is not necessarily 
achieved with conventional mechanical therapy. In addition, access to areas such as 
furcations, concavities, grooves, and distal sites of molars is limited (Aoki et al., 2004). 
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Fig. 1. Scheme of pathogenesis of periodontal disease; role of tetracycline in different phases. 
Currently, efficient anti-infective treatments with reduced side effects are being searched 
for. Local and systemic antibiotics may lead to bacterial resistance, allergies, gastrointestinal 
disorders and others, reducing patient compliance or advising against the prescription 
(Quirynen et al., 2003; Rodrigues et al., 2004).  
Therefore, development of novel systems for scaling and root planing, as well as further 
improvement of currently used mechanical instruments, is required. 
For its various characteristics, such as ablation or vaporization, haemostasis and sterilization 
effect, the use of laser may serve as an adjunct or alternative treatment to conventional 
periodontal therapy (Aoki et al., 2004).  
2. Characteristics of lasers 
The word LASER is the acronym for Light Amplification by Stimulated Emission of 
Radiation. A laser is a device that emits light through a process called stimulated emission, 
featuring collimated (parallel) and coherent (temporally and spatially constant) 
electromagnetic radiation of a single wavelength. Laser light is produced by pumping 
(energizing) a certain substance, or gain medium, within a resonating chamber (Figure 2). 
 
 
Fig. 2. Schematic drawing of the main component of a laser system. 
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The process of lasing occurs when an exited atom is stimulated to emit a photon before the 
process occurs spontaneously. Spontaneous emission of a photon by one atom stimulates 
the release of a subsequent photon and so on. This stimulated emission generates a very 
coherent and synchronous wave, of a single wavelength and in a collimated form (parallel 
rays) of light that is found nowhere else in nature. The various laser systems are usually 
named after the ingredients of the gain medium, but three factors are important to the final 
characteristics of the laser light: as said before, gain medium, source of pump energy, design 
of resonating chamber. Clinically, that is for medical applications, both the laser-delivery 
system (e.g. optical fiber or articulated arm with mirrors) and the application tip are of 
paramount importance, as they may condition the ease of use, range of applications and 
energy efficiency of a laser system. The most common classifications of lasers are those 
related to the type of gain medium and characteristics of the laser light. 
The characteristics of lasers depend on their wavelength (table 1 and figure 3).  
 
Table 1. Type and wavelength of lasers (from Aoki et al. 2004) 
 
Fig. 3. Electromagnetic spectrum and wavelengths of lasers. 
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The term “waveform” describes the way of laser delivery over time, either as a continuous 
or as a pulsed beam emission (table 2). A continuous wave laser beam emits an 
uninterrupted beam at the output power set for as long as the switch is turned on. The 
pulsed beam may be delivered in two different modalities: a free-running pulse, in which 
pulsation  is stored for a certain time and the emission has a peak power greater than the 
power selected on the panel, or gated pulse, in which a continuous wave beam is 
interrupted at various rates by a shutter, having the laser the same power set. 
Criteria Types Examples 
Output Energy Low-output, soft, or therapeutic High-output, hard, or surgical 
Low-output diodes 
 
Diodes, CO2, Nd:YAG, Er:YAG, 
Er,Cr,:YSGG 






Nd:YAG, Er:YAG, Er,Cr,:YSGG, 
KTP 
HeNe, Argon, CO2 






CO2 , Diodes 
CO2, Diodes, Nd:YAG, Er:YAG, 
Er,Cr,:YSGG, KTP 
Table 2. Mode of irradiation and laser denomination. 
The first prototype of laser was developed by Maiman in 1960, using a crystal medium of 
ruby that emitted a coherent radiant light from the crystal when stimulated by energy. The 
first application of laser in dental field was reported by Goldman et al. (1964), describing the 
effect of the ruby laser on enamel and dentin while attempting to remove caries in vitro 
using the ruby laser. Since then, many researchers investigated the effects of various laser 
types on dental hard tissue and caries. However, previous laser systems where basically not 
indicated for hard tissue procedures due to major thermal damage (Frentzen et al., 2002). 
The effect of the laser on a tissue depends on its behaviour within it. It can reflect, scatter, be 
absorbed or transmitted to surrounding tissues (Figure 4). 
 
Fig. 4. Possible effects of laser irradiation on tissue. 
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Basically, as the absorption increases, the reflection, scattering and transmission decrease. 
For most biological tissues, higher absorption occurs in wavelengths with greater 
absorbance in water. The more absorbance occurs, the less the laser light penetrates the 
surrounding tissues with a shallower layer of laser-affected tissue (Ishikawa et al. 2009). 
Since the periodontium is composed of gingiva, periodontal ligament, cementum and 
alveolar bone, both soft and hard tissues are involved in a lasering process. The high power 
carbon dioxide (CO2) and neodymium-doped yttrium aluminium garnet (Nd:YAG) lasers 
are capable of excellent soft tissue ablation with a good haemostatic effect. As such, these 
lasers have been generally proposed for periodontal surgery and oral surgery (Aoki et al. 
2004). However, these lasers are not suitable for treatment of root surface or alveolar bone, 
due to carbonization of these tissues and major thermal side-effects on the target and 
surrounding tissues, with a limitation of employment indications to gingivectomy and 
frenectomy. 
In the late eighties Keller and Hibst  (1989) and Kayano et al. (1991) reported the possibility 
of dental hard tissue ablation by erbium yttrium aluminium garnet (Er:YAG) laser 
irradiation, which is highly absorbed by water, without producing major thermal side-
effects. Er:YAG laser was then proved for periodontal hard tissue procedures such as dental 
calculus removal and decontamination of the diseased root surface. 
Diode and Nd:YAG lasers are also currently under investigation and used by clinicians 
because of their flexible fiber delivery system, which is suitable for pocket insertion. 
Nd.YAG, CO2, Diodes, Er:YAG, erbium chromium-doped yttrium scandium gallium and 
garnet (Er,Cr:YSGG), Argon, excimer and alexandrite lasers are being studied in vitro or are 
in clinical use (table 3). 
 
Table 3. Characteristics and actual or potential clinical use of different laser lights (from 
Aoki et al. 2004) 
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Characteristics, possible development and actual studies will be analyzed for different laser 
types. 
2.1 CO2 laser 
The CO2 laser has a wavelength of 10.600 nm and can be used in either pulsed-wave or 
continuous-wave modes. Because of an excellent capacity for soft tissue ablation, CO2 lasers 
have been successfully used as an adjunctive tool to de-epithelialize the mucoperiosteal flap 
during traditional flap surgery (Centty et al. 1997). The scattering of laser energy within the 
surrounding tissues is low and the layer of heat-altered tissue that remains after 
vaporization is relatively shallow; however the vaporization temperature is high and the 
irradiated surface is easily carbonized. With the CO2 laser, the performance advantages are 
the rapid and simple vaporization of soft tissues with strong haemostasis, which produces a 
clear operating field and requires no suturing (Pick et al., 1995). Gingival hyperplasia is a 
typical indication for CO2 laser treatment. Inorganic components of hard tissues, like bone 
and cementum (and also dental calculus), can reach very high temperatures, due to their 
content in apatite, especially phosphate ions (-PO4), that absorb CO2 laser wavelength much 
more than water (Featherston, 2000).  
2.1.1 Periodontal applications of CO2 laser 
Several studies reported major thermal side effects, such as melting, cracking or 
carbonization when CO2 lasers were used directly on root surface (Aoki et al. 2004). 
However, these negative effects were avoided when irradiation was performed in a pulsed 
mode with a de-focused beam (Barone et al., 2002). The defocused mode of the CO2 laser 
has root conditioning effects, such as smear layer removal, decontamination and the 
preparation of a surface favourable to fibroblast attachment (Crespi et al., 2002). 
Transmission of the CO2 laser through optical fibers was very difficult and therefore the 
system previously employed mirror systems using articulated arms for laser beam delivery. 
In the case of the CO2 laser, because of the lack of an appropriate flexible delivery system 
with suitable contact tips for periodontal pocket therapy, only a few clinical studies have 
been reported on the effects of this laser in the non surgical treatment of periodontitis 
(Miyazaki et al., 2003; Mullins et al., 2007). Also, CO2 irradiation of the periodontal pocket 
using a special tip failed to result in a reduction of bacterial counts, and potentially 
damaged the soft tissue surrounding the periodontal pocket itself with cases of residual 
melted calculus being reported. 
2.2 Nd:YAG laser 
The Nd:YAG laser has a wavelength of 1.064 nm and operates in a free running pulsed 
mode. It is commonly used in periodontal therapy to incise and excise soft tissues as well for 
the curettage and disinfection of periodontal pockets. The Nd:YAG laser has low absorption 
in water, and the energy scatters or penetrates into the biological tissues. In water, the 
Nd:YAG laser will theoretically penetrate to a depth of 60mm before it is attenuated to 10% 
of its original strength (AAP, 2002). In soft tissue treatments, this laser is very effective at 
producing coagulation and haemostasis, in a relatively thick layer of soft tissues. Hence, the 
Nd:YAG laser is basically effective for ablation of potentially hemorrhagic soft tissue, being 
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the width of coagulation from 0.3 to 0.8 mm at 3-10 W of laser power. However these effects 
are primarily caused by tissue heating and therefore irradiated surfaces usually exhibit a 
thick layer of coagulated tissue. Because of its high penetrability, the possible thermal effects 
on tissues laying below the irradiated are, such as dental pulp or bone tissue, is occasionally 
a matter of concern during periodontal treatment (Schwarz et al., 2009). 
In dentistry, soft tissue surgery using the Nd:YAG laser has been widely accepted. In 1990, 
the FDA approved soft tissue removal by means of a pulsed Nd:YAG laser for intraoral soft 
tissue application without anaesthesia, with a minimal bleeding compared to scalpel 
surgery. The delivery system of the laser is flexible and suitable for periodontal 
employment, being a flexible optical fiber with a contact tip of 400 µm. In 1997 the FDA 
approved the use of Nd:YAG laser in sulcular debridement (Aoki et al., 2004).   
2.2.1 Periodontal applications of Nd:YAG laser 
The first in vitro studies on the use of Nd:YAG laser for calculus removal showed that its 
ability to remove calculus at a level equivalent to mechanical treatment is not easily 
clinically expectable. Different studies with different irradiation power and mode gave 
different degrees of calculus removal from the root and different effects on the root itself. 
Tseng & Liew (1990) demonstrated that partial removal and detachment of the calculus from 
the root surface was achieved by 2.0 to 2.75 W of power at 20 Hz pulse. However, melting of 
calculus and thermal damage was noted in localized areas of cementum and even dentin. 
Morlock et al. ( 1992) showed that the Nd:YAG laser at 1.25-1.50 W, pulse 20 Hz, produced 
surface pitting and crater formation with charring, carbonization, melting, even when 
irradiation was performed parallel to root surface. Other authors demonstrated how the root 
surface was modified by Nd:YAG irradiation in a way that affected fibroblast recolonization 
and reattachment.  
Also the removal of smear layer from the root surface is obtained only at powers that are not 
suitable for clinical use, either for a root alteration or for significant intrapulpal temperature rise. 
Other authors demonstrated the possibility of calculus removal from the root with more or 
less extent of root damages. As subgingival calculus is often dark coloured, the Nd:YAG 
laser has the advantage of being absorbed by deposits. However the energy capable of 
detaching the calculus may be inappropriate for clinical usage due to increased thermal 
side-effects. Clinically an application of a low power Nd:YAG laser can result in an 
ineffective and patchy removal of calculus from the root surface. However, it would result 
in an alteration of calculus that should followed by facilitation of  mechanical debridement. 
Nd:YAG laser was the first to be approved by FDA for applying in periodontal pockets . It has 
been widely used by general practioners because of its ease of use. However, in spite of its 
long time use, there is still very insufficient proof of a positive effect from scientific studies. 
Nd:YAG laser cannot achieve root surface debridement to a satisfactory degree, due to 
insufficient ability to remove calculus and to distinguish calculus from the root. If utilized, 
Nd:YAG laser should employed as an adjunct to conventional mechanical treatment to 
exploit the ability of curettage of the soft wall of pocket, to remove infected granulation 
tissue and epithelium, as for its ability of detoxification at a  relatively low energy level. 
Nonetheless, it has to be kept in mind that Nd:YAG laser has the capability of a deep 
penetration in oral tissue and the risk of a pulpal  or alveolar bone temperature rise is high. 
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Characteristics, possible development and actual studies will be analyzed for different laser 
types. 
2.1 CO2 laser 
The CO2 laser has a wavelength of 10.600 nm and can be used in either pulsed-wave or 
continuous-wave modes. Because of an excellent capacity for soft tissue ablation, CO2 lasers 
have been successfully used as an adjunctive tool to de-epithelialize the mucoperiosteal flap 
during traditional flap surgery (Centty et al. 1997). The scattering of laser energy within the 
surrounding tissues is low and the layer of heat-altered tissue that remains after 
vaporization is relatively shallow; however the vaporization temperature is high and the 
irradiated surface is easily carbonized. With the CO2 laser, the performance advantages are 
the rapid and simple vaporization of soft tissues with strong haemostasis, which produces a 
clear operating field and requires no suturing (Pick et al., 1995). Gingival hyperplasia is a 
typical indication for CO2 laser treatment. Inorganic components of hard tissues, like bone 
and cementum (and also dental calculus), can reach very high temperatures, due to their 
content in apatite, especially phosphate ions (-PO4), that absorb CO2 laser wavelength much 
more than water (Featherston, 2000).  
2.1.1 Periodontal applications of CO2 laser 
Several studies reported major thermal side effects, such as melting, cracking or 
carbonization when CO2 lasers were used directly on root surface (Aoki et al. 2004). 
However, these negative effects were avoided when irradiation was performed in a pulsed 
mode with a de-focused beam (Barone et al., 2002). The defocused mode of the CO2 laser 
has root conditioning effects, such as smear layer removal, decontamination and the 
preparation of a surface favourable to fibroblast attachment (Crespi et al., 2002). 
Transmission of the CO2 laser through optical fibers was very difficult and therefore the 
system previously employed mirror systems using articulated arms for laser beam delivery. 
In the case of the CO2 laser, because of the lack of an appropriate flexible delivery system 
with suitable contact tips for periodontal pocket therapy, only a few clinical studies have 
been reported on the effects of this laser in the non surgical treatment of periodontitis 
(Miyazaki et al., 2003; Mullins et al., 2007). Also, CO2 irradiation of the periodontal pocket 
using a special tip failed to result in a reduction of bacterial counts, and potentially 
damaged the soft tissue surrounding the periodontal pocket itself with cases of residual 
melted calculus being reported. 
2.2 Nd:YAG laser 
The Nd:YAG laser has a wavelength of 1.064 nm and operates in a free running pulsed 
mode. It is commonly used in periodontal therapy to incise and excise soft tissues as well for 
the curettage and disinfection of periodontal pockets. The Nd:YAG laser has low absorption 
in water, and the energy scatters or penetrates into the biological tissues. In water, the 
Nd:YAG laser will theoretically penetrate to a depth of 60mm before it is attenuated to 10% 
of its original strength (AAP, 2002). In soft tissue treatments, this laser is very effective at 
producing coagulation and haemostasis, in a relatively thick layer of soft tissues. Hence, the 
Nd:YAG laser is basically effective for ablation of potentially hemorrhagic soft tissue, being 
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the width of coagulation from 0.3 to 0.8 mm at 3-10 W of laser power. However these effects 
are primarily caused by tissue heating and therefore irradiated surfaces usually exhibit a 
thick layer of coagulated tissue. Because of its high penetrability, the possible thermal effects 
on tissues laying below the irradiated are, such as dental pulp or bone tissue, is occasionally 
a matter of concern during periodontal treatment (Schwarz et al., 2009). 
In dentistry, soft tissue surgery using the Nd:YAG laser has been widely accepted. In 1990, 
the FDA approved soft tissue removal by means of a pulsed Nd:YAG laser for intraoral soft 
tissue application without anaesthesia, with a minimal bleeding compared to scalpel 
surgery. The delivery system of the laser is flexible and suitable for periodontal 
employment, being a flexible optical fiber with a contact tip of 400 µm. In 1997 the FDA 
approved the use of Nd:YAG laser in sulcular debridement (Aoki et al., 2004).   
2.2.1 Periodontal applications of Nd:YAG laser 
The first in vitro studies on the use of Nd:YAG laser for calculus removal showed that its 
ability to remove calculus at a level equivalent to mechanical treatment is not easily 
clinically expectable. Different studies with different irradiation power and mode gave 
different degrees of calculus removal from the root and different effects on the root itself. 
Tseng & Liew (1990) demonstrated that partial removal and detachment of the calculus from 
the root surface was achieved by 2.0 to 2.75 W of power at 20 Hz pulse. However, melting of 
calculus and thermal damage was noted in localized areas of cementum and even dentin. 
Morlock et al. ( 1992) showed that the Nd:YAG laser at 1.25-1.50 W, pulse 20 Hz, produced 
surface pitting and crater formation with charring, carbonization, melting, even when 
irradiation was performed parallel to root surface. Other authors demonstrated how the root 
surface was modified by Nd:YAG irradiation in a way that affected fibroblast recolonization 
and reattachment.  
Also the removal of smear layer from the root surface is obtained only at powers that are not 
suitable for clinical use, either for a root alteration or for significant intrapulpal temperature rise. 
Other authors demonstrated the possibility of calculus removal from the root with more or 
less extent of root damages. As subgingival calculus is often dark coloured, the Nd:YAG 
laser has the advantage of being absorbed by deposits. However the energy capable of 
detaching the calculus may be inappropriate for clinical usage due to increased thermal 
side-effects. Clinically an application of a low power Nd:YAG laser can result in an 
ineffective and patchy removal of calculus from the root surface. However, it would result 
in an alteration of calculus that should followed by facilitation of  mechanical debridement. 
Nd:YAG laser was the first to be approved by FDA for applying in periodontal pockets . It has 
been widely used by general practioners because of its ease of use. However, in spite of its 
long time use, there is still very insufficient proof of a positive effect from scientific studies. 
Nd:YAG laser cannot achieve root surface debridement to a satisfactory degree, due to 
insufficient ability to remove calculus and to distinguish calculus from the root. If utilized, 
Nd:YAG laser should employed as an adjunct to conventional mechanical treatment to 
exploit the ability of curettage of the soft wall of pocket, to remove infected granulation 
tissue and epithelium, as for its ability of detoxification at a  relatively low energy level. 
Nonetheless, it has to be kept in mind that Nd:YAG laser has the capability of a deep 
penetration in oral tissue and the risk of a pulpal  or alveolar bone temperature rise is high. 
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2.3 Nd:YAP laser 
The Nd:YAP laser has a wavelength of 1.340 nm and it is mainly absorbed by black-
pigmented tissues. Its employment in periodontal pocket treatment is still under 
investigation at first stages, however the concern related to a potential increase in 
temperature of the target is similar to that of Nd:YAG laser (Lee et al., 2005). 
2.4 Er:YAG laser 
The Er:YAG laser has a wavelength of 2.940 nm. It has a great absorption in water, 
theoretically 10.000 -20.000 times higher than that of CO2 and Nd:YAG lasers. Its light is 
well absorbed by all biological tissue that contain water molecules, so that Er:YAG laser is 
indicated not only for soft tissues but also for ablation of hard tissues (Aoki et al., 2004). In 
dental hard tissues the Er:YAG laser is absorbed by intrinsic water in apatite crystals and by 
OH group of the mineral apatite. So, Er:YAG laser has been used in a free-running pulse 
mode for caries removal and cavity preparation (Cozean et al., 1997). 
Er:YAG laser was first approved for cavity preparation, and in 1999 it was accepted for soft 
tissue surgery, sulcular debridement and finally for osseous surgery. The huge absorption 
by water minimize, in fact, the thermal effect on surrounding tissues during irradiation, 
with a very thin penetration in soft tissues (10-50 µm) and only some degrees of heating in 
hard tissue. Because of the very low water content of hard tissues, since the Er:YAG laser 
emits in the infrared spectrum, some water coolant is advisable to reduce heat generation 
and absorb excessive laser energy (Burkes et al., 1992). 
During Er:YAG laser irradiation, the laser energy is absorbed selectively by water molecules 
and hydrous organic components of biological tissues, causing evaporation of water by a 
“photothermal evaporation”. Moreover, in hard tissue procedures, the water vapour 
production induces an increase of internal pressure within the tissue, resulting in an 
explosive expansion called “microexplosion” (Aiko et al., 2004) principle because of hard 
tissue ablation. The absorption of the Er:YAG laser by inorganic components 
(Hydroxyapatite) is however much lower than that of the CO2 laser, so that the absorption 
in water and in organic compounds with a water content is fast and occurs before heat 
accumulation into inorganic compounds. For these characteristics, Er:YAG laser received 
much attention by researcher both for soft tissue and for hard tissue applications. 
2.4.1 Periodontal applications of Er:YAG laser 
The ability of Er:YAG laser to remove subgingival dental calculus has already been shown 
in in vitro studies (Aoki et al., 1994; Aoki et al. ,2000; Folcwaczny et al.,2000; Frentzen et al., 
2002). In 1994 Aoki et al. first documented the capacity of Er:YAG laser to remove dental 
calculus in an in vitro study, using a pulsed mode under irrigation. The laser was set at 30 
mJ/pulse (energy density of single pulse at the tip:10.6 J/cm2 per pulse) and 10 Hz, in the 
contact mode, directed perpendicular to the root surface using a conventional 600µm tip. 
The ablation of cementum was of little substance and the rise in pulpal temperature 
moderate. Stock et al. (1996) introduced a new tip, a chisel tip, suitable for root surface 
treatment within periodontal pockets. The authors utilized the tip with a power of  
120 mJ/pulse (8 J/cm2 per pulse) and 15 Hz with water spray and an angulation of the tip of 
20° to the root surface, reporting that only smooth ablation traces  were visible in the 
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cementum. The calculus was completely removed without thermal change of the root 
surface. Aoki et al. (1994) evaluated the effectiveness of Er:YAG laser compared to 
conventional ultrasonic scaling. The panel set was 40 mJ/pulse (14.2 J/cm2 per pulse) and 10 
Hz with water spray using a conventional tip at 30° to the root surface. The level of calculus 
removal by laser was similar to that with ultrasonic scaling, although the laser was slightly 
less efficient. The depth of cementum removal varies between 15 and 150 µm depending on 
the output power. At a power up to 100 mJ/pulse (12.2 J/cm2 per pulse) the root substance 
removal is similar to that with curettes and a selective calculus removal can be feasible using 
lower radiation energies (Aoki et al. 2000). 
Thus, the Er:YAG laser does not accomplish selective ablation of dental calculus in vitro, as 
the tissue underlying dental calculus is also removed. However, for a safe but effective 
clinical use, a combination of a higher pulse repetition rate and a lower energy output is 
recommended to obtain a smooth root surface with less tissue removal. 
On the contrary, supragingival scaling on enamel is contraindicated, since complete calculus 
removal occurs with a certain removal of enamel too, and this fact has no positive relevance 
compared to the removal of a thin layer of contaminated cementum. 
Er:YAG laser does not cause carbonization of the irradiated root surface, that becomes 
chalky due to the mechanical ablation. In particular the layer just beneath the ablated 
cementum reveals more structural changes and damages, with microstructural degradation 
and thermal denaturation. The use of a water coolant results in less damage and a cleaner 
surface (Aoki et al. 2004). On periodontal diseased root, the Er:YAG laser treatment shows a 
better attachment and a better condition for fibroblast adherence compared to a diseased 
root treated only by mechanical means. These better results may be due to detoxification 
and disinfection obtained by laser and to the absence of a smear layer on the surface. 
In animal studies Er:YAG laser showed no major thermal side-effects on pulp, when used 
under irrigation. It may be presumed that Er:YAG laser subgingival scaling at low level 
energy, especially with the contact tip directed obliquely or parallel to the root surface, does 
not produce any major deleterious outcomes in the pulp tissue. 
The Er:YAG laser offers several antimicrobial advantages over conventional mechanical 
scaling, due to its bactericidal effect, degradation and removal of bacterial endotoxins, ablation 
effects without producing a smear layer (Aiko et al. 2004). Ando et al. (1996) observed a 
bactericidal effect against P. gingivalis and A. actinomycetemcomitans  even at low energy level 
(Ando et al. 1996). Moreover, the wavelength of Er:YAG laser correspond to the peak of 
absorbance of bacterial lipopolysaccharide, so that the Er:YAG laser can effectively and rapidly 
remove most of the lipopolysaccharide that coat the teeth (Yamaguchi et al.,1997). 
Based on the results of several in vitro studies, a clinical phase of controlling the effects of 
Er:YAG laser started in 1996 by Watanabe et al. (1996). The laser scaling was performed with 
a panel set of 40 mJ/pulse (11.3 J/cm2 per pulse) at 10 Hz using a straight contact tip of 600 
μm. According to authors 95% of calculus was removed, with only some irregularity left on 
tooth surface. More recently, Schwarz et al. (2001) reported a split mouth study comparing 
the effects of conventional scaling and root planing with two different laser tips. Periodontal 
pockets were treated under anaesthesia with hand instruments or one of the two tips, in an 
angulation of 15-20° to the root surface. Laser setting was 160 mJ/pulse with an energy 
density of 18.8 J/cm2 or 14.5 J/cm2 according to the tip. Laser treatment required less time 
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2.3 Nd:YAP laser 
The Nd:YAP laser has a wavelength of 1.340 nm and it is mainly absorbed by black-
pigmented tissues. Its employment in periodontal pocket treatment is still under 
investigation at first stages, however the concern related to a potential increase in 
temperature of the target is similar to that of Nd:YAG laser (Lee et al., 2005). 
2.4 Er:YAG laser 
The Er:YAG laser has a wavelength of 2.940 nm. It has a great absorption in water, 
theoretically 10.000 -20.000 times higher than that of CO2 and Nd:YAG lasers. Its light is 
well absorbed by all biological tissue that contain water molecules, so that Er:YAG laser is 
indicated not only for soft tissues but also for ablation of hard tissues (Aoki et al., 2004). In 
dental hard tissues the Er:YAG laser is absorbed by intrinsic water in apatite crystals and by 
OH group of the mineral apatite. So, Er:YAG laser has been used in a free-running pulse 
mode for caries removal and cavity preparation (Cozean et al., 1997). 
Er:YAG laser was first approved for cavity preparation, and in 1999 it was accepted for soft 
tissue surgery, sulcular debridement and finally for osseous surgery. The huge absorption 
by water minimize, in fact, the thermal effect on surrounding tissues during irradiation, 
with a very thin penetration in soft tissues (10-50 µm) and only some degrees of heating in 
hard tissue. Because of the very low water content of hard tissues, since the Er:YAG laser 
emits in the infrared spectrum, some water coolant is advisable to reduce heat generation 
and absorb excessive laser energy (Burkes et al., 1992). 
During Er:YAG laser irradiation, the laser energy is absorbed selectively by water molecules 
and hydrous organic components of biological tissues, causing evaporation of water by a 
“photothermal evaporation”. Moreover, in hard tissue procedures, the water vapour 
production induces an increase of internal pressure within the tissue, resulting in an 
explosive expansion called “microexplosion” (Aiko et al., 2004) principle because of hard 
tissue ablation. The absorption of the Er:YAG laser by inorganic components 
(Hydroxyapatite) is however much lower than that of the CO2 laser, so that the absorption 
in water and in organic compounds with a water content is fast and occurs before heat 
accumulation into inorganic compounds. For these characteristics, Er:YAG laser received 
much attention by researcher both for soft tissue and for hard tissue applications. 
2.4.1 Periodontal applications of Er:YAG laser 
The ability of Er:YAG laser to remove subgingival dental calculus has already been shown 
in in vitro studies (Aoki et al., 1994; Aoki et al. ,2000; Folcwaczny et al.,2000; Frentzen et al., 
2002). In 1994 Aoki et al. first documented the capacity of Er:YAG laser to remove dental 
calculus in an in vitro study, using a pulsed mode under irrigation. The laser was set at 30 
mJ/pulse (energy density of single pulse at the tip:10.6 J/cm2 per pulse) and 10 Hz, in the 
contact mode, directed perpendicular to the root surface using a conventional 600µm tip. 
The ablation of cementum was of little substance and the rise in pulpal temperature 
moderate. Stock et al. (1996) introduced a new tip, a chisel tip, suitable for root surface 
treatment within periodontal pockets. The authors utilized the tip with a power of  
120 mJ/pulse (8 J/cm2 per pulse) and 15 Hz with water spray and an angulation of the tip of 
20° to the root surface, reporting that only smooth ablation traces  were visible in the 
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cementum. The calculus was completely removed without thermal change of the root 
surface. Aoki et al. (1994) evaluated the effectiveness of Er:YAG laser compared to 
conventional ultrasonic scaling. The panel set was 40 mJ/pulse (14.2 J/cm2 per pulse) and 10 
Hz with water spray using a conventional tip at 30° to the root surface. The level of calculus 
removal by laser was similar to that with ultrasonic scaling, although the laser was slightly 
less efficient. The depth of cementum removal varies between 15 and 150 µm depending on 
the output power. At a power up to 100 mJ/pulse (12.2 J/cm2 per pulse) the root substance 
removal is similar to that with curettes and a selective calculus removal can be feasible using 
lower radiation energies (Aoki et al. 2000). 
Thus, the Er:YAG laser does not accomplish selective ablation of dental calculus in vitro, as 
the tissue underlying dental calculus is also removed. However, for a safe but effective 
clinical use, a combination of a higher pulse repetition rate and a lower energy output is 
recommended to obtain a smooth root surface with less tissue removal. 
On the contrary, supragingival scaling on enamel is contraindicated, since complete calculus 
removal occurs with a certain removal of enamel too, and this fact has no positive relevance 
compared to the removal of a thin layer of contaminated cementum. 
Er:YAG laser does not cause carbonization of the irradiated root surface, that becomes 
chalky due to the mechanical ablation. In particular the layer just beneath the ablated 
cementum reveals more structural changes and damages, with microstructural degradation 
and thermal denaturation. The use of a water coolant results in less damage and a cleaner 
surface (Aoki et al. 2004). On periodontal diseased root, the Er:YAG laser treatment shows a 
better attachment and a better condition for fibroblast adherence compared to a diseased 
root treated only by mechanical means. These better results may be due to detoxification 
and disinfection obtained by laser and to the absence of a smear layer on the surface. 
In animal studies Er:YAG laser showed no major thermal side-effects on pulp, when used 
under irrigation. It may be presumed that Er:YAG laser subgingival scaling at low level 
energy, especially with the contact tip directed obliquely or parallel to the root surface, does 
not produce any major deleterious outcomes in the pulp tissue. 
The Er:YAG laser offers several antimicrobial advantages over conventional mechanical 
scaling, due to its bactericidal effect, degradation and removal of bacterial endotoxins, ablation 
effects without producing a smear layer (Aiko et al. 2004). Ando et al. (1996) observed a 
bactericidal effect against P. gingivalis and A. actinomycetemcomitans  even at low energy level 
(Ando et al. 1996). Moreover, the wavelength of Er:YAG laser correspond to the peak of 
absorbance of bacterial lipopolysaccharide, so that the Er:YAG laser can effectively and rapidly 
remove most of the lipopolysaccharide that coat the teeth (Yamaguchi et al.,1997). 
Based on the results of several in vitro studies, a clinical phase of controlling the effects of 
Er:YAG laser started in 1996 by Watanabe et al. (1996). The laser scaling was performed with 
a panel set of 40 mJ/pulse (11.3 J/cm2 per pulse) at 10 Hz using a straight contact tip of 600 
μm. According to authors 95% of calculus was removed, with only some irregularity left on 
tooth surface. More recently, Schwarz et al. (2001) reported a split mouth study comparing 
the effects of conventional scaling and root planing with two different laser tips. Periodontal 
pockets were treated under anaesthesia with hand instruments or one of the two tips, in an 
angulation of 15-20° to the root surface. Laser setting was 160 mJ/pulse with an energy 
density of 18.8 J/cm2 or 14.5 J/cm2 according to the tip. Laser treatment required less time 
 
Pathogenesis and Treatment of Periodontitis 192 
than scaling and root planing, with similar or better results in terms of periodontal 
parameters (reduction of pockets, reduction of bleeding on probing, gain of attachment 
level). Laser advantage was higher in deep pockets and the clinical attachment gain 
obtained by laser was stable for 2 years. 
Schwarz  et al. (2001) showed that the clinical use of Er:YAG laser resulted in a smooth root 
surface, favourable for new attachment. However, histological studies have not been 
performed yet. 
For clinical application the Er:YAG laser has some limitations that have to be taken into 
account. When used subgingivally, with a water coolant, it causes a splash of water and 
blood from pockets as the result of explosive ablation and so it requires an extraoral 
apparatus for high speed evacuation. Moreover, in periodontal pockets, the operator cannot 
see the calculus and the irradiated surface. Recently as a novel application of laser, the use 
of diode fluorescence spectroscopy for detection of dental calculus has been suggested by 
Hibst et al. (2001) and Keller et al. (2001). 
In summary, in vitro and in vivo researches indicated the safety and effectiveness of clinical 
application of the Er:YAG laser for periodontal pocket treatment. However, the energy set, 
the energy output, the energy at the tip, the shape of the tip, the contact mode are key 
factors to obtain a satisfying clinical result. More studies are needed to design protocols of 
employment, however Er:YAG laser can be considered a promising adjunctive or alternative 
method for non surgical periodontal therapy.  
2.5 Diode lasers 
These lasers are a group of laser operating by a solid-state semiconductor, among which the 
most commonly used are the Gallium-aluminium-arsenide (GaAlAs) laser with a 
wavelength of 810 nm, and the indium-gallium-arsenide-phosphide (InGaAsP) laser at 980 
nm of wavelength. The laser is emitted in continuous-wave mode and gated-pulsed mode 
using a flexible fiber optic delivery system (Figure 5). 
 
Fig. 5. The diode laser fiber in clinical use in a pocket of a patient with chronic periodontitis. 
Laser light at 800-980 nm is very poorly absorbed by water and by hard tissues, being highly 
absorbed by haemoglobin and pigments. The diode laser is indicated for soft tissue surgery 
and for curettage. The diode laser exhibits a great thermal effect at the tip, caused by heat 
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accumulation and produces a very good haemostasis, with an effect similar to 
electrocauterization (ALD, 2000). 
The very user-friendly  hand-piece and the low cost of the unit, would make it suitable for 
periodontal pocket therapy, however the features of the laser light are more indicated for 
sulcular debridement. 
2.5.1 Periodontal applications of diode lasers 
The diode laser used on the root surface after scaling and root planing with curettes, showed 
no  alteration on the root microstructure and the periodontal ligament cells attached on the 
treated roots as on the control roots which were unirradiated (Kreisler et al., 2001). However 
if the root was covered by blood, the roots were altered by laser irradiation with severe 
damages till carbonization. Temperature elevation was time and energy-dependant. The 
diode laser irradiation may jeopardize pulp vitality during root surface instrumentation. 
Schwarz et al. (2003) performed in vivo on hopeless roots, a GaAlAs diode laser treatment 
(810 nm wavelength). They reported that diode laser was ineffective in removing calculus 
and altered the root in an unfavourable way. However, given the recommended parameters, 
the possibility of inducing root surface damages is virtually absent (Cobb et al. 2010). 
Some studies demonstrated that diode laser is effective in bacterial elimination, resulting in a 
better healing. Moritz et al. (1997) showed a significant reduction of bacteria, as A. 
actynomicetemcomitans, with a parallel improvement of periodontal parameters. Caruso et al. 
(2008)  compared the effectiveness of a diode laser (980 nm wavelength) used as an adjunct to 
SRP to SRP alone, with a power output of 2.5 W in a pulse mode (30 Hz) and a tip (400 μm) 
angulated at 20°.  Findings indicated a slightly better periodontal healing, in terms of clinical 
parameters at 4, 8 and 12 weeks. However, the microbiological parameters revealed no 
differences between groups, showing no additional benefit of diode laser on the treated pockets. 
Most recently, 655 nm InGaAsP (indium gallium arsenide phosphate) diode laser radiation 
has been included in an Er:YAG laser device to induce fluorescence in subgingival calculus 
(Folwaczny et al. 2002, Krause et al. 2003). Preliminary clinical and histological results have 
shown that fluorescence- controlled (feedback system) Er:YAG laser radiation enabled an 
effective removal of subgingival calculus and a predictable root surface preservation in 
comparison with hand instruments (Schwarz et al. 2006, Krause et al. 2007). 
In recent years, it has also been suggested that GaAlAs radiation within the milliwatt range, 
referred to as “low-level laser therapy”, may have a positive influence on the proliferation of 
gingival fibroblasts or periodontal ligament fibroblasts, thus supporting periodontal wound 
healing (Khadra et al. 2005) 
2.6 Argon laser 
The argon laser operates at a wavelength of 488 nm (blue) and 514 nm (blue-green). It is 
poorly absorbed by water so that it is not indicated for hard tissue treatments. It is well 
absorbed in pigmented tissues, including haemoglobin and melanin, and in pigmented 
bacteria. Thanks to this characteristic the argon laser was clinically studied to test its effect 
on pigmented bacteria in periodontal pockets in combination with mechanical root planing 
(Finkbeiner 1995). The author reported a significant pocket reduction. Considering the 
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than scaling and root planing, with similar or better results in terms of periodontal 
parameters (reduction of pockets, reduction of bleeding on probing, gain of attachment 
level). Laser advantage was higher in deep pockets and the clinical attachment gain 
obtained by laser was stable for 2 years. 
Schwarz  et al. (2001) showed that the clinical use of Er:YAG laser resulted in a smooth root 
surface, favourable for new attachment. However, histological studies have not been 
performed yet. 
For clinical application the Er:YAG laser has some limitations that have to be taken into 
account. When used subgingivally, with a water coolant, it causes a splash of water and 
blood from pockets as the result of explosive ablation and so it requires an extraoral 
apparatus for high speed evacuation. Moreover, in periodontal pockets, the operator cannot 
see the calculus and the irradiated surface. Recently as a novel application of laser, the use 
of diode fluorescence spectroscopy for detection of dental calculus has been suggested by 
Hibst et al. (2001) and Keller et al. (2001). 
In summary, in vitro and in vivo researches indicated the safety and effectiveness of clinical 
application of the Er:YAG laser for periodontal pocket treatment. However, the energy set, 
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most commonly used are the Gallium-aluminium-arsenide (GaAlAs) laser with a 
wavelength of 810 nm, and the indium-gallium-arsenide-phosphide (InGaAsP) laser at 980 
nm of wavelength. The laser is emitted in continuous-wave mode and gated-pulsed mode 
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Fig. 5. The diode laser fiber in clinical use in a pocket of a patient with chronic periodontitis. 
Laser light at 800-980 nm is very poorly absorbed by water and by hard tissues, being highly 
absorbed by haemoglobin and pigments. The diode laser is indicated for soft tissue surgery 
and for curettage. The diode laser exhibits a great thermal effect at the tip, caused by heat 
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accumulation and produces a very good haemostasis, with an effect similar to 
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Schwarz et al. (2003) performed in vivo on hopeless roots, a GaAlAs diode laser treatment 
(810 nm wavelength). They reported that diode laser was ineffective in removing calculus 
and altered the root in an unfavourable way. However, given the recommended parameters, 
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referred to as “low-level laser therapy”, may have a positive influence on the proliferation of 
gingival fibroblasts or periodontal ligament fibroblasts, thus supporting periodontal wound 
healing (Khadra et al. 2005) 
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advantages of eradication of pigmented bacteria, this laser may be useful for the treatment 
of periodontal pockets, requiring, however, further studies.  
2.7 Alexandrite laser 
In 1995 Rechmann & Henning assumed that the wavelength of alexandrite laser (337nm) 
may be favourable for selective calculus ablation, basing the theory on the difference in 
spectral region of fluorescence emission from dentin and that from subgingival calculus. 
Their study revealed that the alexandrite laser at the power of 1 J/cm2 of pulse and pulse 
repetition of 55Hz under water cooling, could selectively ablate dental calculus, supra and 
sub-gingivally, as well as dental plaque.  The laser has a wavelength in the spectrum of 
ultraviolet and does not produce any damage or effect on enamel or cementum. The 
development of this laser is widely expected in relation to its capability of being selective, 
however, there is a main concern regarding the use of ultraviolet light and further studies 
are needed to demonstrate the safety and effectiveness of this laser.  
3. Photodynamic laser therapy 
Photodynamic therapy (PDT) is a minimally invasive process that utilizes photosensitizing 
drugs (photosensitizers), which, when administered systemically or locally to a patient, may 
be selectively retained by diseased tissues preferentially over normal healthy tissues. These 
drugs can be activated by intense and wavelength-specific light to achieve selective 
photochemical destruction of diseased cells, by the generation of a reaction that produces 
singlet oxygen and free radicals with a subsequent cytotoxic and vasculotoxic effect. Due to 
the highly reactive nature of radicals formed trough the process, activity is confined to their 
immediate environment. Thus activity is selective and dependent on the delivery of the 
photosensitizer to the target (Nastri et al., 2010). Theoretically, neither the photosensitizer 
nor light alone can induce an efficient cytotoxic effect on the cells. The light that activates the 
photosensitizer must be of a specific wavelength with a relatively high intensity. With the 
discovery of lasers that are collimated, coherent and monochromatic, the process became 
more specific and it was possible to use intensive light with low-level energy. 
Depending on the type of drug, photosensitizer may be injected intravenously, ingested 
orally, or applied topically. Currently, PDT has been approved in many countries for clinical 
uses, mostly for the treatment of cancer (Meisel & Kocher, 2005). 
Several studies have shown that PDT has also antimicrobial properties (Photodynamic 
Antimicrobial Therapy). 
The human tissue efficiently transmits the red light and a wider wavelength activation 
photosensitising results in a deeper penetration of light. Most of the photosensitizers are 
activated by red light between 630 nm and 700 nm, corresponding to a depth of penetration 
of light by 0.5 cm (630 nm) to 1.5 cm (about 700 nm). This limits the degree of necrosis or 
apoptosis, and defines the therapeutic effect. While not every district in the human body is 
accessible to light, the periodontal pockets are easily exposed by using particular hand piece 
and the PDT could be effective. 
Various photoactive compounds, natural and synthetic, have a photosensitising potential; 
they include degradation products of chlorophyll polyacetilen, thiophene (Meisel & Kocher, 
2005). 
 
Alternative Treatment Approaches in Chronic Periodontitis: Laser Applications 195 
In antimicrobial photodynamic therapy, the particular photosensitizers are toluidine blue O, 
methylene blue, erithrosine, povidone-iodine, which have been shown to be safe when 
employed in the medical field and are effective in both gram+ and gram- bacteria. As a light 
source, the diode lasers are the light source predominantly applied. 
Nastri et al.(2010) presented a  research with the aim of evaluating the bactericidal in vitro 
effect of laser diodes 830 nm (as the light source) after photosensitization with Toluidine 
Blue (TBO), on  periopathogenic bacteria as Aggregatibacter actinomycetemcomitans, 
Porphyromonas gingivalis, Fusobacterium  nucleatum and Prevotella  intermedia. After evaluating 
the effect on the single bacterial strain, authors also evaluated the ability of  Diode Laser to 
disrupt the structure of biofilms produced by A. actinomycetemcomitans after 
photosensitization with TBO. 
The study suggested that the association of TBO and diode laser light 830 nm was effective 
for the killing of both the main periopathogenic species alone (Aggregatibacter 
actinomycetemcomitans, Prevotella intermedia, Porphyromonas gingivalis, Fusobacterium 
nucleatum) and biofilms. 
In a recent split-mouth study, it was demonstrated that non surgical periodontal treatment 
performed on patients with aggressive periodontitis, by applying photodynamic therapy 
alone, showed clinical improvements similar to that of conventional scaling and root planing 
(De oliveira et al., 2007). Also, it has been demonstrated that scaling and root planing 
combined with photo disinfection, or the application of photodynamic therapy alone, leads to 
reduction of pocket depth and clinical attachment gain (Andersen et al., 2007). 
Braun et al. (2008) evaluated the effect of adjunctive antimicrobial photodynamic therapy 
(methylene blue + 100 mW diode laser) in chronic periodontitis using a split mouth design. 
After 3 months of healing, the adjunctive use of photodynamic therapy resulted in a 
significant higher change in mean relative attachment level, probing pocket depth, sulcus 
fluid flow rate and bleeding on probing at the sites receiving PDT than the control sites. 
Taken together, the few data available from controlled studies suggest that in patients with 
chronic periodontitis, the adjunctive use of PDT to scaling and root planing may result in 
higher reductions in bleeding on probing, probing depth and higher CAL gain on a short 
term basis (3 to 6 months).  
Therefore, photodynamic therapy as a low-level therapy, using a diode laser with short 
irradiation time, is considered not to produce side effects, like thermal changes, injuries to 
gingival or pulp tissues and to the intact periodontal apparatus at the basis of the pocket. 
Nevertheless, it is important to remind that the dye itself can be cytotoxic and that it 
remains in the pocket, potentially interfering with periodontal reattachment and 
compromise patients aesthetics by producing temporary pigmentation of the periodontal 
tissue (Takasaki et al., 2009). In addition it has to be clarified if selective killing of 
periodontopathogens by antimicrobial photodynamic therapy really occurs without 
affecting the normal oral microflora. However, it is still not known how many applications 
of PDT are necessary to completely eliminate bacteria and to prevent recolonization. 
New basic and controlled clinical studies are needed to clarify the advantages or the limits 
of PDT, if it has to become widely applied in clinical practice. However, there can be  several 
indications for PDT, as an adjunctive therapy to mechanical periodontal treatment, during 
surgical therapy or during maintenance.  
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nor light alone can induce an efficient cytotoxic effect on the cells. The light that activates the 
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discovery of lasers that are collimated, coherent and monochromatic, the process became 
more specific and it was possible to use intensive light with low-level energy. 
Depending on the type of drug, photosensitizer may be injected intravenously, ingested 
orally, or applied topically. Currently, PDT has been approved in many countries for clinical 
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Several studies have shown that PDT has also antimicrobial properties (Photodynamic 
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apoptosis, and defines the therapeutic effect. While not every district in the human body is 
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and the PDT could be effective. 
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In antimicrobial photodynamic therapy, the particular photosensitizers are toluidine blue O, 
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source, the diode lasers are the light source predominantly applied. 
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effect of laser diodes 830 nm (as the light source) after photosensitization with Toluidine 
Blue (TBO), on  periopathogenic bacteria as Aggregatibacter actinomycetemcomitans, 
Porphyromonas gingivalis, Fusobacterium  nucleatum and Prevotella  intermedia. After evaluating 
the effect on the single bacterial strain, authors also evaluated the ability of  Diode Laser to 
disrupt the structure of biofilms produced by A. actinomycetemcomitans after 
photosensitization with TBO. 
The study suggested that the association of TBO and diode laser light 830 nm was effective 
for the killing of both the main periopathogenic species alone (Aggregatibacter 
actinomycetemcomitans, Prevotella intermedia, Porphyromonas gingivalis, Fusobacterium 
nucleatum) and biofilms. 
In a recent split-mouth study, it was demonstrated that non surgical periodontal treatment 
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After 3 months of healing, the adjunctive use of photodynamic therapy resulted in a 
significant higher change in mean relative attachment level, probing pocket depth, sulcus 
fluid flow rate and bleeding on probing at the sites receiving PDT than the control sites. 
Taken together, the few data available from controlled studies suggest that in patients with 
chronic periodontitis, the adjunctive use of PDT to scaling and root planing may result in 
higher reductions in bleeding on probing, probing depth and higher CAL gain on a short 
term basis (3 to 6 months).  
Therefore, photodynamic therapy as a low-level therapy, using a diode laser with short 
irradiation time, is considered not to produce side effects, like thermal changes, injuries to 
gingival or pulp tissues and to the intact periodontal apparatus at the basis of the pocket. 
Nevertheless, it is important to remind that the dye itself can be cytotoxic and that it 
remains in the pocket, potentially interfering with periodontal reattachment and 
compromise patients aesthetics by producing temporary pigmentation of the periodontal 
tissue (Takasaki et al., 2009). In addition it has to be clarified if selective killing of 
periodontopathogens by antimicrobial photodynamic therapy really occurs without 
affecting the normal oral microflora. However, it is still not known how many applications 
of PDT are necessary to completely eliminate bacteria and to prevent recolonization. 
New basic and controlled clinical studies are needed to clarify the advantages or the limits 
of PDT, if it has to become widely applied in clinical practice. However, there can be  several 
indications for PDT, as an adjunctive therapy to mechanical periodontal treatment, during 
surgical therapy or during maintenance.  
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4. Advantages of lasers 
Irradiation shows a great power of ablation, haemostasis, detoxification and bactericidal 
effects. These features could potentially be a tool for periodontal therapy, especially for 
cutting of soft tissues as in the debridement of diseased tissue, in this sense being the laser 
an adjunctive therapy to mechanical approaches. However, laser showed strong thermal 
effects, causing melting, carbonization and cracking of hard tissues, such as root and bone 
(Ishikawa et al. 2009). 
The recently developed Er:YAG and Er,Cr:YSGG lasers, can ablate both soft and hard tissues 
and are applicable with water irrigation to a safe periodontal therapy such as scaling and 
root planing, even in an alternative, unique treatment. These lasers may be capable of 
effective removing not only dental plaque but also calculus from the root surface, with 
extremely low mechanical stress and no formation of smear layer on the treated root surface. 
Furthermore, potential biostimulation effects of scattering and penetrating lasers on the cells 
surrounding the irradiated tissues may be helpful for reduction of inflammation and healing 
of periodontal tissues. 
Moreover, considering that most periodontopathogens have the capability of soft tissue 
invasion, not only debridement of the root surface but also removal of the epithelium lining 
and granulation tissue of the gingival wall within the pocket, could be important factors in 
the treatment of moderate to deep pockets in order to promote reattachment (Aoki et al. 
2004). This may be particularly important for non healed pockets or for recurrent acute 
phase in residual pockets. 
5. Disadvantages of lasers 
Although the use of lasers for subgingival curettage and calculus removal in the treatment 
of periodontal pockets has been increasing among practioners, the scientific studies 
indicating positive results of laser are still insufficient. The use of lasers in a safe mode 
during routine clinic is still far to become a reality. The clinician should have a precise 
knowledge of characteristics and effects, of risks and disadvantages of each type of laser 
before using one of them for a certain clinical procedure. It has also to be reminded that 
different lasers have different characteristics and are not useful for everything. Due to the 
high cost of each apparatus, it is very difficult to have all the different lasers indicated for 
different procedures in a private practice  
Improper irradiation of teeth and periodontal pockets by lasers can damage the tooth and 
root surface as well as the attachment at the base of the pockets. Possible damages to 
underlying bone and pulp are also to be considered. The risk of thermal injuries has always 
to be considered, as explained before, and the set of the laser power always accurately 
chosen in order to provide the less risk of damage to bone, root, pulp and surrounding 
tissues. 
Lasers are completely different from conventional mechanical therapy because they exert 
their effects not only in a contact mode but also at distance. Inadvertent irradiation of 
patient’s eyes or tissue outside the target must be strictly prevented. It is necessary that 
patient, operator and assistant wear special glasses to protect for the wavelength of the laser 
that has to be used. Use of wet gauze packs may be occasionally useful for protection of the 
surrounding tissues from accidental beam impact. 
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Furthermore, high speed evacuation systems are required to capture the water and blood 
vaporization produced by laser light and development of new apparatus with little hand 
pieces and thin tips, useful in periodontal pockets, is still at work.  
6. Conclusions 
Laser periodontal treatment for periodontitis is being receiving much attention both from 
researchers and clinicians. At the present state, there is a great need to develop an evidence-
based approach to the study of lasers. The different studies and clinical application, even if 
performed with the same wavelength, may be different in several other set parameters, 
making it very difficult to compare the lasers and the gold standard of periodontal therapy: 
mechanical scaling and root planing. If CAL gain is the main parameter of success in 
periodontal non surgical therapy, there is scarce evidence that laser therapy can be superior 
to conventional treatment. Moreover, the evidence of some additional benefits coming from 
laser therapy as an adjunctive treatment to conventional mechanical treatment is minimal. 
In conclusion, the use of lasers still requires many studies to become a routine therapy with 
the same advantages and low risks of conventional periodontal therapy. The most 
promising one is Er:YAG laser for its ability of calculus removing and with a relatively safe 
modality of use under water cooling. However, the high cost and the little demonstration of 
real superiority to conventional therapy is still a refrain. The perfect wavelength, power set 
and tip have not been studied yet. A reliable procedure for laser application in non surgical 
periodontal therapy should be established by further studies, and clinicians should have the 
precise knowledge of the potential benefits or damages before using this relatively new 
instruments, which are still under debate. 
In summary, the use of lasers to debride root surface is in its infancy. They showed several 
positive effects, due to their characteristics of working in a noncontact mode, useful for very 
deep pockets and furcations, of bacterial detoxification and decontamination, to be more 
patient –tolerated etc. However, lasers show a history of significant side-effects, that should 
at least induce caution for their safe use. 
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